Use of Anti-BCMA chimeric antigen receptor

By administering BCMA-directed CAR-expressing immune cells in conjunction with prior treatments, the method addresses the limitations of conventional therapies for B-cell malignancies, achieving targeted cell depletion and reduced side effects.

JP2024161391AInactive Publication Date: 2024-11-19CELGENE CORP
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024118312
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-07-11
Filing Date
2024-07-24
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for B-cell malignancies such as non-Hodgkin's lymphoma and multiple myeloma are limited by toxic side effects, variable tumor response, and the inefficacy of conventional therapies like chemotherapy and immunotherapies due to rapid antibody elimination and low target antigen expression on cancer cells, while genetically modified CAR T cells face issues of unpredictable efficacy and cytokine storms.

Method used

Administration of immune cells expressing BCMA-directed chimeric antigen receptors (CARs) in combination with prior treatments like proteasome inhibitors and anti-CD38 antibodies, tailored to specific disease stages and histories, to selectively target and deplete BCMA-expressing cells.

Benefits of technology

Enhances therapeutic efficacy by specifically targeting BCMA-expressing cells, reducing tumor burden while minimizing humoral immunity disruption and cytokine storms, offering improved treatment outcomes for B-cell malignancies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161391000001_ABST
    Figure 2024161391000001_ABST
Patent Text Reader

Abstract

To provide a use of a composition of an immunocyte expressing a BCMA-directivity chimeric antigen receptor (CAR) in producing a medicine for treating a disease caused by B cell maturation antigen (BCMA) expression cell in a subject having multiple myeloma, and a pharmaceutical composition containing the immunocyte.SOLUTION: Provided is a use of a composition of an immunocyte expressing a BCMA-directivity CAR in producing a medicine for treating a disease caused by a BCMA expression cell in a subject having high-risk multiple myeloma, where the composition is formulated for administration of 300×106 cells to 600×106 cells, and the subject has received two or more pretreating before administration, and each treatment includes at least one of proteasome inhibitor, immunomodulator and anti-CD38 antibody.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application is the benefit of U.S. Provisional Patent Application No. 62 / 696,802, filed July 11, 2018. The benefit of this application is claimed, the entire disclosure of which is incorporated herein by reference. Sequence Listing This application references a sequence listing, which was submitted with this application as an ASCII text file. The sequence listing is incorporated by reference at 14247-321-228_SEQ_LIST. It was created on July 3, 2019 with the title ING.txt and a size of 27,379. It's a part-time job. 1. Background 1.1.Technical Field The present invention relates to a method for treating a B cell associated condition. More particularly, the present invention relates to a method for treating a B cell associated condition, Improved chimeric antigen receptor (CAR) comprising a murine anti-BCMA antibody or antigen-binding fragment thereof CARs), immune effector cells genetically engineered to express these CARs, and The use of these compositions to effectively treat B-cell related conditions is also disclosed. [Background technology]

[0002] 1.2. Description of Related Art Several important diseases involve B lymphocytes, or B cells. Abnormal physiology includes, but is not limited to, systemic lupus erythematosus (SLE) This can lead to the development of autoimmune diseases. However, it can cause cancers including lymphomas, such as multiple myeloma and non-Hodgkin's lymphoma. vinegar.

[0003] B-cell malignancies, including non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM) The majority of patients with B-cell malignancies are cancer patients, accounting for the majority of cancer deaths. Responses to conventional treatments for B-cell malignancies, including chemotherapy and radiation therapy, have been mixed. Therapeutic approaches have been of limited utility due to toxic side effects. Anti-CD22, anti-CD23, anti-CD52, anti-CD80, and anti-HLA-DR therapeutic antibodies Immunotherapy using this drug is, in part, due to its poor pharmacokinetic profile and the high serum protease activity. Rapid clearance of antibodies by filtration in the endothelium and glomeruli and their penetration into the tumor site and the limited expression levels of target antigens on cancer cells, Attempts to use genetically modified cells expressing chimeric antigen receptors (CARs) have also not been fully successful. In addition, the therapeutic efficacy of a given antigen-binding domain used in a CAR has not been well established. The binding of the antigen-binding domain is unpredictable, and if the binding is too strong, the CAR T cells triggers massive cytokine release, resulting in a deadly condition known as a "cytokine storm." If the antigen-binding domain is too weak, the CAR T cells may produce an immune response. , they do not show sufficient therapeutic effect to eliminate cancer cells. Summary of the Invention

[0004] 2. Overview The present invention generally relates to improved methods of treating B cell-related disorders, such as multiple myeloma. Provide the law.

[0005] In one embodiment, provided herein is a B cell maturation antigen (BCMA)-expressing cell. A method for depleting BC in a subject in need thereof, comprising administering to the subject a BC administering immune cells expressing a chimeric antigen receptor (CAR) directed against MA; The cells are 150 x 10 6 cells ~450×10 6 a dosage of cells, and prior to said administration , the subject has received one or more prior lines of therapy.

[0006] In one embodiment, provided herein is a method for depleting BCMA-expressing cells. in a subject in need thereof, comprising administering to the subject a BCMA-directed chimeric antibody. The method includes administering immune cells expressing a CAR-specific receptor (CAR), the immune cells being 150×1 0 6 cells ~450×10 6 The subject is administered a dosage of cells, and prior to said administration, the subject is Theasome inhibitors, lenalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone Methasone, cyclophosphamide, doxorubicin, carfilzomib, ixazomib, Suplatin, doxorubicin, etoposide, anti-CD38 antibody, panobinostat, and have received at least one prior line of therapy that included at least one of the following: In one embodiment, the anti-CD38 antibody is daratumumab.

[0007] In one embodiment, provided herein is a method for depleting BCMA-expressing cells. in a subject in need thereof, comprising administering to the subject a B cell maturation antigen (BCM) A) administering a therapeutically effective amount of immune cells expressing a directed chimeric antigen receptor (CAR) The immune cells were 150 × 10 6 cells ~450×10 6 Cells are administered in doses Prior to said administration, the subject is receiving a proteasome inhibitor, lenalidomide, pomalidomide, Thalidomide, bortezomib, dexamethasone, cyclophosphamide, doxorubicin, Carfilzomib, ixazomib, cisplatin, doxorubicin, etoposide, anti-CD 38 antibodies (e.g., daratumumab), panobinostat, or elotuzumab Patients who have received one or more prior lines of therapy, including those listed above.

[0008] In another embodiment, provided herein is a method for treating BCMA-expressing cells. A method of treating a disease in a subject in need thereof, comprising administering to the subject This involves administering immune cells expressing a BCMA-directed chimeric antigen receptor (CAR). The immune cells were 150 × 10 6 cells ~450×10 6 A dosage of cells is administered, Prior to administration of the compound, the subject has received one or more prior lines of therapy. In certain embodiments, BCMA-expressing cells treated according to the methods described herein Diseases caused by it include systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, Asthenia, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, antiphospholipid syndrome, Jaggs' disease, Graves' disease, Wegener's granulomatosis, polyarteritis nodosa, Sjogren's syndrome group, pemphigus vulgaris, scleroderma, multiple sclerosis, antiphospholipid syndrome, ANCA-associated vasculitis , Goodpasture's disease, Kawasaki disease, and rapidly progressive glomerulonephritis. In certain embodiments, the subject is treated according to the methods described herein. Diseases caused by BCMA expressing cells also include heavy chain diseases, primary or immune cell diseases. Associated amyloidosis and monoclonal gammopathy of undetermined significance (MGUS) Includes, but is not limited to:

[0009] In another embodiment, provided herein is a method for treating BCMA-expressing cells. A method of treating a disease in a subject in need thereof, comprising administering to the subject This involves administering immune cells expressing a BCMA-directed chimeric antigen receptor (CAR). The immune cells were 150 × 10 6 cells ~450×10 6 A dosage of cells is administered, Prior to administration, the subject was receiving a proteasome inhibitor, lenalidomide, pomalidomide, or thalidomide. Ido, bortezomib, dexamethasone, cyclophosphamide, doxorubicin, carfi Ruzomib, ixazomib, cisplatin, doxorubicin, etoposide, anti-CD38 antibody ≥1 line of prior therapy including ≥1 of the following: panobinostat, elotuzumab, and / or In one embodiment, the anti-CD38 antibody is daratumumab. It is.

[0010] In another embodiment, provided herein is a method for treating BCMA-expressing cells. A method of treating a disease in a subject in need thereof, comprising administering to the subject In this study, we developed immune cells expressing B cell maturation antigen (BCMA)-directed chimeric antigen receptors (CARs). wherein the immune cells comprise 150×10 6 Cell ~450×1 0 6 and prior to said administration, said subject is administered a dosage of a proteasome inhibitor, Nalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone, cyclophosph Famid, doxorubicin, carfilzomib, ixazomib, cisplatin, doxorubicin bicine, etoposide, anti-CD38 antibodies (such as daratumumab), panobinostat, or have received at least one prior line of therapy containing elotuzumab; This is the method.

[0011] In another embodiment, provided herein is a method for treating a BCMA-expressing cancer. The method comprises administering to the subject a BCMA-directed kinase inhibitor, and administering immune cells expressing a CAR (carcinoblastoma antigen receptor), the immune cells being 15 0×10 6 cells ~450×10 6 and prior to said administration, said subject is , and have received one or more lines of prior therapy.

[0012] In another embodiment, provided herein is a method for treating a BCMA-expressing cancer. The method comprises administering to the subject a BCMA-directed kinase inhibitor, and administering immune cells expressing a CAR (carcinoblastoma antigen receptor), the immune cells being 15 0×10 6 cells ~450×10 6 and prior to said administration, said subject is , proteasome inhibitors, lenalidomide, pomalidomide, thalidomide, bortezomib, Dexamethasone, cyclophosphamide, doxorubicin, carfilzomib, ixazomib , cisplatin, doxorubicin, etoposide, anti-CD38 antibody, panobinostat, and elotuzumab. In one embodiment, the anti-CD38 antibody is daratumumab. In some embodiments, the BCMA-expressing cancer is multiple myeloma, chronic lymphocytic leukemia, or Non-Hodgkin's lymphoma (e.g., Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic leukemia) Lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunological Lymphoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, or mantle cell lymphoma ).

[0013] In another embodiment, provided herein is a method for treating a BCMA-expressing cancer. The present invention relates to a method for administering to a subject in need thereof a B cell maturation antigen ( The present invention relates to a method for treating cancer, comprising administering to a patient a therapeutically effective amount of immune cells expressing a chimeric antigen receptor (CAR) directed against BCMA. The immune cells were administered at a concentration of 150 × 10 6 cells ~450×10 6 Cell dosage and prior to said administration, said subject is receiving a proteasome inhibitor, lenalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone, cyclophosphamide, doxorubicin Cinnamoyl, carfilzomib, ixazomib, cisplatin, doxorubicin, etoposide, Anti-CD38 antibodies (such as daratumumab), panobinostat, or elotuzumab In certain embodiments, the patient has received one or more prior lines of therapy, including one or more of the following: In terms of morphology, BCMA-expressing cancers include multiple myeloma, chronic lymphocytic leukemia, or Non-Hodgkin's lymphoma (e.g., Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic leukemia) Lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunology blastic large cell lymphoma, precursor B-lymphoblastic lymphoma, or mantle cell lymphoma) It is.

[0014] In another embodiment, provided herein is a method for treating a BCMA-expressing cancer. The present invention relates to a method for administering to a subject in need thereof a B cell maturation antigen ( The present invention relates to a method for treating cancer, comprising administering to a patient a therapeutically effective amount of immune cells expressing a chimeric antigen receptor (CAR) directed against BCMA. The immune cells were administered at a concentration of 150 × 10 6 cells ~450×10 6 Cell dosage and prior to said administration, said subject is receiving a proteasome inhibitor, lenalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone, cyclophosphamide, doxorubicin Cinnamoyl, carfilzomib, ixazomib, cisplatin, doxorubicin, etoposide, Anti-CD38 antibodies (such as daratumumab), panobinostat, or elotuzumab Patients with BCMA-expressing cancer who have received at least one prior line of therapy, including Multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma (e.g., Burkitt's lymphoma) lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large cell lymphoma Follicular B-cell lymphoma, Follicular lymphoma, Large immunoblastic cell lymphoma, Precursor B-lymphoblast lymphoma, and mantle cell lymphoma.

[0015] In one embodiment, provided herein is a method for treating relapsed, refractory or high-risk multiple myeloma. A method of treating myeloma in a subject in need thereof, comprising administering to the subject , T cells expressing B cell maturation antigen (BCMA)-directed chimeric antigen receptors (CARs) (e.g. For example, autologous T cells), the T cells may be administered in a concentration of about 150×10 6 cells ~ about 6 00×10 6The cells are administered (e.g., injected) in a range of doses, and prior to administration, the subject These include proteasome inhibitors, immunomodulatory agents (e.g., IMiD compounds), dexamethasone, and One or more prior lines of therapy that included one or more CD38 antibodies (e.g., one prior line of therapy, or have received 2 prior treatments, 3 prior treatments, or more than 3 prior treatments. In one embodiment, provided herein is a method for treating relapsed, refractory or high-risk multiple myeloma. A method of treating myeloma in a subject in need thereof, comprising administering to the subject: T cells expressing B cell maturation antigen (BCMA)-directed chimeric antigen receptors (CARs) (e.g. For example, autologous T cells), the T cells may be administered in amounts of about 150×10 6 cells ~about 60 0×10 6 The cells are administered (e.g., injected) in a range of doses, and prior to the administration, the subject , proteasome inhibitors, lenalidomide, pomalidomide, thalidomide, bortezomib, Dexamethasone, cyclophosphamide, doxorubicin, carfilzomib, ixazomib cisplatin, doxorubicin, etoposide, and anti-CD38 antibodies (such as daratumumab) 1 prior line of therapy including at least one of the following: panobinostat, elotuzumab, or ≥ 1 prior therapy (e.g., 1 prior therapy, 2 prior therapies, 3 prior therapies, > 3 prior therapies) In some embodiments, the subject is diagnosed with multiple myeloma. In one embodiment, the subject has multiple myeloma, which is high-risk multiple myeloma. In one embodiment, the subject has multiple myeloma that is relapsed or refractory multiple myeloma. In some embodiments, the subject treated according to the methods described herein has The subject has received only one prior treatment. Subjects treated according to the method described herein have received 3 to 7 prior therapies. In certain embodiments, the subject treated according to the methods described herein has more than three In some embodiments, the subject has received prior treatment with at least one of: Refractory to two or three prior treatment regimens (e.g., to the last prior treatment) refractory to treatment (e.g., within 60 days of the subject completing treatment with the treatment regimen) In one embodiment, the method includes the step of treating relapsed or refractory multiple myeloma. In one embodiment, the method is for treating relapsed multiple myeloma. In one embodiment, the method is for treating refractory multiple myeloma. In one embodiment, the subject is receiving treatment with a proteasome inhibitor, an immunomodulatory drug (IMiD). combinations), dexamethasone and / or anti-CD38 antibody treatment. In one embodiment, the method is for treating high-risk multiple myeloma. In some embodiments, the high-risk multiple myeloma is R-ISS stage III. and / or diseases characterized by early relapse (e.g., proteasome inhibitors, immunomodulatory Date of last treatment regimen, such as last treatment regimen with sparing and / or dexamethasone In one embodiment, the subject with a tumor is a patient with a B cell tumor. Prior to administration of T cells expressing a chimeric antigen receptor (CAR) directed against the BCMA-specific tumour In one embodiment, BCMA expression by tumors has been evaluated. Primary myeloma is treated according to the methods described herein. In some embodiments, In some embodiments, the T cells are administered by intravenous infusion. is 150 x 10 6 cells ~450×10 6 Cells, 300×10 6 cells ~600×10 6 Thin cell, 350×10 6 cells ~600×10 6 cells, 350×10 6 cells ~550×10 6 Thin cell, 400×10 6 cells ~600×10 6 cells, 150 x 10 6 cells ~300×10 6 Thin cells, or 400 x 10 6 cells ~500×10 6 It is administered in doses ranging from 100 to 200 cells / ml. In some embodiments, the T cells are about 150×10 6 cells, approximately 200 x 10 6 cells, approx. 2 50×10 6 Cells, approximately 300 x 10 6 Cells, approximately 350 x 10 6 Cells, approximately 400 x 10 6 Thin cells, approximately 450 x 10 6 cells, approximately 500 x 10 6 cells, or approximately 550 x 10 6 Cell dose In one embodiment, the T cells are administered at about 450×10 6 The dose of cells is In some embodiments, the subject is administered a B-cell maturation antigen (BCMA)-directed chimeric antibody. A single infusion of T cells expressing a CAR receptor is administered. T cells expressing B cell maturation antigen (BCMA)-directed chimeric antigen receptors (CARs) is repeated (e.g., a second administration of T cells can be administered to the subject).

[0016] In a specific embodiment of any of the embodiments described herein, the B cell maturation antibody Immune cells expressing BCMA-directed chimeric antigen receptors (CARs) were approximately 150 × 1 0 6 Cells ~ approx. 300×10 6 The cells are administered in a dosage amount. In a specific embodiment of any of the above, the chimeric antigen receptor agonist (CAAG)-directed B-cell maturation antigen (BCMA) is Immune cells expressing the receptor (CAR) were approximately 350 × 10 6 Cells ~ approx. 550×10 6 cell In certain specific embodiments of any of the embodiments described herein, In this study, we developed an immune deficiency virus (HIV)-associated B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-expressing The cells are approximately 400 x 10 6 Cells ~ approx. 500×10 6 The cells are administered in a dosage amount. In a specific embodiment of any of the embodiments described in, B cell maturation antigen (BCM A) Immune cells expressing a directional chimeric antigen receptor (CAR) were approximately 150 × 10 6 Cell~ Approximately 250×10 6 Any of the embodiments described herein is administered in a dosage of cells. In a specific embodiment, a chimeric antigen receptor (CAR) directed against B cell maturation antigen (BCMA) is The number of immune cells expressing AR was approximately 300 × 10 6 Cells ~ approx. 500×10 6 Cell Dosage In a specific embodiment of any of the embodiments described herein, B Immune cells expressing cell-cell maturation antigen (BCMA)-directed chimeric antigen receptors (CARs) have been reported to be ca. 350×10 6 Cells ~ approx. 450×10 6 The cells are administered in a dosage amount as described herein. In a specific embodiment of any of the above embodiments, the B-cell maturation antigen (BCMA)-directed Immune cells expressing chimeric antigen receptors (CARs) were approximately 300 × 10 6 Cells ~ approx. 450× 10 6 The dosage of cells is administered. In an embodiment, a chimeric antigen receptor (CAR) directed against B cell maturation antigen (BCMA) is generated. The number of immune cells expressing the 6 Cells ~ approx. 450×10 6 Administered in cell doses In a specific embodiment of any of the embodiments described herein, a B cell maturation antibody is Immune cells expressing BCMA-directed chimeric antigen receptors (CARs) were approximately 300 × 1 0 6 Cells ~ approx. 600×10 6 The cells are administered in a dosage amount. In a specific embodiment of any of the above, the chimeric antigen receptor agonist (CAAG)-directed B-cell maturation antigen (BCMA) is Immune cells expressing the receptor (CAR) were approximately 250 × 10 6 Cells ~ approx. 500×10 6 cell In certain specific embodiments of any of the embodiments described herein, In this study, we developed an immune deficiency virus (HIV)-associated B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-expressing The cells are approximately 350 × 10 6 Cells ~ approx. 500×10 6 The cells are administered in a dosage amount. In a specific embodiment of any of the embodiments described in A) Immune cells expressing a directional chimeric antigen receptor (CAR) were approximately 400 × 10 6 Cell~ Approximately 600×10 6 Any of the embodiments described herein is administered in a dosage of cells. In a specific embodiment, a chimeric antigen receptor (CAR) directed against B cell maturation antigen (BCMA) is The number of immune cells expressing AR was approximately 400 × 10 6 Cells ~ approx. 450×10 6 Cell Dosage In a specific embodiment of any of the embodiments described herein, B Immune cells expressing cell-cell maturation antigen (BCMA)-directed chimeric antigen receptors (CARs) have been reported to be ca. 200×10 6 Cells ~ approx. 400×10 6 The cells are administered in a dosage amount as described herein. In a specific embodiment of any of the above embodiments, the B-cell maturation antigen (BCMA)-directed Immune cells expressing chimeric antigen receptors (CARs) were approximately 200 × 10 6 Cells ~ approx. 350× 10 6 The dosage of cells is administered. In an embodiment, a chimeric antigen receptor (CAR) directed against B cell maturation antigen (BCMA) is generated. The number of immune cells expressing the 6 Cells ~ approx. 300×10 6 Administered in cell doses In a specific embodiment of any of the embodiments described herein, a B cell maturation antibody is Immune cells expressing BCMA-directed chimeric antigen receptors (CARs) were approximately 450 × 1 0 6 Cells ~ approx. 500×10 6 The cells are administered in a dosage amount. In a specific embodiment of any of the above, the chimeric antigen receptor agonist (CAAG)-directed B-cell maturation antigen (BCMA) is Immune cells expressing the receptor (CAR) were approximately 250 × 10 6 Cells ~ approx. 400×10 6 cell In certain specific embodiments of any of the embodiments described herein, In this study, we developed an immune deficiency virus (HIV)-associated B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-expressing The cells are approximately 250 × 10 6 Cells ~ approx. 350×10 6 The cells are administered in a dosage amount. In a specific embodiment of any of the embodiments described in, B cell maturation antigen (BCM A) Immune cells expressing a directional chimeric antigen receptor (CAR) were approximately 450 × 10 6 Cellular In certain specific embodiments of any of the embodiments described herein, In the present invention, the immune cells are T cells (e.g., autologous T cells). In a specific embodiment of any of the embodiments, the subject to be treated is, prior to administration, For the production of immune cells expressing BCMA-directed chimeric antigen receptors (CARs) The patient undergoes a leukapheresis procedure to harvest autologous immune cells for transplantation. In a specific embodiment of any of the embodiments described above, immune cells (e.g., T cells) are The cells are administered by intravenous infusion.

[0017] In specific embodiments of any of the embodiments disclosed herein, the subject being treated Elephants were given an immune defence system expressing a B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR). Prior to administration of the cells, lymphodepletion (LD) chemotherapy is administered. LD chemotherapy includes fludarabine and / or cyclophosphamide. In an embodiment, the LD chemotherapy includes fludarabine (e.g., about 30 mg intravenously). g / m 2 ) and cyclophosphamide (e.g., about 300 mg / m 2 ) and the period is 1, 2, 3, 4, 5, 6, or 7 days (e.g., 3 days). In a specific embodiment, the LD chemotherapy is any of the chemotherapeutic agents described in Section 5.9. In a specific embodiment, the subject is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 3 3, 4, 5, 6, or 7 days later (e.g., 2 or 3 days after administration of LD chemotherapy); The immune cells expressing B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) In a specific embodiment, the subject is administered at least one At least one week, at least two weeks (at least 14 days), at least three weeks, at least 4 weeks, at least 5 weeks, or at least 6 weeks of any therapy In any specific embodiment of the present invention disclosed herein, The subject to be treated is a subject who has a B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR). They received only one prior treatment regimen prior to administration of the expressing immune cells.

[0018] In a specific embodiment of any of the above embodiments, prior to said administering, said subject , daratumumab, pomalidomide, and dexamethasone (DPd); daratumumab, bortezomib Zomib and dexamethasone (DVd); Ixazomib, lenalidomide, and dexamethasone daratumumab, lenalidomide and dexamethasone; bortezomib, lenalidomide and dexamethasone Lidomide and dexamethasone (RVd); Bortezomib, cyclophosphamide and dexamethasone Bortezomib, doxorubicin and dexamethasone (BCd); Bortezomib, doxorubicin and dexamethasone; Carfilzo mib, lenalidomide and dexamethasone (CRd); bortezomib and dexamethasone; Bortezomib, thalidomide and dexamethasone; lenalidomide and dexamethasone; de xamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, Toposide and bortezomib (VTD-PACE); lenalidomide and low-dose dexamethasone bortezomib, cyclophosphamide and dexamethasone; carfilzomib and dexamethasone Samethasone; lenalidomide alone; bortezomib alone; daratumumab alone; elotuzumab, Lenalidomide, and dexamethasone; elotuzumab, lenalidomide, and dexamethasone; Bendamustine, bortezomib and dexamethasone; Bendamustine, lenalidomide and and dexamethasone; pomalidomide and dexamethasone; pomalidomide, bortezomib and Dexamethasone; pomalidomide, carfilzomib and dexamethasone; bortezomib and and liposomal doxorubicin; cyclophosphamide, lenalidomide, and dexamethasone elotuzumab, bortezomib and dexamethasone; ixazomib and dexamethasone ;Panobinostat, bortezomib and dexamethasone;Panobinostat and Carfi or prior chemotherapy including pomalidomide, cyclophosphamide, and dexamethasone Have received at least one Inn.

[0019] In a specific embodiment of any of the above embodiments, prior to said administering, said subject , proteasome inhibitors, lenalidomide, pomalidomide, thalidomide, bortezomib, Dexamethasone (e.g., low-dose dexamethasone), cyclophosphamide, doxorubicin Cinnamoyl, carfilzomib, ixazomib, cisplatin, doxorubicin, etoposide, Bendamustine, liposomal doxorubicin, anti-CD38 antibody, panobinostat, and Patients have received at least one prior line of therapy that included at least one of the following: In a specific embodiment, the anti-CD38 antibody is daratumumab.

[0020] In certain more specific embodiments of any of the above, the subject is 2 or more of the lines of prior therapy, 3 or more of the lines of prior therapy, 4 or more of the above, 5 or more of the above lines of prior therapy, 6 or more of the above lines of prior therapy, or have received seven or more of the above prior lines of therapy. In certain other more specific embodiments, the subject has received three or more of the prior lines of therapy. Patients who have received up to two of the prior lines of therapy or up to one of the prior lines of therapy I have done it before.

[0021] For any of the above embodiments, the subject undergoes lymphocyte depletion prior to said administration. For any of the above embodiments, the subject may then harvest and isolate the immune cells, e.g., T cells. In order to isolate the patient, the patient undergoes apheresis. In the method, the subject exhibits the following at the time of the apheresis: M protein (serum Protein electrophoresis (sPEP) or urinary protein electrophoresis (uPEP) (sPE) P ≥ 0.5 g / dL or uPEP ≥ 200 mg / 24 hours; measured in serum or urine No identifiable disease, serum immunoglobulin free light chains ≥ 10 mg / dL, and abnormal serum immunoglobulins globulin kappa lambda free light chain ratio; and / or East Coast of the United States Eastern Cooperative Oncology Group (ECOG) performance status ≦1. More Specific Embodiments In the method, the subject is further administered a proteasome inhibitor, an immunomodulatory agent, and / or a medicament for the treatment of apheresis. Prior treatment with anti-CD38 antibodies and anti-lenalidomide or pomalidomide was also included. Have received at least three of the prior lines of therapy; For at least three of each, at least one At least 2 consecutive cycles of chemotherapy; and / or evidence of progression within 1 day of A specific example of any of the above embodiments has been described. In embodiments, the subject exhibits, at the time of administration: M protein (serum protein). Protein electrophoresis (sPEP) or urine protein electrophoresis (uPEP): sPEP ≥ 0.5g / dL or uPEP ≥ 200mg / 24 hours; measurable in serum or urine There is no clinically significant disease, serum immunoglobulin free light chains ≥ 10 mg / dL, and abnormal serum immunoglobulins bryn kappa lambda free light chain ratio, light chain multiple myeloma; and / or US Eastern Counseling Centers for Cancer Examination of the Eastern Cohort Group (ECOG) performance status ≦1. In this case, the subject is further treated with a proteasome inhibitor, an immunomodulatory agent (e.g., Prior treatment with anti-CD38 antibodies, including lenalidomide or pomalidomide have received at least three of the prior lines of therapy; For each of the three, at least one Have received 2 consecutive cycles; on or within 60 days of most recent line of therapy and / or evidence of progression to at least one of the prior lines of therapy The efficacy (minimal response or better) has been achieved.

[0022] In another more specific embodiment, the subject further comprises one or more prior anti-myeloma treatments. regimen only; the following high-risk factors: R-ISS stage III, and (i ) If the subject has undergone induction therapy and stem cell transplant, progression within 12 months from the date of the first transplant (PD); or (ii) if the subject received only the induction procedure, at least The final treatment regimen must contain an immunosuppressant, an immunomodulator, and dexamethasone. Patients were randomly assigned to receive either the 1st or 2nd trimester of treatment and had early relapse defined as PD <12 months after the start of treatment.

[0023] In a specific embodiment of any of the above embodiments, the subject receives The patient will have a progression-free survival of at least 6 months or at least 12 months after administration of the drug.

[0024] In a specific embodiment of any of the above embodiments, the chimeric antigen receptor is B Antibodies or antibody fragments that target CMA, such as single chain Fv antibody fragments (scFv), e.g. For example, the chimeric antigen receptor comprises BCMA02 scFv. In one embodiment, the chimeric antigen receptor comprises a murine single chain Fv antibody fragment that targets MA. The receptor is a mouse anti-BCMA scFv that binds to a BCMA polypeptide, a CD8α polypeptide Hinge domain containing peptide, CD8α transmembrane domain, CD137(4-1BB) cell In one embodiment, the CD3ζ primary signaling domain is a CD3ζ co-stimulatory domain. In one embodiment, the chimeric antigen receptor comprises a murine scFv that targets BCMA, and the scFV is that of the anti-BCMA02 CAR of SEQ ID NO: 9. In the present specification, the chimeric antigen receptor is or includes SEQ ID NO: 9. In a more specific embodiment of any of the above embodiments, the immune cells are bb2121 cells. In one embodiment, the immune cells are administered a murine single chain Fv antibody fragment that targets BCMA. In one embodiment, the immune cell comprises a chimeric antigen receptor comprising the BCMA polypeptide. A mouse anti-BCMA scFv that binds to a CD8α polypeptide, a hinge domain comprising CD8α transmembrane domain, CD137 (4-1BB) intracellular costimulatory signaling domain In one embodiment, the chimeric antigen receptor comprises a CD3ζ primary signaling domain and a CD3ζ primary signaling domain. In one embodiment, the immune cell is a chimeric antigen receptor that is or comprises SEQ ID NO:9. Contains a receptor. [Brief description of the drawings]

[0025] 3. Brief description of the drawings [Figure 1] A schematic diagram of the murine B-cell maturation antigen (muBCMA) CAR construct is shown.

[0026] [Figure 2A] Shown is the amount of IFNγ released from anti-BCMA02 CAR T cells, anti-BCMA10 CAR T cells, and CAR19Δ T cells after 24 hours of co-culture with BCMA-expressing K562 cells.

[0027] [Figure 2B] The amount of IFNγ released from anti-BCMA02 CAR T cells, anti-BCMA10 CAR T cells, and CAR19Δ T cells after 24 hours of co-culture with K562 cells, which lack BCMA expression, is shown compared to K562 cells expressing BCMA.

[0028] [Diagram 3]Shown are the amounts of inflammatory cytokines in growth media from non-transduced control T cells, anti-BCMA02 CAR T cells, anti-BCMA10 CAR T cells, and CAR19Δ T cells stimulated for 10 days prior to assay.

[0029] [Figure 4] Shows the amount of inflammatory cytokines produced by anti-BCMA02 CAR T cells, anti-BCMA10 CAR T cells, and CAR19Δ T cells in the absence of antigen stimulation.

[0030] [Diagram 5] Figure 2 shows the expression of phenotypic markers of activation at the end of manufacturing of anti-BCMA CAR T cells. HLA-DR and CD25 expression was measured in anti-BCMA02 CAR T cells, anti-BCMA10 CAR T cells, and CAR19Δ T cells.

[0031] [Figure 6] Activated caspase-3 levels in anti-BCMA10 and anti-BCMA02 CAR T cells in the absence of antigen stimulation. Activation of caspase-3 is a necessary step in apoptosis and is important for AICD.

[0032] [Figure 7] Figure 1 shows the amount of inflammatory cytokine release in anti-BCMA02 and anti-BCMA10 CAR T cells in media containing fetal bovine serum (FBS), human AB serum (HABS), or 100ng / ml soluble BCMA.

[0033] [Figure 8A] Shown are tumor volumes in NOD scid gamma (NSG) mice bearing experimental subcutaneous human multiple myeloma (RPMI-8226) tumors of approximately 100 mm3. Mice were treated with vehicle, 107 anti-BCMA02 CAR T cells, 107 anti-BCMA10 CAR T cells, or bortezomib (VELCADE®).

[0034] [Figure 8B] Shown are tumor volumes in NOD scid gamma (NSG) mice bearing experimental subcutaneous human multiple myeloma (RPMI-8226) tumors of approximately 100 mm3. Mice were treated with vehicle, 107 anti-BCMA02 CAR T cells, 107 anti-BCMA10 CAR T cells, or bortezomib (VELCADE®).

[0035] [Figure 9] The level of BCMA expression in lymphoma and leukemia cell lines (circles) and the activity of anti-BCMACAR T cells against each cell line (IFNγ release, squares) are shown. BCMA negative (BCMA-) tumor cell lines: myeloid leukemia (K562), acute lymphoblastic leukemia (NALM-6 and NALM-16); mantle cell lymphoma (REC-1); or Hodgkin lymphoma (HDLM-2) showed little or no IFNγ release. BCMA positive (BCMA+) tumor cell lines: B cell chronic lymphoblastic leukemia (MEC-1), mantle cell lymphoma (JeKo-1), Hodgkin lymphoma (RPMI-6666), Burkitt lymphoma (Daudi and Ramos cells), and multiple myeloma (RPMI-8226) showed substantial IFNγ release.

[0036] [Figure 10A] Shows the in vivo activity of vehicle, anti-CD19Δ CAR T cells, anti-CD19 CAR T cells, and anti-BCMA CAR T cells against BCMA-expressing Burkitt lymphoma cells (Daudi cells) in the NSG mouse model when CAR T cells were administered to mice 8 days after tumor induction.

[0037] [Figure 10B]Shows the in vivo activity of vehicle, anti-CD19Δ CAR T cells, anti-CD19 CAR T cells, and anti-BCMA CAR T cells against BCMA-expressing Burkitt's lymphoma cells (Daudi cells) in the NSG mouse model when CAR T cells were administered to mice 18 days after tumor induction.

[0038] [Figure 11] We show potent in vitro activity of anti-BCMA CAR T cells achieved with a 50 percent reduction in anti-BCMA CAR expression. (Figure 11A) T cell populations were transduced with 4x8-5x107 transducing units of lentivirus encoding the anti-BCMA CAR molecule (MOI 5-40). The resulting T cell populations were normalized to contain 26±4% anti-BCMA CAR positive T cells. (Figure 11B) The MFI of normalized anti-BCMA CAR T cells ranged from 885-1875 as assayed by flow cytometry. (Figure 11C) K562 and K562-BCMA cells were co-cultured with normalized anti-BCMA CAR T cells at effector (E; T cells) to target (T; 1:1 mixture of K562 and K562 BCMA cells) ratios of 20:1 or 10:1 and showed comparable cytolytic activity.

[0039] [Figure 12A] Figure 1 shows the reliability of the anti-BCMA CAR T cell manufacturing process. Anti-BCMA CAR T cell products manufactured from PBMCs of 11 individual donors show comparable levels of expansion compared to corresponding cultures of non-transduced donor T cells. [Figure 12B] Demonstrating the reliability of the anti-BCMA CAR T cell manufacturing process. Anti-BCMA CAR T cell products manufactured from 11 donors showed comparable lentiviral transduction efficiencies (VCN). [Figure 12C] Demonstrating the reliability of the anti-BCMA CAR T cell manufacturing process. Prevalence of anti-BCMA CAR positive T cells was measured by flow cytometry and BCMA expression was found to be comparable across all donors. [Figure 12D] The reliability of the anti-BCMA CAR T cell manufacturing process is demonstrated. Anti-BCMA CAR T cell products manufactured from 11 donors demonstrated therapeutically relevant levels of IFNγ release when exposed to BCMA-expressing K562 cells.

[0040] [Figure 13] Venn diagram of CD127, CD197 and CD38 co-expression in CD62L positive anti-BCMA02 T cells cultured for 10 days in the presence of IL-2 or IL-2 and ZSTK474. Anti-BCMA02 CAR T cells treated with ZSTK474 showed an increased percentage of cells co-expressing CD127, CD197 and CD38 compared to anti-BCMA CAR T cells cultured with IL-2 only.

[0041] [Figure 14] Cultures treated with IL-2 and ZSTK474 (n=7) show an increased percentage of CD8-expressing anti-BCMA02 CAR T cells compared to cultures treated with IL-2 alone. CD8 expression was determined using a fluorescently labeled anti-CD8 antibody and flow cytometry.

[0042] [Figure 15] Figure 1 shows the amount of IFN-γ released by anti-BCMA02 CAR T cells from 14 donors after culture with IL-2 alone or IL-2 and ZSTK474. At the end of the culture period, the same number of anti-BCMA02 CAR T cells were re-cultured with medium alone for 24 hours. The amount of IFN-γ released at 24 hours was quantified by ELISA. Culture in ZSTK474 did not significantly increase sustained cytokine release of anti-BCMA02 CAR T cells compared to anti-BCMA02 CAR T cells cultured with IL-2 alone.

[0043] [Figure 16]Figure 1 shows the anti-tumor activity of anti-BCMA02 CAR T cells treated with IL-2, or IL-2 and ZSTK474, or truncated signaling-deficient anti-BCMA02 (tBCMA02) CAR T cells treated with IL-2 and ZSTK474 in the progressive Daudi tumor model. Complete tumor regression was observed in 50% of mice receiving anti-BCMA02 CAR T cells treated with IL-2 and ZSTK474.

[0044] [Figure 17] Figure 1 shows the anti-tumor activity of anti-BCMA02 CAR T cells treated with IL-2, or IL-2 and ZSTK474 in a multiple myeloma tumor (RPMI-8226) model. Animals treated with anti-BCMA02 CAR T cells cultured with IL-2 or IL-2 and ZSTK474 completely prevented tumor growth.

[0045] 4. Brief description of sequence identifiers SEQ ID NOs: 1-3 are exemplary light chain CDR sequences for BCMA CARs contemplated herein. The amino acid sequence of

[0046] SEQ ID NOs: 4-6 are exemplary heavy chain CDR sequences for BCMA CARs contemplated herein. The amino acid sequence of

[0047] SEQ ID NO:7 is the amino acid sequence of an exemplary light chain sequence of a BCMA CAR contemplated herein. The sequence is described.

[0048] SEQ ID NO:8 is the amino acid sequence of an exemplary heavy chain sequence of a BCMA CAR contemplated herein. The sequence is described.

[0049] SEQ ID NO: 9 describes the amino acid sequence of an exemplary BCMA CAR contemplated herein. do.

[0050] SEQ ID NO: 10 is a polynucleotide encoding an exemplary BCMA CAR contemplated herein. The nucleotide sequence is given below.

[0051] SEQ ID NO:11 sets forth the amino acid sequence of human BCMA.

[0052] SEQ ID NOs: 12 to 22 set forth the amino acid sequences of various linkers.

[0053] SEQ ID NOs: 23 to 35 are the addresses of protease cleavage sites and self-cleaving polypeptide cleavage sites. The amino acid sequence is given below.

[0054] SEQ ID NO: 36 depicts the polynucleotide sequence of a vector encoding BCMA CAR. Posted. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0055] 5. Detailed Description 5.1. Overview The present invention relates generally to improved compositions and methods for treating B-cell associated conditions. As used herein, the term "B cell-associated condition" refers to inappropriate B cell activity. and for conditions associated with B-cell malignancies.

[0056] In certain embodiments, the present invention uses genetically modified immune effector cells. The genetic approach is directed at improving adoptive cell therapy for B cell-related conditions. These findings provide a potential means to enhance immune recognition and elimination of cancer cells. One promising strategy is to Immunoglobulins have been engineered to express chimeric antigen receptors (CARs) that redirect cytotoxicity to cancer cells. However, the only way to treat B cell disorders is to genetically engineer immune effector cells. Existing adoptive cellular immunotherapy for B-cell immunization involves the use of adoptive cells on all or a majority of B cells. Because they target antigens expressed on the retina, there is a significant risk of compromising humoral immunity. Thus, such therapy is clinically undesirable and has been well received in the art. There is a need for more efficient therapies that preserve humoral immunity and treat B cell-related conditions.

[0057] The improved compositions and methods of adoptive cell therapy disclosed herein include those that target B cell maturation antigens ( BCMA, CD269 or tumor necrosis factor receptor superfamily member 17;T This can be facilitated by targeting B cells that express NFRSF17, also known as It was shown that the IL-161-dependent IL-16 receptor agonist (IL-16) can proliferate, persist long-term in vivo, and reduce humoral immune dysfunction. The present invention provides genetically modified immune effector cells that can

[0058] BCMA is a member of the tumor necrosis factor receptor superfamily (e.g., Th ompson et al., J. Exp. Medicine, 192(1):129- 135,2000, and Mackay et al., Annu. Rev. Immuno l, 21:231-264, 2003). BCMA is a B cell activating factor (BAFF). ) and proliferation-inducing ligand (APRIL) (see, e.g., Mackay et al. ., 2003 and Kalled et al., Immunological Revi. ews, 204:43-54, 2005). Among non-malignant cells, BCMA is primarily It has been reported to be expressed in a subset of plasminogen activators and mature B cells (e.g., L aabi et al.,EMBO J.,77(1):3897-3904,1992 ;Laabi et al., Nucleic Acids Res.,22(7):1 147-1154,,1994;Kalled et al.,2005;O'Conn or et al., J. Exp. Medicine, 199(1):91-97,20 04; and Ng et al., J. Immunol., 73(2):807-817, 2004. BCMA-deficient mice are healthy and have normal numbers of B cells but have a long life span. plasma cell survival is impaired (e.g., O'Connor et al., 2004 ; Xu et al.,Mol.Cell.Biol.,21(12):4067-407 4, 2001; and Schiemann et al., Science, 293(55 37):2 111-21 14, 2001. BCMA RNA is a signaling molecule that is essential for the development of multiple myeloma. BCMA protein has been widely detected in leukocyte and other lymphomas, and has been shown to be It has been detected on the surface of plasma cells from patients with multiple myeloma by researchers (e.g., Nova k et al.,Blood,103(2):689-694,2004;Neri et al., Clinical Cancer Research, 73(19):5 903-5909,2007;Bellucci et al.,Blood,105( 10):3945-3950, 2005; and Moreaux et al., Bloo d,703(8):3148-3157,2004.

[0059] In various embodiments, a CAR comprising a mouse anti-BCMA antibody sequence is synthesized by inducing expression of a specific human antibody. It was highly effective compared to BCMA CARs containing the CAR sequence and showed robust in vivo proliferation. It recognizes human B cells expressing BMCA and induces cytotoxicity against BCMA-expressing B cells. The cytokines released by activated T cells induce a rapid inflammatory response in the body. This is a cytokine storm, a deadly condition that accelerates non-infectious fevers by triggering No inciting symptoms.

[0060] In one embodiment, the mouse anti-BCMA antibody or antigen-binding fragment, the transmembrane domain, and and one or more intracellular signaling domains.

[0061] In one embodiment, the immune effector cells express a CAR as contemplated herein. A T cell expressing a CAR is herein referred to as a CAR. These are called T cells or CAR-modified T cells.

[0062] In various embodiments, the genetically modified immune effector cells contemplated herein The cells are used to treat B cell-associated conditions, such as B cell-associated autoimmune diseases or B cell malignancies. It is administered to patients with

[0063] The practice of the present invention is based on chemical compounds within the skill of the art, unless expressly stated to the contrary. Chemistry, Biochemistry, Organic Chemistry, Molecular Biology, Microbiology, Recombinant DNA Technology, Genetics, Immunology and cell biology, many of which are presented for illustrative purposes only. Such techniques are fully explained in the literature. Mbrook, et al., Molecular Cloning: A Labora tory Manual(3rd Edition,2001);Sambrook,e t al.,Molecular Cloning:A Laboratory Man ual(2nd Edition,1989);Maniatis et al.,Mo lecular Cloning:A Laboratory Manual(1982 );Ausubel et al.,Current Protocols in Mo lecular Biology(John Wiley and Sons,upda ted July 2008);Short Protocols in Molecu lar Biology:A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub.Associates and Wiley-Intersci ence;Glover,DNA Cloning:A Practical Appr oach,vol.I & II(IRL Press,Oxford,1985);A nand,Techniques for the Analysis of Comp lex Genomes,(Academic Press,New York,199 2);Transcription and Translation(B.Hames & S.Higgins,Eds.,1984);Perbal,A Practic al Guide to Molecular Cloning(1984);Harl ow and Lane,Antibodies,(Cold Spring Harb or Laboratory Press,Cold Spring Harbor,N .Y.,1998)Current Protocols in Immunology Q.E.Coligan,A.M.Kruisbeek,D.H.Margulies ,EM Shevach and W. Strober, eds.,1991);An and Advances in Immunology; Please refer to research articles in journals such as Immunology.

[0064] 5.2.Definition Unless otherwise defined, all technical and scientific terms used herein belong to the present invention. The term "convertible phosphate" has the same meaning as that commonly understood by those skilled in the art. Any methods and materials similar or equivalent to those described herein may be used for the implementation or testing of the present invention. Although any of the above methods may be used, preferred embodiments of the compositions, methods and materials are described herein. For purposes of the present invention, the following terms are defined below.

[0065] The articles "a," "an," and "the" are used herein to refer to the grammatical meaning of the article. The target word is one or more than one (i.e., at least one or more than one) For example, "an element" is used to refer to one " means an element or one or more elements of

[0066] The use of alternatives (e.g., "or") means either one, both, or both of the alternatives. It is to be understood that any combination is meant.

[0067] The term "and / or" means either or both of the alternatives. I want to be understood.

[0068] As used herein, the terms "about" or "approximately" refer to a quantity, level, or quantity of interest. 15 for a rule, value, number, frequency, percentage, dimension, size, amount, weight or length Fluctuates by %, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% Specifies a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length. In one embodiment, the term "about" or "approximately" refers to a reference quantity, level, or ±15% for values, numbers, frequencies, percentages, dimensions, sizes, amounts, weights or lengths , ±10%, ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, or ±1% of quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or indicates a range of lengths.

[0069] Throughout this specification, unless the context otherwise requires, the words "comprises" and "includes" are used interchangeably. The terms "includes" and "comprises" and "comprising" are used interchangeably. The phrase "inclusion of" or "substitution of" indicates the inclusion of the specified step or element or group of steps or elements. but does not imply the exclusion of any other step or element or group of steps or elements. It is understood that "consisting of" does not mean " "consisting of" means including and limited to the items that follow. "consisting of" means that the listed elements are necessary or mandatory and other elements are not present. "consisting essentially of" "of" includes any element listed after that phrase and excludes other elements from the list. that do not interfere with or contribute to the activity or function specified in the disclosure of the element being Therefore, the phrase "consisting essentially of" means that the An element is necessary or essential, but does not substantially affect the activity or function of the listed elements. indicates that the element does not exist.

[0070] Throughout this specification, the terms "one embodiment," "embodiment," "particular embodiment," "related embodiment," "relevant embodiment," "relevant" and "relevant" are used interchangeably. "embodiment," "certain embodiment," "additional embodiment," or "further embodiment" " or combinations thereof are intended to be illustrative of the particular features, structures, or a feature is included in at least one embodiment of the present invention. The appearance of the above phrases in various places throughout this specification does not necessarily all refer to the same embodiment. Moreover, any particular feature, structure, or characteristic may be incorporated in or on the basis of one or more embodiments. In one embodiment, the combination may be performed in any suitable manner. It is also understood that the express recitation of a feature constitutes a basis for excluding that feature in a particular embodiment. .

[0071] 5.3. Chimeric Antigen Receptors In various embodiments, the cytotoxicity of immune effector cells is redirected to B cells. These engineered receptors are described herein. Herein, this is referred to as a chimeric antigen receptor (CAR). CARs are used to bind to a desired antigen (e.g., BCM A) combines antibody-based specificity with the T cell receptor activating intracellular domain The present invention relates to a method for the production of chimeric proteins that exhibit specific anti-BCMA cellular immune activity. When used in, the term "chimera" refers to various proteins or DNA of different origins. This describes that it is composed of part A.

[0072] The CARs contemplated herein comprise an extracellular domain that binds to BCMA (the binding domain or (also called antigen-specific binding domain or antigen-specific binding domain), transmembrane domain, and intracellular signal transduction domain. The CAR contains an anti-BCMA antigen-binding domain and BCMA on the surface of the target cell. Upon binding, clustering of the CAR occurs and an activating stimulus is transmitted to the CAR-containing cell. The main feature of CARs is their ability to redirect the specificity of immune effector cells. This allows for cell-specific targeting of monoclonal antibodies, soluble ligands or cell-specific co-transduction They use receptors to mediate proliferation, cytokine production, phagocytosis, or cell death of target antigen-expressing cells. It induces the production of molecules capable of mediating immune responses in a major histocompatibility (MHC)-independent manner.

[0073] In various embodiments, the CAR comprises a mouse anti-BCMA specific binding domain. an extracellular binding domain; a transmembrane domain; one or more intracellular costimulatory signaling domains; and Contains the primary signaling domain.

[0074] In certain embodiments, the CAR comprises a murine anti-BCMA antibody or an antigen-binding fragment thereof. an extracellular binding domain comprising one or more hinge or spacer domains; a transmembrane domain containing an intracellular costimulatory signaling domain; and a primary signaling domain Including the main.

[0075] 5.3.1. Binding Domains In certain embodiments, the CARs contemplated herein are human B A mouse anti-BCMA antibody or antigen-binding fragment thereof that specifically binds to a CMA polypeptide. As used herein, a "binding domain," a "cell "Extracellular domain", "extracellular binding domain", "antigen-specific binding domain", and "extracellular The term "antigen-specific binding domain" is used interchangeably and refers to a domain that binds a target antigen of interest, e.g. The present invention provides a CAR capable of specifically binding to BCMA. The binding domain may be natural or synthetic. The polypeptides may be derived from either recombinant, semi-synthetic, or recombinant sources.

[0076] "Specific binding affinity" or "specifically binds" or "specifically bound" or The terms "specifically bind" or "specifically target" as used herein The anti-BCMA antibody or its antigen-binding fragment (or CAR containing the same) The binding affinity of the antibody to BCMA is greater than that of the antibody binding to the BCMA. A fusion protein containing the CAR or binding domain (or a fusion protein containing the CAR or binding domain) ) is, for example, about 10 5 M -1 or higher affinity or K a (i.e., specified in units 1 / M If a compound binds to or associates with BCMA with a constant β-blocking agent (the equilibrium association constant for the binding interaction of β-blocking agent and β-blocking agent), it is considered to be “specifically associated” with BCMA. In certain embodiments, the binding domain (or a fusion protein thereof) The quality of the material is about 10 6 M -1 , 10 7 M -1 , 10 8 M -1 , 10 9 M -1 , 10 10 M - 1 , 10 11 M -1 , 10 12 M -1 , or 10 13 M -1 More than K a Binds to target A "high affinity" binding domain (or a single-chain fusion protein thereof) has a binding affinity of at least 10 7 M -1 , at least 10 8 M -1 , at least 10 9 M -1 , at least 10 10 M - 1 , at least 10 11 M -1 , at least 10 12 M -1 , at least 10 13 M -1 , or more K a It refers to a binding domain having the following structure:

[0077] Alternatively, affinity is expressed as the equilibrium dissociation constant (K) of a particular binding interaction in units M. d )(for example , 10 -5 M~10 -13 M or less). The affinity of the domain polypeptide and the CAR protein can be determined using conventional techniques, e.g. , by competitive ELISA (enzyme-linked immunosorbent assay) or by using labeled ligands. , or Biacore T100 (Biacore, Inc. (Piscatawa A surface plasmon resonance instrument such as the one available from Epson (NYSE: EPSON) or the EPIC system can also be used. or EnSpire (sourced from Corning and Perkin Elmer, respectively) By binding, association, or displacement assays using optical biosensor technologies such as , can be readily determined (see, for example, Scatchard et al. 949) Ann. NY Acad. Sci. 51:660; and U.S. Pat. No. 5,283,336. ,173; see also 5,468,614, or equivalents).

[0078] In one embodiment, the affinity of specific binding is about 2-fold greater than background binding. Approximately 5 times higher than background binding, approximately 10 times higher than background binding, Approximately 20 times higher than background binding, approximately 50 times higher than background binding, about 100-fold greater than background binding, or about 1000-fold or greater than background binding. stomach.

[0079] In certain embodiments, the extracellular binding domain of a CAR is an antibody or an antigen-binding fragment thereof. "Antibody" refers to a molecule that contains an antigenic determinant, such as one that is recognized by immune cells. A light molecule that specifically recognizes and binds to an epitope of an antigen, such as a peptide, lipid, polysaccharide, or nucleic acid. A binding agent that is a polypeptide comprising at least a low or high immunoglobulin variable region. Point.

[0080] "Antigen (Ag)" refers to a compound, composition, or substance capable of stimulating the production of antibodies or a T-cell response in an animal, including compositions that are injected or absorbed into an animal, such as compositions that include a cancer-specific protein. Antigens react with the products of specific humoral or cellular immunity, including immunity elicited by heterologous antigens, such as those of the present disclosure. In certain embodiments, the target antigen is an epitope of a BCMA polypeptide.

[0081] "Epitope" or "antigenic determinant" refers to a region of an antigen to which a binding agent binds. A pitope is a set of non-terminal amino acids juxtaposed by contiguous amino acids or by tertiary folding of a protein. Epitopes formed from consecutive amino acids can be either Typically, epitopes formed by tertiary folding are preserved upon exposure to denaturing solvents. Epitopes are typically lost upon treatment with denaturing solvents. Epitopes are typically at least Typically, the amino acid sequence is at least 3, more typically at least 5, about 9, or about 8-10 amino acids. It contains a complex spatial three-dimensional structure.

[0082] The antibodies include camel Ig, Ig NAR, Fab fragments, Fab' fragments, and F(ab)'2 fragments. fragment, F(ab)'3 fragment, Fv, single chain Fv protein ("scFv"), bis-scF v, (scFv)2, minibody, diabody, triabody, tetrabody, disulfide Fido-stabilized Fv proteins ("dsFv"), and single domain antibodies (sdAbs, nano Antibody antigen-binding fragments include the portion of a full-length antibody that is involved in antigen binding. The term also refers to chimeric antibodies (e.g., humanized murine antibodies), heteroconjugates, Also included are genetically engineered forms of antibodies (including bispecific antibodies) and antigen-binding fragments thereof. Pierce Catalog and Handbook,1994-1995(Pi erce Chemical Co., Rockford, IL); Kuby, J., I mmunology,3rd Ed.,WHFreeman & Co.,New See also York, 1997.

[0083] As will be appreciated by those of skill in the art, and as described elsewhere herein, a complete antibody may be Each heavy chain comprises a variable region and a first, second, and third amino acid sequence. Each light chain consists of a variable region and a constant region. Mammalian light chains are classified as either α, δ, ε, γ, or μ. Mammalian light chains are classified as either λ or κ. Immunoglobulins containing delta, epsilon, gamma, and mu heavy chains are classified as immunoglobulin (Ig) A, IgD, They are classified as IgE, IgG, and IgM. Complete antibodies form a "Y" shape. The stem of the IgE and IgM proteins is composed of the second and third constant regions, which are joined together by the two heavy chains. In the case of , the fourth constant region is also composed of a disulfide bond (interchain) formed in the hinge. The heavy chains γ, α, and δ are composed of three tandem Ig domains. The heavy chains μ and ε have a constant region that binds the four immunoglobulins, and a hinge region that enhances flexibility. The second and third constant regions are each composed of a C Each arm of the Y is called the H2 domain and the CH3 domain of a single light chain. It contains a variable region and a first constant region of a single heavy chain combined with a variable region and a constant region. and the variable region of the heavy chain is responsible for antigen binding.

[0084] The light and heavy chain variable regions each contain three complementarity determining regions (CDRs). They contain "framework" regions interrupted by hypervariable regions. CDRs are conventionally Thus, for example, Kabat et al. (Wu, TT and Kabat, EA ,J Exp Med.132(2):211-50,(1970);Borden,P .and Kabat EA,PNAS,84:2440-2443(1987); (Kabat et al., Sequences of Proteins of I mmunological interest,USDepartment of See Health and Human Services, 1991; see also ) or by the sequence according to Chothia et al. ia, C. and Lesk, AM, J Mol. Biol., 196(4):90 1-917(1987), Chothia, C. et al, Nature, 342:8 The term "structure" can be defined or identified by its structure, as defined by the International Standards Board of Education (ISBN 77-883 (1989)).

[0085] The framework region sequences of various light and heavy chains are relatively conserved among species, including humans. The framework region of an antibody, i.e., the framework for the constituent light and heavy chains, The combined CDRs serve to position and align the CDRs in three-dimensional space. The CDRs of each chain are typically designated CDR1, CDR2, CDR3, CDR4, CDR5, CDR6, CDR7, CDR8, CDR9, CDR10, CDR11, CDR12, CDR13, CDR14, CDR15, CDR16, CDR17, CDR18, CDR19, CDR111, CDR112, CDR113, CDR114, CDR115, C CDRs 1, 2, and 3 are numbered sequentially from the N-terminus. Typically, each CDR is Thus, the C The DRs are designated CDRH1, CDRH2, and CDRH3 and correspond to the variable domains of the antibody light chain. The CDRs located in the different regions are called CDRL1, CDRL2, and CDRL3. Antibodies with different binding sites for different antigens (i.e., different binding sites for different antigens) have different CDRs. CDRs differ from antibody to antibody, but only a limited number of CDRs are directly involved in antigen binding. These positions within the CDRs are called specificity determining residues (SDRs). The light chain C suitable for constructing the humanized BCMA CAR contemplated herein is Illustrative examples of DR include the CDR sequences set forth in SEQ ID NOs: 1 to 3. Suitable for constructing the humanized BCMA CAR contemplated herein include, but are not limited to, Illustrative examples of suitable heavy chain CDRs include the CDR sequences set forth in SEQ ID NOs: 4 to 6. However, it is not limited to these.

[0086] "V H References to " or "VH" refer to the variable region of an immunoglobulin heavy chain, an antibody, and / or any of the antibody fragments disclosed herein, including those of the Fab, scFv, dsFv, Fab, or other antibody fragments disclosed herein. "V L References to "VL" or "VL" refer to the variable region of an immunoglobulin light chain, an antibody, Fv, scFv, dsFv, Fab, or other antibody fragments disclosed herein. include.

[0087] A "monoclonal antibody" is a antibody produced by a single clone of B lymphocytes or by the immunoreaction of a single antibody. The antibody produced by cells transfected with the monoclonal and heavy chain genes. Local antibodies can be produced by methods known to those skilled in the art, for example, by fusion of myeloma cells with immune spleen cells. They are produced by creating hybrid antibody-forming cells. includes humanized monoclonal antibodies.

[0088] "Chimeric antibodies" are antibodies that combine framework residues from one species, such as human, with those from another, such as mouse. and CDRs (which generally confer antigen binding) from another species. In one embodiment, the CAR contemplated herein is a chimeric antibody or an antigen-binding fragment thereof. The antibody comprises an antigen-specific binding domain.

[0089] A "humanized" antibody is one that has human framework regions and a non-human (e.g., mouse, rat, or and one or more CDRs derived from a human (or synthetic) immunoglobulin. The non-human immunoglobulin that provides the CDRs is called the "donor" and provides the framework. The donor human immunoglobulin is called the "acceptor."

[0090] In certain embodiments, the murine anti-BCMA antibody or antigen-binding fragment thereof includes, but is not limited to, camel Ig (camelid antibody (VHH)), Ig NAR, Fab Fragment, Fab' fragment, F(ab)'2 fragment, F(ab)'3 fragment, Fv, single chain Fv antibody ("scFv"), bis-scFv, (scFv)2, minibody, diabody, tribody abodies, tetrabodies, disulfide-stabilized Fv proteins ("dsFv"), and monoclonal antibodies Single domain antibodies (sdAbs, nanobodies) are included.

[0091] As used herein, "camelid Ig" or "camelid VHH" refers to a heavy chain antibody Refers to the smallest known antigen-binding unit (Koch-Nolte, et al., FASEB J., 21:3490-3498(2007)). "Antibody" refers to an antibody that contains two VH domains and no light chains (Riechm ann L. et al, J. Immunol. Methods 231:25-38( 1999);WO94 / 04678;WO94 / 25591;U.S. Pat. No. 79).

[0092] "IgNAR" stands for "immunoglobulin novel antigen receptor" and is a single variable novel antigen receptor. (VNAR) domain and a homodimer of five constant novel antigen receptor (CNAR) domains IgNAR refers to an antibody class derived from the shark immune repertoire consisting of the smallest They represent some of the best known immunoglobulin-based protein scaffolds and are extremely stable. Its inherent stability is due to (i) the fact that the underlying Ig scaffold has Compared to conventional antibody VH and VL domains found in antibodies, the charged, surface-exposed parent domains (ii) the presence of interloop disulfide bridges and intraloop water Both of the stabilizing structural features of the complementarity determining region (CDR) loops, including the pattern of molecular binding, This could be due to the following.

[0093] When antibodies are digested with papain, they are divided into fragments called "Fab" fragments, each of which contains a single antigen-binding site. Two identical antigen-binding fragments containing the ribozyme A (RI) and a residual "Fc" fragment are produced, and the Fc name is used. This reflects the ability to crystallize easily. Pepsin treatment yields the F(ab')2 fragment. This fragment has two antigen-binding sites and is still capable of cross-linking antigen.

[0094] "Fv" is the minimum antibody fragment that contains a complete antigen-binding site. Thus, two-chain Fv species contain one heavy chain variable domain and one light chain variable domain in tight, non-covalent association. In the case of single-chain Fv (scFv) species, it consists of one heavy chain variable domain and and one light chain variable domain can be covalently linked by a flexible peptide linker. This allows the light and heavy chains to associate in a "dimeric" structure similar to that of a two-chain Fv species. The three hypervariable regions (HVRs) of each variable domain interact to form the VH- It is in this configuration that defines an antigen-binding site on the surface of the VL dimer. As a whole, the six HVRs confer antigen-binding specificity to the antibody. Even if the main (or half of an Fv containing only three HVRs specific to an antigen) It has the ability to recognize and bind to antigen, although with lower affinity than the binding site.

[0095] The Fab fragment contains the heavy chain variable domain and the light chain variable domain, and the light chain constant domain. and the first constant domain (CH1) of the heavy chain. The Fab' fragment contains the heavy chain CH1 domain. At the carboxy terminus of the amino acid sequence, several residues, including one or more cysteines derived from the antibody hinge region, are Fab'-SH differs from Fab fragments in that it has an additional residue from the constant domain. is the designation herein for Fab' in which the stain residue(s) bear a free thiol group F(ab')2 antibody fragments are essentially Fab' fragments with hinge cysteines between the fragments. Other chemical couplings of antibody fragments are also known.

[0096] The term "diabody" refers to an antibody fragment that contains two antigen-binding sites, one light chain and one non-light chain. A heavy chain variable domain (VH) linked to a variable domain (VL) on the same polypeptide chain (VH -VL) that is short enough that pairing does not occur between the two domains on the same chain. By using a short linker, these domains can be paired with complementary domains on another chain. Diabodies can be bivalent or bispecific. Diabodies are described, for example, in EP 404,097; WO 1993 / 01161; Hud son et al., Nat. Med. 9:129-134 (2003); and Hol Linger et al., PNAS USA 90:6444-6448 (1993 ) Triabodies and tetrabodies are also described more fully in H Udson et al., Nat. Med. 9:129-134 (2003) It is being done.

[0097] A "single domain antibody" or "sdAb" or "nanobody" refers to a single domain antibody It refers to an antibody fragment consisting of the variable region (VH domain) or the variable region of the antibody light chain (VL domain). (Holt, L., et al, 2003, Trends in Biotechno logy,21(11):484-490).

[0098] "Single-chain Fv" or "scFv" antibody fragments are fragments of the VH and VL domains of an antibody. These domains may be present in a single polypeptide chain in any orientation (e.g., VL Generally, the scFv polypeptide comprises a VH domain, a VH domain-VH or a VH-VL. and a polypeptide linker between the VL domain, thereby enabling the scFv to bind to an antigen. This allows the scFv to form the desired structure for binding. Pluckthun,The Pharmacology of Monoclonal Antibodies,vol.113,Rosenburg and Moore eds., (Springer-Verlag, New York, 1994), pp. See 269-315.

[0099] In certain preferred embodiments, the CAR contemplated herein is a murine scFv. Single chain antibodies contain a specific antigen-binding domain. The V region genes of such hybridomas can be cloned from the V region genes of the hybridomas. The variable region of the heavy chain (V H ) and the variable light chain (V L ) to clone The techniques that can be used for this purpose are described, for example, in Orlandi et al., PNAS, 1 989;86:3833-3837.

[0100] In certain embodiments, the antigen-specific binding domain is linked to a human BCMA polypeptide. A preferred scFv for constructing the BCMA CAR contemplated herein is a mouse scFv that binds to the BCMA CAR. Illustrative examples of suitable variable heavy chains include, but are not limited to, those set forth in SEQ ID NO:8. The amino acid sequences are suitable for constructing the BCMA CARs contemplated herein. Illustrative examples of suitable variable light chains include, but are not limited to, the amino acid sequence set forth in SEQ ID NO:7. amino acid sequences.

[0101] The BCMA-specific binding domains provided herein also include 1, 2, 3, 4, 5, or The CDRs include CDRL1, CDRL2 and CDR L3 and CDRH1, CDRH2 and CDRH3 of the heavy chain. In certain embodiments, the CDRs may be BCMA specific or modified non-human CDRs. The heterologous binding domain comprises (a) a light chain CDRL1, a light chain CDRL2, and a light chain CDRL3. and (b) a light chain variable region comprising a heavy chain CDRH1, a heavy chain CDRH2, and a heavy chain CDRH3. and a heavy chain variable region.

[0102] Linker In certain embodiments, the CARs contemplated herein have between the various domains: For example, it may include linker residues added for proper spacing and conformation of the molecule. In certain embodiments, the linker is a variable region linking sequence. , V H and V L Spacer that links the domains and accommodates the interaction of the two sub-binding domains The resulting polypeptide has the same light chain and The antibody comprises a heavy chain variable region and a heavy chain variable region and retains the same specific binding affinity for the target molecule. The CARs contemplated herein may include one, two, three, four, five or more linkers. In this embodiment, the length of the linker is about 1 to about 25 amino acids, about 5 to about 20 amino acids, An amino acid, or about 10 to about 20 amino acids, or any length therebetween. In some embodiments, the linker is 1, 2, 3, 4, 5, 6, 7, 8 , 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 2 2, 23, 24, 25 or more amino acids in length.

[0103] Illustrative examples of linkers include glycine polymers (G) n ;Glycine-serine polymer -(G 1-5 S 1-5 ) n (where n is an integer of at least 1, 2, 3, 4, or 5) glycine-alanine polymers; alanine-serine polymers; and Other flexible linkers known in the art include glycine and glycine- Serine polymers are relatively unstructured and therefore may be used in the CA It may be possible for the fusion protein to function as a neutral tether between domains of a fusion protein such as R. Glycine also has much more Φ-Ψ space available than alanine and has a long side chain. Residues are less restricted than residues (Scheraga, Rev. Computational C hem. 11173-142 (1992). Those skilled in the art will appreciate that in particular embodiments The design of the CAR may include a fully or partially flexible linker, so that Therefore, the linker should be flexible as well as flexible linker to provide the desired CAR structure. , it will be appreciated that the structure may also include one or more portions that provide a less flexible structure.

[0104] Other exemplary linkers include the following amino acid sequences: GGG;DGGGS (SEQ ID NO:1) 2); TGEKP (SEQ ID NO: 13) (see, e.g., Liu et al., PNAS 552 5-5530 (1997); GGRR (SEQ ID NO: 14) (Pomerantz t al.1995, supra);(GGGGS) n (where n=1, 2, 3, 4 or 5 and GGGGS is identified as SEQ ID NO: 15 (Kim et al., PNAS 93,1156-1160(1996.);EGKSSGSGSESKVD(SEQ ID NO: 16)(Chaudhary et al., 1990, Proc. Natl. Acad .Sci.USA87:1066-1070);KESGSVSSEQLAQFR SLD (SEQ ID NO: 17) (Bird et al., 1988, Science 242 : 423-426), GGRRGGGS (SEQ ID NO: 18); LQRDGERP (SEQ ID NO: No. 19); LRQKDGGGSERP (SEQ ID NO: 20); LRQKd(GGGS)2ER P (SEQ ID NO: 21). The anchor is a computer program capable of modeling both the DNA binding site and the peptide itself. Using a computer program (Desjarlais & Berg, PNAS 90: 2256-2260 (1993), PNAS 91:11099-11103 (1994 ), or can be rationally designed by phage display methods. In one embodiment, the linker has the following amino acid sequence: GSTSGSGKPGSGEGSTKG ( SEQ ID NO:22) (Cooper et al., Blood, 101(4):1637- 1644 (2003)).

[0105] 5.3.3. Spacer Domain In certain embodiments, the binding domain of a CAR can be further comprised of one or more "spacer domains." " which allows for proper cell / cell contact, antigen binding and activation. This refers to the region that separates the antigen-binding domain from the effector cell surface so that the et al., Gene Therapy, 1999;6:412-419). Spacer The domains may be derived from either natural, synthetic, semi-synthetic, or recombinant sources. In certain embodiments, the spacer domain can include, but is not limited to, one or more overlapping The part of an immunoglobulin that contains the chain constant regions, e.g., CH2 and CH3. Spacer The domain may be a natural or modified immunoglobulin hinge region. The amino acid sequence of the region may be included.

[0106] In one embodiment, the spacer domain comprises the CH2 and C of IgG1 or IgG4. Contains the H3 domain.

[0107] Hinge domain The binding domain of a CAR is generally followed by one or more "hinge domains" that The main focus is on the antigen-binding domain to allow proper cell / cell contact, antigen binding and activation. CARs generally serve to localize the target domain away from the effector cell surface. It contains one or more hinge domains between the binding domain and the transmembrane domain (TM). The domains may be derived from either natural, synthetic, semi-synthetic, or recombinant sources. The main sequence is a natural or modified immunoglobulin hinge region. It may comprise an amino acid sequence.

[0108] An "altered hinge region" refers to a region that has (a) up to 30% amino acid changes (e.g., up to 25 %, 20%, 15%, 10%, or 5% amino acid substitutions or deletions) (b) regions with up to 30% amino acid changes (e.g., up to 25%, 20%, 15%, 10% 10 amino acids in length (e.g., 5% amino acid substitutions or deletions) a portion of the native hinge region that is at least 12, 13, 14 or 15 amino acids in length; or (c) Core hinge region (4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, if At least 15, or at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, The term refers to a portion of the native hinge region that includes the nucleotide sequence of the nucleotide sequence (which may be 15 or 16 amino acids long). In embodiments, one or more cysteine ​​residues in a native immunoglobulin hinge region are or more other amino acid residues (e.g., one or more serine residues). The modified immunoglobulin hinge region may alternatively or additionally be a wild-type immunoglobulin hinge region. The proline residue in the range region may be replaced by another amino acid residue (e.g., a serine residue). do.

[0109] Other exemplary hinge domains suitable for use in the CARs described herein include are derived from the extracellular domains of type 1 membrane proteins such as CD8α, CD4, CD28, and CD7. The hinge regions of these molecules may be wild-type hinge regions or modified hinge regions. In another embodiment, the hinge domain comprises a CD8α hinge region.

[0110] 5.3.5. Transmembrane Domains The transmembrane (TM) domain fuses the extracellular binding moiety and the intracellular signaling domain. TM is the part of the CAR that anchors the CAR to the plasma membrane of immune effector cells. The domains may be derived from either natural, synthetic, semi-synthetic, or recombinant sources. In is the alpha, beta or zeta chain of the T cell receptor, CD3ε, CD3ζ, C D4, CD5, CD8α, CD9, CD16, CD22, CD27, CD28, CD33 , CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD 152, CD154, and PD-1 (i.e., at least these transmembrane In certain embodiments, the TM domain is synthetic and It contains mainly hydrophobic residues such as phenylalanine and valine.

[0111] In one embodiment, the CAR contemplated herein comprises a TM domain derived from CD8α. In another embodiment, the CAR contemplated herein is derived from CD8α. A preferred TM domain that links the TM domain of the CAR with the intracellular signaling domain. or short oligopeptides between 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids in length. and peptide or polypeptide linkers. Glycine-serine based linkers are particularly Provided is a linker suitable for

[0112] 5.3.6. Intracellular Signaling Domains In certain embodiments, the CARs contemplated herein comprise an intracellular signaling domain. "Intracellular signaling domain" refers to an intracellular signaling domain that is capable of binding to a human BCMA polypeptide. Transmitting the message of effective BCMA CAR binding to immune effector cells Functions of CAR cells, such as activation, cytokine production, proliferation and cytotoxic activity release of cytotoxic factors on target cells to which the CAR is bound, or release of the extracellular CAR domain of the antigen The portion of CAR that is involved in eliciting other cellular responses induced by binding to cytochrome P450. Point.

[0113] The term "effector function" refers to a specialized function of an immune effector cell. The effector functions of the cells include, for example, the production of helper proteins, including cytolytic activity or the secretion of cytokines. Thus, the term "intracellular signaling domain" refers to an effector Proteins that transmit signals for specific cell functions and direct the cell to perform specific functions. Usually, the entire intracellular signaling domain is employed, but in many cases In this case, it is not necessary to use the entire domain. When using a truncated portion, such a portion may be used as a signal for effector function. As long as it transmits the signal, it can be used in place of the entire domain. The term in refers to an intracellular signaling pathway sufficient to transmit the signal for effector function. The term "amino acid sequence" is intended to include any truncated portion of the target domain.

[0114] Signals generated through the TCR alone are not sufficient for full activation of T cells; It is known that a secondary or costimulatory signal is also required. Activation is achieved by primary antigen-dependent activation via the TCR (e.g., the TCR / CD3 complex). A primary signaling domain that initiates a secondary signal or co-stimulation in an antigen-independent manner. Two distinct classes of costimulatory signaling domains that act to provide stimulatory signals It can be said that the signal transduction is mediated by the intracellular signaling domain of In certain embodiments, the CARs contemplated herein comprise one or more "costimulatory signaling domains." " and a "primary signaling domain."

[0115] The primary signaling domain mediates the primary activity of the TCR complex, either stimulatory or inhibitory. The primary signaling domain that acts to stimulate immune receptors It may contain signal transduction motifs known as tyrosine-based activation motifs or ITAMs. do.

[0116] Illustrative examples of ITAMs containing primary signaling domains that are particularly useful in the present invention. These include TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, and C Particularly preferred are those derived from CD22, CD79a, CD79b, and CD66d. In one embodiment, the CAR comprises a CD3ζ primary signaling domain and one or more co-stimulatory domains. It contains a primary intracellular signaling domain and a costimulatory signaling domain. The reach domains can be linked in tandem to the carboxyl terminus of the transmembrane domain in any order. do.

[0117] The CARs contemplated herein are intended to enhance the efficacy and proliferation of T cells expressing the CAR receptor. As used herein, "co-stimulatory domains" refer to a set of one or more co-stimulatory signaling domains that act to upregulate the IL-1 signaling domain. The term "costimulatory signaling domain," or "costimulatory domain," refers to a co-stimulatory molecule. Refers to the intracellular signaling domain. Costimulatory molecules increase the efficiency of T lymphocytes upon binding to antigen. Other than antigen receptors or Fc receptors, they provide secondary signals necessary for efficient activation and function. Illustrative examples of such costimulatory molecules include CARD11, CARD21, CARD31, CARD41, CARD51, CARD61, CARD71, CARD81, CARD91, CARD101, CARD112, CARD113, CARD114, CARD115, CARD116, CARD117, CARD118, CARD119, CARD121, CARD122, CARD12 D2, CD7, CD27, CD28, CD30, CD40, CD54(ICAM), CD 83, CD134(OX40), CD137(4-1BB), CD150(SLAMF1 ), CD152 (CTLA4), CD223 (LAG3), CD270 (HVEM), C D273(PD-L2), CD274(PD-L1), CD278(ICOS), DAP 10, LAT, NKD2CSLP76, TRIM, and ZAP70. In one embodiment, the CAR is selected from the group consisting of CD28, CD137, and CD134. and one or more costimulatory signaling domains that are linked to the CD3ζ primary signaling domain. include.

[0118] In another embodiment, the CAR comprises CD28 and CD137 costimulatory signaling domains. and the CD3ζ primary signaling domain.

[0119] In yet another embodiment, the CAR is a CAR that expresses a CD28 and CD134 costimulatory signaling domain. It contains the CD3ζ primary signaling domain and the CD3ζ primary signaling domain.

[0120] In one embodiment, the CAR comprises CD137 and CD134 costimulatory signaling domains. and the CD3ζ primary signaling domain.

[0121] In certain embodiments, the CARs contemplated herein are BCs expressed on B cells. The present invention relates to a method for the preparation of a BCMA polypeptide comprising administering to a patient a therapeutically effective amount of a BCMA antibody or an antigen-binding fragment thereof, the method ... polypeptide, the method comprising administering to a patient a therapeutically effective amount of a BCMA antibody or an antigen-binding fragment thereof, the method comprising administering to a patient a therapeutically effective nothing.

[0122] In one embodiment, the CAR is a murine anti-BCMA that binds to a BCMA polypeptide. scFv; alpha, beta or zeta chains of the T cell receptor, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD16, CD22, CD27, CD28, CD3 3, CD37, CD45, CD64, CD80, CD86, CD134, CD137, C Membrane derived from a polypeptide selected from the group consisting of D152, CD154, and PD1 transmembrane domain; as well as CARD11, CD2, CD7, CD27, CD28, CD30 , CD40, CD54(ICAM), CD83, CD134(OX40), CD137( 4-1BB), CD150(SLAMF1), CD152(CTLA4), CD223( LAG3), CD270(HVEM), CD273(PD-L2), CD274(PD- L1), CD278(ICOS), DAP10, LAT, NKD2CSLP76, TRI M, and one or more intracellular costimulatory molecules selected from the group consisting of ZAP70, signaling domains; as well as TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, Primary clones derived from CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d It contains a signal transduction domain.

[0123] In one embodiment, the CAR is a murine anti-BCMA that binds to a BCMA polypeptide. scFv; alpha, beta or zeta chains of the T cell receptor, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD16, CD22, CD27, CD28, CD3 3, CD37, CD45, CD64, CD80, CD86, CD134, CD137, C Membrane derived from a polypeptide selected from the group consisting of D152, CD154, and PD1 transmembrane domain; as well as CARD11, CD2, CD7, CD27, CD28, CD30 , CD40, CD54(ICAM), CD83, CD134(OX40), CD137( 4-1BB), CD150(SLAMF1), CD152(CTLA4), CD223( LAG3), CD270(HVEM), CD273(PD-L2), CD274(PD- L1), CD278(ICOS), DAP10, LAT, NKD2CSLP76, TRI M, and one or more intracellular costimulatory molecules selected from the group consisting of ZAP70, signaling domains; as well as TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, Primary clones derived from CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d It contains a signal transduction domain.

[0124] In one embodiment, the CAR is a murine anti-BCMA that binds to a BCMA polypeptide. scFv; a hinge domain selected from the group consisting of IgG1 hinge / CH2 / CH3, IgG4 hinge / CH2 / CH3, and CD8α hinge; a transmembrane domain derived from a polypeptide selected from the group consisting of the alpha, beta or zeta chain of the T cell receptor, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD80, CD86, CD134, CD137, CD152, CD154, and PD1; and a polypeptide selected from the group consisting of CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 ( one or more intracellular costimulatory signaling domains derived from a costimulatory molecule selected from the group consisting of: OX40), CD137 (4-1BB), CD150 (SLAMF1), CD152 (CTLA4), CD223 (LAG3), CD270 (HVEM), CD273 (PD-L2), CD274 (PD-L1), CD278 (ICOS), DAP10, LAT, NKD2CSLP76, TRIM, and ZAP701; and one or more primary signaling domains derived from a polypeptide selected from the group consisting of TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD3 zeta, CD22, CD79a, CD79b, and CD66d.

[0125] In one embodiment, the CAR is a murine anti-BCMA that binds to a BCMA polypeptide. scFv; IgG1 hinge / CH2 / CH3, IgG4 hinge / CH2 / CH3, and C D8α hinge; the alpha chain of the T cell receptor, α or zeta chain, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD 80, CD86, CD134, CD137, CD152, CD154, and PD1 a transmembrane domain derived from a polypeptide selected from the group consisting of CARD11, CARD21, CARD31, CARD41, CARD51, CARD61, CARD71, CARD81, CARD91, CARD101, CARD112, CARD113, CARD124, CARD125, CARD136, CARD137, CARD141, CARD142, CARD143, CARD144 D2, CD7, CD27, CD28, CD30, CD40, CD54(ICAM), CD 83, CD134(OX40), CD137(4-1BB), CD150(SLAMF1 ), CD152 (CTLA4), CD223 (LAG3), CD270 (HVEM), C D273(PD-L2), CD274(PD-L1), CD278(ICOS), DAP 10, LAT, NKD2CSLP76, TRIM, and ZAP70 one or more intracellular costimulatory signaling domains derived from a costimulatory molecule selected from the group consisting of TCRζ , FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79 one or more of the polypeptides selected from the group consisting of CD79b, CD66d, and CD79e. The primary signaling domain of

[0126] In one embodiment, the CAR is a murine anti-BCMA that binds to a BCMA polypeptide. scFv; IgG1 hinge / CH2 / CH3, IgG4 hinge / CH2 / CH3, and C D8α hinge; the alpha chain of the T cell receptor, α or zeta chain, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD 80, CD86, CD134, CD137, CD152, CD154, and PD1 a transmembrane domain derived from a polypeptide selected from the group consisting of the TM domain of CAR; Linked to an intracellular signaling domain, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or a short oligopeptide or polypeptide linker between 10 amino acids in length; and CARD11, CD2, CD7, CD27, CD28, CD30, CD40, and CD54 (ICAM), CD83, CD134(OX40), CD137(4-1BB), CD1 50 (SLAMF1), CD152 (CTLA4), CD223 (LAG3), CD27 0(HVEM), CD273(PD-L2), CD274(PD-L1), CD278( ICOS), DAP10, LAT, NKD2CSLP76, TRIM, and ZAP70 one or more intracellular costimulatory signaling domains derived from a costimulatory molecule selected from the group consisting of: ; and TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, The primary signaling domains from CD22, CD79a, CD79b, and CD66d include.

[0127] In one embodiment, the CAR is a murine anti-BCMA that binds to a BCMA polypeptide. scFv; IgG1 hinge / CH2 / CH3, IgG4 hinge / CH2 / CH3, and C D8α hinge; the alpha chain of the T cell receptor, α or zeta chain, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD 80, CD86, CD134, CD137, CD152, CD154, and PD1 a transmembrane domain derived from a polypeptide selected from the group consisting of the TM domain of CAR; Linked to an intracellular signaling domain, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or a short oligopeptide or polypeptide linker between 10 amino acids in length; and CARD11, CD2, CD7, CD27, CD28, CD30, CD40, and CD54 (ICAM), CD83, CD134(OX40), CD137(4-1BB), CD1 50 (SLAMF1), CD152 (CTLA4), CD223 (LAG3), CD27 0(HVEM), CD273(PD-L2), CD274(PD-L1), CD278( ICOS), DAP10, LAT, NKD2CSLP76, TRIM, and ZAP70 one or more intracellular costimulatory signaling domains derived from a costimulatory molecule selected from the group consisting of: ; and TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, A polypeptide selected from the group consisting of CD22, CD79a, CD79b, and CD66d. The polypeptides contain one or more primary signaling domains derived from tid.

[0128] In certain embodiments, the CAR is a murine anti-BCMA polypeptide. A scFv; IgG1 hinge / CH2 / CH3 polypeptide and CD8α polypeptide a polypeptide linker of about 3 to about 10 amino acids; α transmembrane domain; CD137 intracellular costimulatory signaling domain; and CD3ζ The ribosome includes the second signaling domain.

[0129] In certain embodiments, the CAR is a murine anti-BCMA polypeptide. A scFv; a hinge domain comprising a CD8α polypeptide; from about 3 to about 10 amino acids The CD8α transmembrane domain containing the polypeptide linker; the CD134 intracellular costimulatory signal the CD3ζ primary signaling domain; and the CD3ζ primary signaling domain.

[0130] In certain embodiments, the CAR is a murine anti-BCMA polypeptide. A scFv; a hinge domain comprising a CD8α polypeptide; from about 3 to about 10 amino acids CD8α transmembrane domain with a polypeptide linker;CD28 intracellular costimulatory signal transduction domain; and the CD3ζ primary signaling domain.

[0131] In certain embodiments, the CAR is a murine anti-BCMA polypeptide. A scFv; CD8α polypeptide containing hinge domain; CD8α transmembrane domain; CD137 (4-1BB) intracellular costimulatory signaling domain; and CD3ζ primary signaling domain It contains a transduction domain.

[0132] Furthermore, the design of the CARs contemplated herein may be used in combination with unmodified T cells or other CARs. Proliferation, long-term improvement of T cells expressing CAR compared to T cells engineered to express R This allows for improved durability and acceptable cytotoxicity.

[0133] Polypeptides The invention relates, in part, to CAR polypeptides and fragments thereof, cells and compositions comprising same, As well as vectors expressing the polypeptides are contemplated. In a preferred embodiment, the sequence Polypeptides comprising one or more CARs as set forth in number 9 are provided.

[0134] The terms "polypeptide", "polypeptide fragment", "peptide" and "protein" are used interchangeably. and, unless expressly stated to the contrary, are used in accordance with their conventional meaning, i.e., a series of The amino acid sequence is used as the amino acid sequence. A polypeptide is not limited to a particular length, for example, a full-length polypeptide. It may include fragments of a protein sequence or a full-length protein, and may include post-translational modifications of a polypeptide, e.g. For example, glycosylation, acetylation, phosphorylation, and the like, as well as other modifications known in the art. In various embodiments, the present invention may include other modifications, both natural and non-natural, that are included in the A contemplated CAR polypeptide comprises a signal (or leader) sequence at the N-terminus of the protein. The present invention includes a sequence that directs the transport of the protein co- or post-translationally. Illustrative examples of suitable signal sequences useful in the CARs disclosed herein include IgG1 These include, but are not limited to, the heavy chain signal sequence and the CD8α signal sequence. The polypeptides may be synthesized using any of a variety of well-known recombinant and / or synthetic techniques. The polypeptides contemplated herein can be specifically prepared by the methods of the present disclosure. A sequence having a deletion of one or more amino acids of a CAR or a CAR disclosed herein; This includes sequences with additions and / or substitutions.

[0135] The terms "isolated peptide" or "isolated polypeptide" and the like are used herein. When a peptide or polypeptide is synthesized, it is absorbed from the cellular environment and from association with other components of the cell. refers to the in vitro isolation and / or purification of peptide molecules (i.e., in vivo Similarly, an "isolated cell" refers to an in vivo tissue. or cells obtained from an organ and are substantially free of extracellular matrix.

[0136] Polypeptides include "polypeptide variants." Polypeptide variants are The polypeptide may differ from the native polypeptide by one or more substitutions, deletions, additions and / or insertions. Such variants may be naturally occurring or may be, for example, variants of the above polypeptide sequences. For example, in certain embodiments, In this study, the binding domain, hinge, TM domain, and costimulatory signal transduction domain of the CAR polypeptide were One or more substitutions, deletions, additions, and / or deletions in the delivery domain or primary signaling domain Introducing insertions to improve the binding affinity and / or other biological properties of the CAR Preferably, the polypeptide of the present invention is At least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or a polypeptide having 99% amino acid identity.

[0137] Polypeptides include "polypeptide fragments." Polypeptide fragments may be naturally occurring or synthetic. Amino-terminal deletions, carboxyl-terminal deletions, and / or internal deletions of recombinantly produced polypeptides. or a polypeptide that may be a monomer or a polymer having substitutions. In one embodiment, the polypeptide fragment comprises an amino acid chain having a length of at least 5 to about 500 amino acids. In certain embodiments, the fragment may comprise at least 5, 6, 7, 8, 9, 10 , 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 3 7, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 , 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 150, It is understood that the nucleic acid sequence may be 200, 250, 300, 350, 400, or 450 amino acids long. Particularly useful polypeptide fragments are functional fragments that contain the antigen-binding domain or fragment of an antibody. For mouse anti-BCMA antibodies, useful fragments include the CD domain of the heavy or light chain. R3 region, CDR region; heavy or light chain variable region; one of the antibody chains that contains two CDRs These include, but are not limited to, a sequence or variable region.

[0138] The polypeptide may be used to facilitate synthesis, purification or identification of the polypeptide, or To enhance binding of the polypeptide to the solid support, a linker or other sequence (e.g. For example, the nucleic acid may be fused in-frame or conjugated to a poly-His.

[0139] As described above, the polypeptides of the present invention may include amino acid substitutions, deletions, truncations, and insertions. Such manipulations can be generally known in the art and can be modified in a variety of ways, including by the use of techniques known in the art. For example, amino acid sequence variants of a reference polypeptide may occur due to DNA mutations. Methods for mutagenesis and alteration of nucleotide sequences are well known in the art. For example, Kunkel (1985, Proc. Natl. Acad.Sci.USA.82:488-492), Kunkel et al.,( 1987, Methods in Enzymol, 154: 367-382), US No. 4,873,192, Watson, JDet al., (Molecula r Biology of the Gene,Fourth Edition,Ben jamin / Cummings, Menlo Park, Calif., 1987) and See the references cited therein. For guidance on appropriate amino acid substitutions that do not affect genomic DNA structure, see Dayhoff et al., (1978) Atlas of Protein Sequence and Structural cture(Natl.Biomed.Res.Found.,Washington, DC) model.

[0140] In certain embodiments, the variant contains conservative substitutions. is a peptide in which an amino acid is replaced with another amino acid that has similar properties. Those skilled in the art will appreciate that the secondary structure and hydrophobic and hydrophilic nature of the polypeptide can be substantially altered. It would be expected that the structures of the polynucleotides and polypeptides of the present invention would not Modifications can be made to produce variant or derivative polynucleotides that still have the desired properties. A functional molecule encoding a peptide is obtained. The amino acid sequence of the polypeptide is altered to It would be desirable to create variant polypeptides that are equivalent or even improved. In this case, the skilled artisan can, for example, identify one of the codons of the coding DNA sequence according to Table 1. One or more of the following may be changed: Table 1 - Amino acid codons [Table 1]

[0141] Any amino acid residue can be substituted, inserted, or deleted without losing biological activity. Guidance on determining whether to use the DNASTAR™ software is available in the art. These can be found using well-known computer programs in Alternatively, the amino acid changes in the protein variants disclosed herein are conservative amino acids. Conservative amino acid changes are substitutions of similar charged or uncharged amino acids. A natural acid change involves the substitution of one of a family of amino acids that are related in their side chains. Amino acids are generally divided into four families: acidic (aspartic acid, glutamic acid), basic polar (lysine, arginine, histidine), non-polar (alanine, valine, leucine, isopropyl isine, proline, phenylalanine, methionine, tryptophan), and uncharged polar (Glycine, Asparagine, Glutamine, Cysteine, Serine, Threonine, Tyrosine) Phenylalanine, tryptophan, and tyrosine are sometimes referred to as aromatic amino acids. In peptides or proteins, the amino acid preference is Such conservative substitutions are known to those of skill in the art and generally will not alter the biological activity of the resulting molecule. Those skilled in the art will generally recognize that a single amino acid in a non-essential region can be easily synthesized. It is recognized that acid substitutions do not substantially alter the biological activity of the polypeptide (e.g., Watson et al.Molecular Biology of the Ge ne,4th Edition,1987,The Benjamin / Cumming Exemplary conservative substitutions are described in U.S. Provisional Patent Application No. 61 / 2003. 41,647, the disclosure of which is incorporated herein by reference.

[0142] In making such changes, the hydropathic index of amino acids may be considered. The importance of the hydropathic amino acid index in conferring specific biological functions to proteins The thickness is generally understood in the art (Kyte and Doolit (See, e.g., 1982; incorporated herein by reference). Each amino acid is determined by its hydrophobicity and Based on the charge characteristics, hydropathic indices have been assigned (Kyte and Do olittle, 1982). The values ​​are isoleucine (+4.5); valine (+4.2 );Leucine(+3.8);Phenylalanine(+2.8);Cysteine / Cysteine( +2.5);Methionine(+1.9);Alanine(+1.8);Glycine(-0.4); Threonine (-0.7); Serine (-0.8); Tryptophan (-0.9); Tyrosine (-1.3); Proline (-1.6); Histidine (-3.2); Glutamic acid (-3. 5); Glutamine (-3.5); Aspartic acid (-3.5); Asparagine (-3.5 ); lysine (-3.9); and arginine (-4.5).

[0143] Certain amino acids may be more easily differentiated from other amino acids having a similar hydropathic index or score. It is possible to substitute the nucleotides and still obtain a protein with similar biological activity, i.e. That is, the ability to obtain biologically functional equivalent proteins is well within the skill of the art. When making such changes, it is important to select amines with hydrophobicity and hydrophilicity indices within ±2. Acid substitutions are preferred, with those within ±1 being particularly preferred, and those within ±0.5 being even more particularly preferred. It is also preferred that similar amino acid substitutions can be made effectively based on hydrophilicity. It is understood in the art.

[0144] As detailed in U.S. Pat. No. 4,554,101, the following hydrophilicity values ​​are assigned to amino acid residues: Assigned: Arginine (+3.0); Lysine (+3.0); Aspartic acid ( +3.0±1); glutamic acid (+3.0±1); serine (+0.3); asparagine ( +0.2);Glutamine(+0.2);Glycine(0);Threonine(-0.4);Pro Phosphorus (-0.5±1); Alanine (-0.5); Histidine (-0.5); Cysteine ​​( -1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); Soloeusine (-1.8); Tyrosine (-2.3); Phenylalanine (-2.5); Tri ptophan (-3.4). An amino acid is replaced by another amino acid that has a similar hydrophilicity value. It is still possible to produce biologically equivalent proteins, particularly immunologically equivalent proteins. It is understood that such a change can result in a protein with a hydrophilicity value of ±2. Amino acid substitutions within ±1 are preferred, those within ±0.5 are particularly preferred. Even more particularly preferred.

[0145] As outlined above, amino acid substitutions are determined based on the relative similarity of the amino acid side-chain substituents, e.g. This may be based on its hydrophobicity, hydrophilicity, charge, size, and the like.

[0146] Polypeptide variants include glycosylated forms, aggregative conjugates with other molecules, and covalent conjugates with unrelated chemical moieties (e.g., PEGylated molecules). Covalent variants are known in the art to be capable of resolving any of the above-mentioned problems found in the amino acid chain. They can be prepared by linking a functional group to the group that can be used or to the N- or C-terminal residues. Variants also include allelic variants, species variants, and muteins. Truncations or deletions of regions that do not affect the functional activity of the protein are also variants.

[0147] In one embodiment, where expression of more than one polypeptide is desired, the polypeptides encoding them are The polynucleotide sequence may be separated by an IRES sequence, as discussed elsewhere herein. In another embodiment, the two or more polypeptides can include one or more self-cleaving polypeptides. The polypeptide may be expressed as a fusion protein comprising a truncated polypeptide sequence.

[0148] The polypeptides of the present invention include fusion polypeptides. , fusion polypeptides and polynucleotides encoding the fusion polypeptides, e.g., CA Fusion polypeptides and fusion proteins are provided that have at least 2, 3, 4, 5 , 6, 7, 8, 9, or 10 or more polypeptide segments. Fusion polypeptides typically link the C-terminus to the N-terminus, but can also link the C-terminus to the C-terminus. Alternatively, the N-terminus may be linked to the N-terminus, or the N-terminus to the C-terminus. The polypeptides may be in any order or in a specified order. The fusion protein may also be modified with conservative modifications, so long as the desired transcriptional activity of the fusion polypeptide is preserved. Also includes variants, polymorphic variants, alleles, mutants, subsequences, and interspecies homologs. Fusion polypeptides can be produced by chemical synthesis or by chemical linkage between two moieties. Fusion polypeptides can be prepared by conventional techniques or generally using other standard techniques. The ligated DNA sequence comprising the above is preferably a transcription or translation vector as described elsewhere herein. Operatively linked to the control element.

[0149] In one embodiment, the fusion partner can be synthesized in a higher yield than the original recombinant protein. , which contain sequences that aid in the expression of the protein (expression enhancers). , to increase the solubility of the protein or to target the protein to a desired intracellular compartment. or to facilitate transport of the fusion protein across the cell membrane. It can be selected as follows.

[0150] The fusion polypeptides include a polypeptide domain having a polynucleotide sequence between each of the polypeptide domains described herein. In addition, the polypeptide portion may further comprise an optional linker. Exemplary polypeptide cleavage signals include polypeptide cleavage signals. Protease cleavage sites, nuclease cleavage sites (e.g., rare restriction enzyme recognition sites, self-cleavage sites) Ribozyme recognition sites) and self-cleaving viral oligopeptides and other polypeptide cleavage recognition (deFelipe and Ryan, 2004.Traffic, 5(8);616-26).

[0151] Suitable protease cleavage sites and self-cleaving peptides are known to those of skill in the art (e.g. , Ryan et al.,1997.J.Gener.Virol.78,699-7 22;Scymczak et al.(2004)Nature Biotech.5 Exemplary protease cleavage sites include the potyvirus NI a protease (e.g., tobacco etch virus protease), potyvirus HC protease Protease, potyvirus P1 (P35) protease, biovirus NIa protease protease, biovirus RNA-2-encoded protease, foot-and-mouth disease virus L protease, Enterovirus 2A protease, rhinovirus 2A protease, picorna 3C protease protease, comovirus 24K protease, nepovirus 24K protease, RTS V (Rice tungro spherical virus) 3C-like protease, PYVF (Parsnip yellow spot Viral) 3C-like protease, heparin, thrombin, factor Xa and enterokinase Due to its high cleavage stringency, it is possible to V (Tobacco Etch Virus) protease cleavage site, e.g., EXXYXQ(G / S) ( SEQ ID NO: 23), for example, ENLYFQG (SEQ ID NO: 24) and ENLYFQS (SEQ ID NO: No. 25) (where X represents any amino acid (TEV cleavage occurs between Q and G or occurs between Q and S) is preferred in one embodiment.

[0152] In certain embodiments, the self-cleaving peptides are selected from the group consisting of potyviruses and cardioviruses. 2A peptide, FMDV (foot-and-mouth disease virus), Equine rhinitis A virus, Thosea a The polypeptide sequences include those obtained from porcine teschovirus, as well as from porcine teschovirus. nothing.

[0153] In certain embodiments, the self-cleaving polypeptide site is a 2A or 2A-like site. , sequences or domains (Donnelly et al., 2001. J. Gen .Virol.82:1027-1041). Table 2: Exemplary 2A sites include the following sequences: [Table 2]

[0154] In a preferred embodiment, the polypeptide contemplated herein is a CAR polypeptide. Includes do.

[0155] Polynucleotides In a preferred embodiment, a polynucleotide encoding one or more CAR polypeptides is As used herein, a "polynucleotide" is provided, e.g., SEQ ID NO: 10. The term "nucleic acid" or "messenger RNA (mRNA), RNA, genome gene RNA (gRNA), positive strand RNA (RNA(+)), negative strand RNA (RNA( -), genomic DNA (gDNA), complementary DNA (cDNA) or recombinant DNA Polynucleotides include single-stranded and double-stranded polynucleotides. The polynucleotides of the present invention may be derived from any of the reference sequences described herein (e.g., At least about 50%, 55%, 60%, 65%, 70%, 75%, %, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% and wherein typically, A variant maintains at least one biological activity of the reference sequence. In one embodiment, the invention relates to an expression vector, a viral vector, and a transfer vector. The present invention contemplates polynucleotides, including plasmids, as well as compositions and cells containing the same.

[0156] In certain embodiments, at least about 5, 10, 25, 50, 15, 20, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, , 100, 150, 200, 250, 300, 350, 400, 500, 1000, 12 50, 1500, 1750, or 2000 or more consecutive amino acid residues and all intermediate In this context, a polynucleotide encoding the length of "Intermediate length" refers to any length of the quoted value, e.g., 6, 7, 8, 9, etc., 101, 10 means 2, 103 etc., 151, 152, 153 etc., 201, 202, 203 etc. It is easily understood that.

[0157] As used herein, the terms "polynucleotide variant" and "variant" and the like The term refers to a polynucleotide that exhibits substantial sequence identity to a reference polynucleotide sequence. or a polypeptide that hybridizes to a reference sequence under stringent conditions as defined below. These terms refer to a polynucleotide that is one or more nucleotides in length compared to a reference polynucleotide. Nucleotides are added or deleted, or replaced with different nucleotides In this regard, mutations, additions, deletions and substitutions are included. Certain modifications, including but not limited to those mentioned above, can be made to the reference polynucleotide, thereby The resulting polynucleotide retains the biological function or activity of the reference polynucleotide. It is well understood in the art that this is the case.

[0158] Statements including "sequence identity" or, for example, "a sequence 50% identical to" are intended to be within the scope of the present invention. As used herein, it is understood that sequences are compared on a nucleotide-by-nucleotide basis or over a comparison window. The percentage of sequence identity is calculated based on the amino acid sequence. "Increment" compares two optimally aligned sequences over a comparison window. , identical nucleic acid bases (e.g., A, T, C, G, I) or identical amino acid residues in both sequences Groups (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Ph e, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cy s and Met) to obtain the number of positions where the match is present, and the number of positions where the match is Divide by the total number of positions in the comparison window (i.e., the window size) and multiply the result by 100 To obtain the percentage of sequence identity, the sequence identity can be calculated by multiplying the sequence identity by the number of sequences. At least about 50%, 55%, 60%, 65%, 70%, %, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or Nucleotides and polypeptides with 100% sequence identity are included, typically polynucleotides. A peptide variant retains at least one biological activity of the reference polypeptide.

[0159] Used to describe the sequence relationships between two or more polynucleotides or polypeptides The terms used include "reference sequence," "comparison window," "sequence identity," "sequence identity window," "comparison ... "Reference sequence" includes "percentage of identity" and "substantial identity." and amino acid residues in length, at least 12, but often 15-18, In the case of the polynucleotide, the length is at least 25 monomer units. ) Similar sequences between two polynucleotides (i.e., the complete polynucleotide sequence) (2) may contain sequences that are diverse between the two polynucleotides, A sequence comparison between (above) polynucleotides is typically performed by comparing the sequences of the two polynucleotides. over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window" is a window that is the optimal alignment of two sequences. , then comparing the sequence to a reference sequence at the same number of contiguous positions, at least six, typically A conceptual sequence consisting of about 50 to about 100, more usually about 100 to about 150, consecutive positions. The comparison window refers to the segment of the reference region that is to be aligned to obtain the optimal alignment of two sequences. Approximately 20% or less additions or deletions (i.e., The optimal alignment of sequences for aligning the comparison window may include gaps. The alignment was performed using the Wisconsin Genetics Software algorithm ( ePackage Release 7.0(Genetics Computer Group, 575 Science Drive Madison, WI, USA) GAP, BESTFIT, FASTA, and TFASTA) on a computer or by surveying and selecting from a variety of methods. alignment (i.e., the highest homology percentage over the comparison window) Also see, for example, Altschul et al., BL disclosed by Nucl. Acids Res. 25:3389, 1997 The AST family of programs may be consulted. For a detailed discussion of sequence analysis, see Ausub el et al.,Current Protocols in Molecular Biology,John Wiley & Sons Inc,1994-1998 (Chapter 15, Unit 19.3).

[0160] As used herein, an "isolated polynucleotide" refers to a polynucleotide that is not contiguous in nature. A polynucleotide purified from sequences that are flanked by, for example, fragments that are typically "Isolated polynucleotide" also refers to a DNA fragment that has been removed from the sequence in which it is found. Complementary DNA (cDNA), recombinant DNA, or DNA that does not occur in nature and is created by human hands The term also refers to other polynucleotides that have been contemplated.

[0161] Terms describing the orientation of a polynucleotide include the 5' (usually the polynucleotide with a free phosphate group) nucleotide) and 3' (usually a polynucleotide with a free hydroxyl (OH) group The polynucleotide sequence may be in the 5'→3' or 3'→5' direction. For DNA and mRNA, the 5' to 3' strand can be annotated by its sequence. Since the sequence is identical to that of the premRNA, it is a substitute for thymine (T) in DNA. (excluding uracil (U) in RNA, which is an alternative) For DNA and mRNA, the strand transcribed by RNA polymerase is called the "strand". The complementary 3'→5' strand, which is the strand that is removed, is the "template" strand, the "antisense" strand, and the "minus" strand. or "non-coding" strand. As used herein, the term "reverse orientation" is a 5'→3' sequence written in a 3'→5' orientation, or a 3'→ Refers to the 5' sequence.

[0162] The terms "complementary" and "complementarity" refer to polynucleotides related by the base-pairing rules. It refers to a nucleotide (i.e., a sequence of nucleotides). For example, the DNA sequence 5'AGTC The complement of ATG3' is 3'TCAGTAC5'. The latter sequence is It is often written as the reverse complement 5'CATGACT3', with the 3' end on the right. A sequence that is identical to the reverse complement of a given sequence is said to be a palindromic sequence. Alternatively, there may be cases where only some of the nucleic acid bases match according to the base-pairing rules. It may be "complete" or "total" complementarity.

[0163] Furthermore, those skilled in the art will appreciate that, as a result of the degeneracy of the genetic code, the polypeptides described herein may There are many nucleotide sequences that code for a peptide or a variant thereof. It is understood that some of these polynucleotides are not necessarily identical to the nucleic acid sequences of any native gene. It has minimal homology to the nucleotide sequence. However, due to differences in codon usage, Polynucleotides that vary depending on, for example, human and / or primate codon preferences Specifically contemplated by the present invention are polynucleotides that are modified as described herein. An allele of a gene that contains a polynucleotide sequence that is to be cloned may also be used. Altered as a result of one or more mutations, such as deletions, additions and / or substitutions of peptides It is an endogenous gene.

[0164] As used herein, the term "nucleic acid cassette" refers to a nucleic acid sequence that expresses RNA and subsequently produces a protein. A nucleic acid cassette refers to a genetic sequence in a vector that can express a gene of interest. The nucleic acid cassette contains a gene, such as a CAR. The nucleic acid in the cassette is transcribed into RNA. These are then translated, if necessary, into proteins or polypeptides that are necessary for the activity of the transformed cell. They undergo the appropriate post-translational modifications required to target the appropriate intracellular or extracellular compartments. The vector is designed to allow secretion into the appropriate compartment for biological activity. Preferably, the cassette is positioned and sequenced within the vector for easy insertion. and, for example, a restriction endonuclease site at each end. In a preferred embodiment of the present invention, the nucleic acid cassette comprises a nucleic acid sequence for treating a B cell malignancy. The cassette contains the sequence of a chimeric antigen receptor for use in therapy. The cassette can be removed and made into a single unit. The gene may be inserted into a plasmid or viral vector as a

[0165] In certain embodiments, the polynucleotide comprises at least one polynucleotide of interest. As used herein, the term "polynucleotide of interest" includes a polynucleotide. An expression vector encoding a polypeptide (i.e., a polypeptide of interest) that is desired to be expressed. A vector refers to a polynucleotide that is inserted into a In certain embodiments, the nucleic acid sequence may comprise 9 or 10 polynucleotides of interest. The polynucleotide of interest is a polypeptide that provides a therapeutic effect in the treatment or prevention of a disease or disorder. A polynucleotide of interest and a coding sequence for a peptide are provided. The polypeptides produced by the method of the present invention include polynucleotides encoding the wild-type polypeptides, as well as polypeptides encoding the wild-type polypeptides. In certain embodiments, the functional variants include both functional variants and fragments of the is at least 80%, at least 90%, at least 95%, or at least 99% identical In certain embodiments, a functional variant or fragment is a variant of the corresponding wild-type polypeptide. At least 50%, at least 60%, at least 70%, or at least Both have 80%, or at least 90%.

[0166] In one embodiment, the polynucleotide of interest does not encode a polypeptide, but Transfect iRNA, siRNA, or shRNA, ribozymes, or other inhibitory RNA. In various other embodiments, the polynucleotide serves as a template for transcription. A polynucleotide of interest encoding a CAR and one or more additional polynucleotides of interest. RNAi, including but not limited to siRNA, miRNA, shRNA, and ribosomal RNAi. Zymes, for example, include, but are not limited to, inhibitory nucleic acid sequences.

[0167] As used herein, the term "siRNA" or "small interfering RNA" refers to a In animals, sequence-specific post-transcriptional gene silencing, translation inhibition, transcription inhibition, or This refers to a short polynucleotide sequence that mediates the process of pigenetic RNAi (Z amore et al.,2000,Cell,101,25-33;Fire et al. al.,1998,Nature,391,806;Hamilton et al. ,1999,Science,286,950-951;Lin et al.,199 9,Nature,402,128-129;Sharp,1999,Genes & Dev., 13, 139-141; and Strauss, 1999, Science, 2 86,886). In certain embodiments, the siRNA comprises the same number of nucleosides. The first and second strands have a first chain and a second chain having a first chain and a second chain having a second chain. The two terminal nucleosides are offset so that they do not pair with residues on the complementary strand. In certain cases, the two unpaired nucleosides are thymidine residues. NA allows siRNA or its fragments to mediate downregulation of target genes. The target gene is a gene that has a sufficient homology to the target gene and is of sufficient length in terms of nucleotides. Therefore, the siRNA must be at least partially specific to the target RNA. It is not necessary for there to be perfect complementarity between the siRNA and the target. The correlation is due to the fact that siRNA or its cleavage products are the result of RNAi cleavage of the target RNA. must be sufficient to allow sequence-specific silencing such as The degree of complementarity or homology with the target strand is most important in the antisense strand. While perfect complementarity in the antisense strand is often desired, some embodiments may , one or more, but preferably 10, 8, 6, 5, 4, 3, 2 or Mismatches are most tolerated in the terminal regions, If present, it is preferably in the terminal regions, or e.g., the 5' and / or 3' termini. The sense strand is the double-stranded region of the molecule, and is within 6, 5, 4, or 3 nucleotides of the It only needs to have sufficient complementarity with the antisense strand so as to maintain the entire sequence. .

[0168] In addition, siRNAs may be modified or contain nucleoside analogues. The single-stranded regions of the NA may be modified or replaced with nucleoside analogs, e.g., unpaired. The region linking the two complementary regions may include a short region or a hairpin structure region, for example, It may have modifications or nucleoside analogues. For example, siR Modifications that stabilize one or more of the 3' or 5' ends of the NA, or antisense sequences Modifications that render the RNA agent more accessible to RISC are also useful. are C6, C7, C12) amino linker, thiol linker, carboxyl linker, non Nucleotide spacers (C3, C6, C9, C12, abasic, triethylene glycol hexaethylene glycol), special biotin, or available as a phosphoramidite It has an additional DMT-protected hydroxyl group, allowing multiple couplings during RNA synthesis. Each strand of the siRNA may contain a fluorescein reagent that allows for the synthesis of 30, 25, 24, 2 The strand may be up to 3, 22, 21, or 20 nucleotides in length. Each strand is 19 nucleotides long. For example, each strand can be 21-25 nucleotides long. Preferred siRNAs are 17, 18, 19, 29, 21, 22, 23, 24, or 2 a duplex region of 5 nucleotide pairs and one or more overhangs of 2-3 nucleotides; Preferably, it has one or two 3' overhangs of 2-3 nucleotides.

[0169] As used herein, the term "miRNA" or "microRNA" refers to Typically, a foldback sequence of approximately 70 nucleotides known as pre-miRNA is generated. It refers to small non-coding RNA of 20 to 22 nucleotides that is excised from the NA precursor structure. miRNAs are expressed in one of two ways, depending on the degree of complementarity between the miRNA and the target. First, they negatively regulate their targets by binding to the mRNA sequences that code for proteins. miRNAs that bind with perfect or near perfect complementarity are involved in the RNA-mediated interference (RNAi) pathway. imperfectly complementary sites in the 3' untranslated region (UTR) of their mRNA targets miRNAs that exert their regulatory effects by binding to target proteins are used in the RNAi pathway. post-transcriptionally, apparently via a RISC complex that is similar, or perhaps identical, to that of represses the expression of target genes at the level of translation. Consistent with translational regulation, miRNAs that regulate the expression of genes reduce the protein levels of their target genes, but these genes The mRNA levels of miRNAs are minimally affected. NA and artificially designed miRNAs that can specifically target any mRNA sequence. For example, in one embodiment, one skilled in the art can use human miRNA ( For example, miR-30 or miR-21) are short hairpin R genes expressed as primary transcripts. A NA construct can be designed that incorporates the Drosha processing site. This adds a nucleotide sequence to the hairpin construct, significantly increasing knockdown efficiency. It has been shown that the hairpin stem is a 22-nucleotide Nucleotide dsRNA (e.g., antisense has perfect complementarity to a desired target) The hairpin is composed of a 15- to 19-nucleotide loop derived from human miR. Adding miR loops and miR30 flanking sequences on either side of the miRNA Compared to conventional shRNA designs that do not contain Drosha, the expressed hairpin Drosha and Dicer processing are increased by more than 10-fold. Increased sequestering converts more siRNA / miRNA products into more expressed products. The effect of the hairpin will also be greater.

[0170] As used herein, the term "shRNA" or "small hairpin RNA" refers to refers to the double-stranded structure formed by a single self-complementary RNA strand. Nucleotides that are identical to any part of the coding or noncoding sequence of the shRNA constructs containing an insertion or deletion sequence for the target sequence are preferred. RNA sequences containing deletions and single point mutations have also been shown to be effective in inhibition. More than 90% sequence identity between the harmful RNA and a portion of the target gene, or In certain preferred embodiments, the shRN The length of the duplex forming portion of A is at least 20, 21 or 22 nucleotides in length, e.g. For example, it corresponds to the size of the RNA product generated by Dicer-dependent cleavage. In certain embodiments, the shRNA construct comprises at least 25, 50, 100, In certain embodiments, the shRNA codon is 200, 300, or 400 bases in length. The shRNA construct is 400-800 bases long. It is highly tolerant to variations in row and loop size.

[0171] As used herein, the term "ribozyme" refers to a ribozyme that specifically binds to a target mRNA. It refers to a catalytically active RNA molecule that allows for cleavage. There are several subtypes, e.g. Both merhead and hairpin ribozymes have been described. Stability is achieved by replacing the non-catalytic base ribonucleotides with deoxyribonucleotides. This can be improved by using a ribozyme that cleaves mRNA at a site-specific recognition sequence. can be used to destroy specific mRNAs, but the use of hammerhead ribozymes Hammerhead ribozymes are preferred because they form complementary base pairs with target mRNA. It cleaves the mRNA at the position specified by the ranking region. The only requirement is that the target mRNA The hammerhead type RNA has the following two base sequences: 5'-UG-3'. The construction and production of bozymes is well known in the art.

[0172] Polynucleotides of interest, including siRNA, miRNA, shRNA, or ribozymes A preferred method for delivery of the peptide is, for example, a constitutively overexpressed peptide, as described elsewhere herein. ol III, e.g., human U6 snRNA promoter, mouse U6 snRNA promoter promoter, human and mouse H1 RNA promoter and human tRNA-val promoter or a constitutively highly expressed pol II promoter. include.

[0173] The polynucleotides of the present invention may be prepared as described elsewhere herein or in the art. As is known in the art, promoters and and / or enhancers, untranslated regions (UTRs), signal sequences, Kozak sequences, polynucleotides, and Adenylation signal, additional restriction enzyme sites, multiple cloning sites, internal ribosome insertion sites, Entry sites (IRES), recombinase recognition sites (e.g., LoxP, FRT, and A tt site), a stop codon, a transcription termination signal, and a polypeptide encoding a self-cleaving polypeptide. It may be combined with other DNA sequences such as oligonucleotides, epitope tags, etc., so that The overall length of the polynucleotide may vary widely. A nucleotide fragment may be used, the full length of which is preferably It is intended that the invention be limited to ease of preparation and use in situ hybridization.

[0174] Polynucleotides can be prepared using a variety of well-defined nucleic acid sequences known and available in the art. The compounds can be prepared, manipulated and / or expressed using any of the techniques described herein. In order to express the desired polypeptide, the nucleotide sequence encoding the polypeptide is appropriately The vector may be inserted into any suitable vector. Examples of vectors include plasmids, autonomously replicating sequences, and transfer elements. Further exemplary vectors include, but are not limited to, plasmids, fungi, and the like. phagemid, cosmid, yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC), or Artificial chromosomes such as P1-derived artificial chromosomes (PACs), lambda phage or M13 phage and animal viruses. Examples of virus categories include, but are not limited to, retroviruses (lentiviruses), viruses), adenoviruses, adeno-associated viruses, herpes viruses (e.g. Herpes simplex virus), poxvirus, baculovirus, papillomavirus, and papovaviruses (e.g., SV40). For expression in mammalian cells, use the pClneo vector (Promega); pLenti4 / V5-DEST was used for lentivirus-mediated gene transfer and expression in (trademark), pLenti6 / V5-DEST(trademark), and pLenti6.2 / V5- GW / lacZ (Invitrogen). The coding sequences of the disclosed chimeric proteins are capable of expressing the chimeric proteins in mammalian cells. For expression of the protein, the polypeptide can be ligated into such an expression vector.

[0175] In one embodiment, the vector encoding the CAR contemplated herein is 36.

[0176] In certain embodiments, the vector is an episomal vector, or one that is maintained extrachromosomally. As used herein, the term "episome" refers to a vector that is without being integrated into chromosomal DNA and gradually lost from dividing host cells The term refers to a vector that is capable of replicating without any restriction, and the vector is an extrachromosomal or episomal vector. The vector may be a lymphotropic herpes virus or a cancer Herpesvirus, adenovirus, SV40, bovine papillomavirus, or yeast The origin of DNA replication or "ori" derived from, specifically, oriP of EBV Sequences encoding lymphotropic herpesvirus or gammaherpesvirus replication origins In a specific embodiment, the lymphotropic herpes virus is engineered to have a sequence , Epstein-Barr virus (EBV), Kaposi's sarcoma herpesvirus (KSHV), The virus may be a herpes simplex virus (HS), or a Marek's disease virus (MDV). EBV and Kaposi's sarcoma herpesvirus (KSHV) are gamma Herpes viruses are also an example. Typically, the host cell is primed for viral replication, which activates replication. Includes transactivator proteins.

[0177] "Regulatory elements" or "control sequences" present in an expression vector are those that regulate the function of a host cell's proteins. The non-translated regions of the vector (origin of replication, selection cassette) interact with each other to carry out transcription and translation. , promoter, enhancer, translation initiation signal (Shine Dalgarno sequence or Kozak sequence), introns, polyadenylation sequences, 5' and 3' untranslated regions Such elements may vary in their strength and specificity. Depending on the host, any number of suitable promoters may be used, including ubiquitous and inducible promoters. Various transcription and translation elements can be used.

[0178] In certain embodiments, vectors for use in practicing the present invention include, but are not limited to, expression vectors and viral vectors, including, but not limited to, promoters and / or "Endogenous" regulatory sequences include exogenous, endogenous, or heterologous regulatory sequences, such as enhancers. An "exogenous" regulatory sequence is one that is naturally linked to a given gene in the genome. By molecular manipulation (i.e., molecular biology techniques), the transcription of the gene is linked to These are arranged in parallel so that they can be induced by the enhancer / promoter "Heterologous" regulatory sequences are exogenous sequences that originate from a species different from the cell being genetically engineered. It is.

[0179] As used herein, the term "promoter" refers to a promoter to which RNA polymerase binds. It refers to the recognition site of a polynucleotide (DNA or RNA). RNA polymerase is a The promoter is used to initiate and transcribe a polynucleotide operably linked to the promoter. In this embodiment, a promoter operable in a mammalian cell is a promoter that is AT-rich region located approximately 25-30 bases upstream and / or 70-80 bases from the transcription start Another sequence found upstream is the CNCAAT region (where N can be any nucleotide). ).

[0180] The term "enhancer" refers to a gene that can result in increased transcription and can also be used to In some cases, they contain sequences that can function regardless of orientation relative to other regulatory sequences. An enhancer is a segment of DNA that regulates the function of a promoter and / or other enhancers. Promoter / enhancer elements can function synergistically or additionally with promoter / enhancer elements. The term "promoter" includes sequences that can provide both promoter and enhancer functions. It refers to a segment of DNA that contains

[0181] The term "operably linked" means that the elements described function in their intended manner. In one embodiment, the term refers to a nucleic acid An expression control sequence (such as a promoter and / or enhancer) and a second polynucleotide "regulatory" refers to a functional link between a gene sequence, such as a polynucleotide of interest, and a target gene, The sequence directs transcription of a nucleic acid corresponding to a second sequence.

[0182] As used herein, the term "constitutive expression control sequence" refers to an operably linked Promoters, enhancers, or other transcription factors that allow intermittent or continuous transcription of sequences that are refers to promoter / enhancer. Constitutive expression control sequences are expressed in a wide variety of cells and tissues. "Ubiquitous" promoters, enhancers, or promoter sequences that allow expression in a species Motors / enhancers, or expression in restricted cell and tissue types "Cell-specific," "cell type-specific," "cell line-specific," or "tissue-specific" profiles that The promoter may be a promoter, an enhancer, or a promoter / enhancer, respectively.

[0183] Exemplary ubiquitous expression control sequences suitable for use in certain embodiments of the present invention Examples include the cytomegalovirus (CMV) immediate early promoter, the viral simian virus SV40 (e.g., early or late), Moloney murine leukemia virus ( MoMLV) LTR promoter, Rous sarcoma virus (RSV) LTR, herpes simplex Viral (HSV) (thymidine kinase) promoter, H5 from vaccinia virus , P7.5, and P11 promoters, elongation factor 1-alpha (EF1a) promoter , Early growth response 1 (EGR1), Ferritin H (FerH), Ferritin L (FerL) , glyceraldehyde 3-phosphate dehydrogenase (GAPDH), eukaryotic translation initiation factor EIF4A1, heat shock 70 kDa protein 5 (HSPA5), heat shock Heat shock protein 90 kDa beta member 1 (HSP90B1), a heat shock protein 70 kDa (HSP70), β-kinesin (β-KIN), human ROSA26 locus ( Irions et al.,Nature Biotechnology 25,14 77-1482(2007)), ubiquitin C promoter (UBC), phosphoglyceryl Phosphate kinase-1 (PGK) promoter, cytomegalovirus enhancer / chicken β -actin (CAG) promoter, β-actin promoter and myeloproliferative sarcoma The negative regulatory region of the viral enhancer deletion dl587rev primer binding site substitution (MN D) Promoter (Challita et al., J Virol. 69(2):7 48-55(1995)), but are not limited to these.

[0184] In one embodiment, a vector of the invention comprises an MND promoter.

[0185] In one embodiment, the vector of the invention comprises the first intron of the human EF1a gene. including the EF1a promoter.

[0186] In one embodiment, the vector of the invention comprises the first intron of the human EF1a gene. It lacks the EF1a promoter.

[0187] In certain embodiments, a polynucleotide comprising a CAR derived from a T cell specific promoter is In some cases, it may be desirable to express a tide.

[0188] As used herein, "conditional expression" includes, but is not limited to, inducible expression. expression; suppressive expression; in cells or tissues with a particular physiological, biological, or pathological condition This definition may refer to any kind of conditional expression, including expression that is conserved in a cell type or tissue. It is not intended to exclude tissue-specific expression. Certain embodiments of the present invention include Provides conditional expression of a polynucleotide of interest, e.g., expression is conferred by a specific target gene in a cell, tissue, organism, etc. By expressing a polynucleotide or by subjecting the polynucleotide to a treatment or condition that increases or decreases expression of the polypeptide to be isolated; is regulated by

[0189] Illustrative examples of inducible promoters / systems include those that induce glucocorticoid or estrogen A steroid-inducible promoter, such as the promoter of the gene encoding the steroid receptor (corresponding the metallothionine promoter (inducible by treatment with hormones that stimulate the production of various heavy metals) ), MX-1 promoter (inducible by treatment with interferon) ), the "GeneSwitch" mifepristone-controllable system (Sirin et al. .,2003,Gene,323:67), cumic acid-inducible gene switch (WO200 2 / 088346), tetracycline-dependent regulatory system, etc. Not done.

[0190] Conditional expression can also be achieved by using site-specific DNA recombinases. According to certain embodiments of the present invention, the vector may be a site-specific recombinant vector. At least one site(s) for binase-mediated recombination (typically As used herein, the term "recombinase" or "site-specific recombinase" refers to a The term "recombinase" refers to a recombinant protein that contains one or more recombination sites (e.g., 2, 3, 4, 5, 7, 1 0, 12, 15, 20, 30, 50, etc.) Proteins, enzymes, cofactors, or associated proteins that mediate integration, Type Proteins (Landy, Current Opinion in Biotechn 3:699-707 (1993), or a variant or derivative thereof (e.g., For example, fusion proteins containing the recombinant protein sequence or a fragment thereof, fragments, and variants thereof. Recombinants suitable for use in certain embodiments of the present invention may be Illustrative examples of genes include Cre, Int, IHF, Xis, Flp, Fis, Hin, Gin, ΦC31, Cin, Tn3 resolvase, TndX, XerC, XerD, Tn These include, but are not limited to, pX, Hjc, Gin, SpCCE1, and ParA. do not have.

[0191] The vector contains recombination sites for any of a wide variety of site-specific recombinases. The target site for the site-specific recombinase may be located within a vector, e.g., a retroviral vector. Any site(s) required for integration of viral or lentiviral vectors As used herein, "recombinant sequences," " The term "recombination site" or "site-specific recombination site" refers to a site that is recognized by a recombinase. It refers to the specific nucleic acid sequence that recognizes and binds to.

[0192] For example, one recombination site for the Cre recombinase is loxP, which is Two 13-base pair inverted repeats (recombinase binding sites) are located on either side of the 13-base pair core sequence. It is a 34-base pair sequence containing the ribosome-specific ribosome-specific ribosome (Sauer, B., Current Opinion, 2002). pinion in Biotechnology 5:521-527(1994) See FIG. 1. Other exemplary loxP sites include lox511 (Hoess et al. l.,1996;Bethke and Sauer,1997), lox5171(L Lee and Saito,1998), lox2272(Lee and Saito , 1998), m2 (Langer et al., 2002), lox71 (Albe rt et al., 1995), and lox66 (Albert et al., 19 95), but are not limited to these.

[0193] Suitable recognition sites for FLP recombinase include FRT (McLeod, et al., 1996), F1, F2, F3 (Schlake and Bode, 1994), F4 ,F5(Schlake and Bode,1994), FRT(LE)(Senec off et al., 1988), FRT(RE) (Senecoff et al. ,1988).

[0194] Other examples of recognition sequences are the attB, attP, attL, and attR sequences recognized by the recombinase enzyme λ integrase, e.g., phi-c31. φC31 SSR mediates recombination only between the heterologous sites attB (34 bp long) and attP (39 bp long) (Groth et al., 2000). attB and attP are named after the phage integrase binding sites on the bacterial and phage genomes, respectively, and both contain imperfect inverted repeats that can be bound by φC31 homodimers (Groth et al., 2000). The product sites attL and attR are effectively inactive to further φC31-mediated recombination (Belteki et al., 2003), rendering the reaction irreversible. It has been found that it is easier to catalyze insertion by inserting attB-containing DNA into a genomic attP site than by inserting an attP site into a genomic attB site (Thyagarajan et al., 2001; Belteki et al., 2003). Thus, a typical strategy is to place an attP-containing "docking site" into a defined locus by homologous recombination and then align it with an attB-containing import sequence for insertion.

[0195] As used herein, an "internal ribosome entry site" or "IRES" refers to a Direct intracellular ribosomal RNAi sequence to the initiation codon, such as ATG, of a cistron (protein coding region). Refers to an element that promotes inflammasome entry, thereby resulting in cap-independent gene translation. See, e.g., Jackson et al., 1990. Trends Biochem Sci 15(12):477-83) and Jackson and Kaminski See, RNA 1995, 1(10):985-1000. In the present invention, the vectors contemplated by the present invention include a vector encoding one or more polypeptides. In certain embodiments, the polypeptide comprises one or more polypeptides of interest. In order to achieve efficient translation of each of the Separated by an ES sequence or a polynucleotide sequence encoding a self-cleaving polypeptide. It is possible.

[0196] As used herein, the term "Kozak sequence" refers to the small ribosomal sequence. Short nucleotides that greatly facilitate the initial binding of mRNA to the subunit and increase translation The consensus Kozak sequence is (GCC)RCCATGG ( where R is a purine (A or G) (Kozak, 1986. Cell. 44 ( 2):283-92, and Kozak, 1987. Nucleic Acids R es.15(20):8125-48). In certain embodiments, The vector to be produced contains a consensus Kozak sequence and can encode the desired polypeptide, e.g., It includes a polynucleotide encoding a CAR.

[0197] In some embodiments of the present invention, a polynucleotide or a nucleic acid having a polynucleotide Cells are then transfected with inducible GFP to reduce the risk of direct toxicity and / or unregulated proliferation. In a specific embodiment, the suicide gene is a poly It is not immunogenic to the host or cells that bear the nucleotide. Certain examples of suicide genes are caspase-9 or caspase-8 or cytosine deoxyribonuclease. Caspase-9 is a cytosine kinase that is activated by specific dimer-inducing compounds (CIDs). It can be made into

[0198] In certain embodiments, the vector is an immune effector cell of the invention, e.g., Gene segments that render T cells susceptible to negative selection in vivo "Negative selection" refers to the process by which the injected cells are able to adapt to the in vivo conditions of the individual. This means that a phenotype that can be negatively selected is one that can be eliminated as a result of a change in the This may result from the insertion of a gene that confers sensitivity to the administered agent, for example a compound. Negative selection genes are known in the art and include, inter alia: Herpes simplex virus type I thymidine kinase (HSV-I) confers sensitivity to anciclovir TK) gene (Wigler et al., Cell 11:223, 1977); Cellular hypoxanthine phosphoribosyltransferase (HPRT) gene, cellular adenine Phosphoribosyltransferase (APRT) gene and bacterial cytosine deaminase (Mullen et al.,Proc.Natl.Acad.Sci.USA.89 :33(1992)).

[0199] In some embodiments, genetically modified immune effector cells, such as T cells, Positive selection allows for the selection of cells of a negatively selected phenotype in vitro The positive selection marker is a gene. When introduced into a host cell, it allows for positive selection of cells that carry the gene. The gene may be a gene that expresses a dominant phenotype. Such genes are known in the art. In particular, hygromycin-B resistant genotype 1 (Hygromycin B resistant genotype 2) has been reported. B phosphotransferase gene (hph), encoding resistance to the antibiotic G418 The aminoglycoside phosphotransferase gene (neo or ap h), dihydrofolate reductase (DHFR) gene, adenosine deaminase (ADA), and multidrug resistance (MDR) genes.

[0200] Preferably, the positive selection marker and the negative selection element are The deletion of the positive selection marker is linked such that deletion of the positive selection marker also entails deletion of the positive selection marker. Alternatively, the loss of one of the positive and negative selection markers may be indicative of the loss of the other. The desired positive and negative selections described above are then used to forcibly select the desired mutants. The present invention provides a fusion polynucleotide that produces as its expression product a polypeptide that confers both the characteristics of a target gene and a target gene for selection. One example of a tide is the hygromycin phosphotransferase thymidine kinase fusion gene. The expression of this gene is a marker of positive selection in vitro. hygromycin B resistance for in vivo negative selection Lupton SD, et al. al,Mol.and Cell.Biology 1 1:3374-3378,1 991. Additionally, in a preferred embodiment, a chimeric receptor encoding The polynucleotides of the present invention are useful for the synthesis of fusion genes, particularly in in vitro positive selection. Hygromycin B resistance for selection and for negative selection in vivo retroviral vectors containing a fusion gene that confers ganciclovir sensitivity to For example, the HyTK described in Lupton, SD et al. (1991) supra. It is present in retroviral vectors. It also contains dominant positive and negative selectable markers. The present invention describes the use of bifunctional selectable fusion genes resulting from the fusion of a gene with a selectable marker. PCT US91 / 08442 and PCT / US9 See also publication no. 4 / 05601.

[0201] Preferred positive selection markers are selected from the group consisting of hph, nco, and gpt. A preferred negative selection marker is derived from a gene that is expressed in a cytosine deaminase gene, H A gene selected from the group consisting of SV-ITK, VZVTK, HPRT, APRT and gpt. Particularly preferred markers are bifunctional selectable fusion genes, which are The selection marker is derived from hph or neo, and the negative selection marker is cytosine It is derived from the aminase or TK gene or a selection marker.

[0202] Viral Vectors

[0203] In certain embodiments, the cell (e.g., immune effector cell) encodes a CAR. A retroviral vector, such as a lentiviral vector, is used to transduce the For example, immune effector cells express the intracellular signals CD3ζ, CD28, 4-1BB, and Ox40. or any combination thereof, and a polypeptide that binds to a BCMA polypeptide. A vector encoding a CAR comprising a mouse anti-BCMA antibody or an antigen-binding fragment thereof is formed. These transduced cells are then able to elicit a CAR-mediated cytotoxic response. It is possible.

[0204] Retroviruses are a common tool for gene delivery (Miller, 2000, N ature. 357:455-460). In certain embodiments, the retrovirus is Used to deliver a polynucleotide encoding a chimeric antigen receptor (CAR) to a cell. As used herein, the term "retrovirus" refers to a virus that is capable of transmitting a specific genomic RNA. reverse transcribes the genomic DNA into a linear double-stranded DNA copy, which is then covalently linked to the host genome. The term refers to an RNA virus that integrates into the host genome. The provirus serves as a template for RNA polymerase II. and an RNA molecule that encodes the structural proteins and enzymes required for the production of new virus particles. Induce the expression of

[0205] Exemplary retroviruses suitable for use in certain embodiments include Moloney murine whitefly. Murine sarcoma virus (MMuLV), Moloney murine sarcoma virus (MoMSV), Harvey Murine sarcoma virus (HaMuSV), mouse mammary tumor virus (MuMTV), gibbon Leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Mouse leukemia virus, murine stem cell virus (MSCV) and Rous sarcoma virus (RSV)) and lentiviruses.

[0206] As used herein, the term "lentivirus" refers to a complex retrovirus. Exemplary lentiviruses include HIV (human immunodeficiency virus), HIV type 1 and HIV type 2; Visna-Maedi virus (VMV) Caprine arthritis-encephalitis virus (CAEV); Equine infectious anemia virus (EIAV); Bovine immunodeficiency virus (FIV); Bovine immunodeficiency virus (BIV); and Simian immunodeficiency virus (SIV). In one embodiment, the HIV A base vector backbone (i.e., HIV cis-acting sequence elements) is preferred. In some embodiments, lentiviruses are used to deliver polynucleotides containing CAR to cells. It is used.

[0207] Retroviral vectors, and more particularly lentiviral vectors, are particular embodiments of the present invention. Thus, the term "retrovirus" or "retroviruses" may be used in carrying out the embodiments. The term "viral vector" as used herein means a "lentivirus" or a "viral vector," respectively. The term "lentiviral vector" is meant to include "virus vectors," "lentiviral vectors," and "lentiviral vectors."

[0208] The term "vector" as used herein refers to any molecule capable of transporting or carrying another nucleic acid molecule. The term "transfected nucleic acid" is used to refer to a nucleic acid molecule capable of being transfected into a vector nucleic acid molecule. Linked, e.g., inserted. The vector may contain sequences that induce autonomous replication in cells. , and may contain sufficient sequences to permit integration into the host cell DNA. Examples of such vectors include plasmids (e.g., DNA plasmids or RNA plasmids), transgenes, and vectors. Useful viruses include sposon, cosmid, bacterial artificial chromosome, and viral vectors. Retroviruses include, for example, replication-defective retroviruses and lentiviruses.

[0209] As will be appreciated by those of skill in the art, the term "viral vector" typically refers to a nucleic acid molecule Nucleotides containing viral-derived nucleic acid elements that facilitate the transport or integration of the virus into the genome of the cell. Acid molecules (e.g., transfer plasmids) or viral particles that mediate nucleic acid transport A virus particle is typically a small molecule that is made up of various viral structures. The vector may comprise components of a host cell in addition to the nucleic acid(s).

[0210] The term viral vector refers to a virus or vector capable of delivering nucleic acid into a cell. The term can refer to either the viral particle, or the nucleic acid being delivered itself. Transfer plasmids and plasmids contain structural and / or functional genes primarily derived from viruses. The term "retroviral vector" is derived primarily from retroviruses. Viral vectors or vectors containing structural and functional genetic elements, or parts thereof, which refers to a plasmid. The term "lentiviral vector" is used primarily for lentiviruses. Containing structural and functional genetic elements derived from, or portions thereof (including the long terminal repeats), The term "hybrid vector" refers to a retrovirus vector or a plasmid. Roviral sequences, e.g., lentiviral and non-lentiviral viral sequences In one embodiment, the present invention refers to a vector, LTR, or other nucleic acid that contains both the Bridging vectors are vectors that contain retrotransferases for reverse transcription, replication, integration and / or packaging. Vectors or transfer vectors that contain proviral sequences, e.g., lentiviral sequences. Refers to Rasmid.

[0211] In certain embodiments, the terms "lentiviral vector" and "lentiviral expression vector" refer to The term "transfector" refers to a lentiviral transfer plasmid and / or an infectious lentiviral vector. As used herein, the term "virus particle" refers to a cloning site, a promoter, a Where reference is made to elements such as sequences, regulatory elements, heterologous nucleic acids, etc., the sequences of these elements are In the lentiviral particle of the present invention, it is present in the form of RNA, and in the DNA plasmid of the present invention, It should be understood that it exists in the form of DNA.

[0212] At both ends of the provirus are structures called "long terminal repeats" or "LTRs." The term "long terminal repeat (LTR)" refers to the sequence of bases located at both ends of retroviral DNA. It refers to a pair of domains, which in their native sequence are orthogonal repeats, U3, R and U5. LTRs generally contain regions that regulate the expression of retroviral genes (e.g., gene transcription). The ribosomal RNA provides essential functions for the transcription of the ribosomal RNA (promotion, initiation and polyadenylation of the transcription factor 1 (RI)) and viral replication. The LTRs contain transcriptional regulatory elements, polyadenylation signals and are involved in the replication and assembly of the viral genome. It contains multiple regulatory signals, including sequences required for integration. The viral LTR contains U3, The U3 region contains enhancers and promoters. The U5 region is a sequence between the primer binding site and the R region, and contains the polynucleotide sequence It contains an adenylation sequence. The R (repeat) region is flanked by the U3 and U5 regions. The TR is composed of the U3, R and U5 regions and is located at both the 5' and 3' ends of the viral genome. Adjacent to the 5'LTR are the genomic reverse transcription (tRNA primer binding site) and This is a sequence (psi site) required for efficient packaging of viral RNA into particles.

[0213] As used herein, a "packaging signal" or "packaging sequence" The term "antigen" refers to the proteins required to insert viral RNA into the viral capsid or particle. The term refers to sequences located within the retroviral genome that are involved in the replication of the genomic DNA of a retrovirus. al.,1995.J.of Virology,Vol.69,No.4;pp.21 Some retroviral vectors use the viral genome The minimal packaging signal (also called the psi [Ψ] sequence) required for encapsidation of Thus, as used herein, "packaging sequence", "packaging The terms "caging signal," "psi," and the symbol "Ψ" refer to the Used for non-coding sequences required for encapsidation of retroviral RNA strands. It is used.

[0214] In various embodiments, the vector comprises a modified 5'LTR and / or a modified 3'LTR. One or both of the LTRs may contain one or more deletions, insertions, or substitutions. The 3'LTR may include one or more modifications, including but not limited to, modifications to the 3'LTR. Improve the safety of lentivirus or retrovirus systems by making them replication-deficient As used herein, the term "replication-deficient" refers to a gene that is capable of replicating an infectious Refers to a virus that is unable to replicate completely and efficiently, such that virions are not produced (e.g., The term "replication-competent" refers to a virus that is capable of replicating virally. Replication-competent wild-type or mutant viruses capable of producing infectious virions. This refers to a lentivirus that is a replication-competent progeny of a given lentivirus (e.g., a replication-competent lentiviral progeny).

[0215] "Self-inactivating" (SIN) vectors are designed to inhibit viral transcription for more than one round of viral replication. To prevent this, the right (3') LTR enhancer-promoter region, known as the U3 region, Replication-defective vectors, e.g., retroviral vectors, in which the replication-defective region has been altered (e.g., deleted or substituted). This refers to a virus or lentiviral vector that is inserted into the right (3') The LTR U3 region is used as a template for the left (5') LTR U3 region, Without the enhancer-promoter, no viral transcripts will be produced. In a further embodiment, the 3'LTR is a nucleotide sequence in which the U5 region is, for example, an ideal poly(A) sequence. The 3'LTR, 5'LTR, or 3' and 5'LTR are modified to be replaced with It should be noted that modifications to the LTR, such as modifications to both the LTR and the LTR, are also encompassed by the present invention. sea ​​bream.

[0216] The U3 region of the 5'LTR drives transcription of the viral genome during viral particle production. Replacement of the promoter region with a heterologous promoter provides an additional safety benefit. Examples of heterologous promoters that can be used include those derived from the virus Simian Virus. SV40 (e.g., early or late), cytomegalovirus (CMV) (e.g., For example, immediate early stage), Moloney murine leukemia virus (MoMLV), Rous sarcoma virus ( Respiratory syncytial virus (RSV) and herpes simplex virus (HSV) (thymidine kinase) promoters were Typical promoters drive high levels of transcription in a Tat-independent manner. This substitution allows the absence of a complete U3 sequence in the virus production system. This reduces the likelihood of recombination generating replication-competent virus. In this regard, heterologous promoters have been useful in regulating the way in which the viral genome is transcribed. For example, a heterologous promoter can be expressed by a viral genome only in the presence of an inducer. The transcription factors can be induced to cause transcription of all or part of the genome. These chemical compounds or the physiological conditions under which the host cells are cultured, such as temperature or pH, Includes, but is not limited to:

[0217] In some embodiments, the viral vector comprises a TAR element. The term refers to a "transactivating" gene located in the R region of a lentivirus (e.g., HIV) LTR. This refers to the "activation response" genetic element. This element is expressed by the lentiviral transactivator (tat) It interacts with genetic elements to enhance viral replication. However, this element is not 5' Required in embodiments where the U3 region of the LTR is replaced by a heterologous promoter I can't.

[0218] The "R region" begins at the start of the capping sequence (i.e., the start of transcription) and ends at the polyA sequence The R region refers to the region within a retroviral LTR that ends just before the start of the U3 region. The R region is also defined as the region between the U1 and U2 regions. It serves the role of enabling transport from one end of the genome to the other.

[0219] As used herein, the term "FLAP element" refers to a sequence that is encoded by a retrovirus ( For example, the central polypurine tract and the central target of HIV-1 or HIV-2 A FLAP element refers to a nucleic acid that contains a nucleotide sequence (cPPT and CTS) that terminates the nucleotide sequence. U.S. Patent No. 6,682,907 and Zennou, et al., 2000, Cell , 101:173. During reverse transcription of HIV-1, the positive strand of DNA is centrifuged. The central initiation and termination sequences in the cPPT ( The central termination of the HIV-1 central DNA (CTS) leads to a triple-stranded DNA structure. This results in the formation of a flap. Without wishing to be bound by any theory, DN The A flap may act as a cis-acting determinant of lentiviral genome nuclear transport and / or In certain embodiments, the retrovirus or retroviral vector may be used to increase viral titer. The antiviral vector backbone contains one or more nucleotides upstream or downstream of the heterologous gene of interest in the vector. For example, in certain embodiments, the transfer plasmid In one embodiment, the vector of the invention is a single HIV-1 Contains the detached FLAP element.

[0220] In one embodiment, a retroviral or lentiviral transfer vector The term "nuclear export element" refers to a nuclear export protein that is capable of transporting a protein from the nucleus of a cell to a target cell. This refers to a cis-acting post-transcriptional regulator that controls the transport of RNA transcripts into the nucleus. Exemplary elements include the human immunodeficiency virus (HIV) rev response element (RRE) (e.g. , Cullen et al., 1991. J. Virol. 65:1053; and Cu See, e.g., Illen et al., 1991. Cell 58:423), and hepatitis B virus. These include, but are not limited to, RNA post-transcriptional regulatory elements (HPREs). A nuclear export element is located within the 3'UTR of a gene and is inserted as one or more copies. You can enter.

[0221] In certain embodiments, expression of a heterologous sequence in a viral vector is controlled by post-transcriptional regulatory elements, An efficient polyadenylation site and, optionally, a transcription termination signal are incorporated into the vector. Various post-transcriptional regulatory elements, e.g., woodchuck hepatitis virus Post-transcriptional regulatory element (WPRE; Zufferey et al., 1999, J. Viro l.,73:2886); Hepatitis B virus post-transcriptional regulatory element (HPRE) (H uang et al.,Mol.Cell.Biol.,5:3864); and equivalents (Liu et al., 1995, Genes Dev., 9:1766) In certain embodiments, the vectors of the invention can increase the expression of heterologous nucleic acids in the host. The target contains a post-transcriptional regulatory element such as a WPRE or HPRE.

[0222] In certain embodiments, the vectors of the invention include a post-transcriptional sequence such as a WPRE or HPRE. It lacks or does not contain control elements (PTEs). In some cases, these elements increases the risk of cell transformation and / or substantially reduces the amount of mRNA transcripts. This is because they do not significantly increase or enhance mRNA stability. Thus, in some embodiments, the vectors of the invention lack or contain a PTE. In another embodiment, the vector of the invention does not contain the WPRE or lacking or not containing HPRE.

[0223] Elements that provide for efficient termination and polyadenylation of the heterologous nucleic acid transcript are essential for the regulation of heterologous gene expression. Transcription termination signals are generally found downstream of the polyadenylation signal. In certain embodiments, the vector comprises a polynucleotide encoding the polypeptide to be expressed. The term "poly A site" as used herein also refers to a polyadenylation sequence 3' to the nucleotide. The term "polyA sequence" refers to the sequence that terminates and amplifies the nascent RNA transcript by RNA polymerase II. Polyadenylation sequences refer to DNA sequences that direct both transcription and polyadenylation. Adding a poly(A) tail to the 3' end of the coding sequence enhances the stability of the mRNA. This contributes to increased translation efficiency. Efficient polyadenylation of recombinant transcripts is desirable because they are stable and rapidly degraded. As an illustrative example of a polyA signal that can be used in the vector of the present invention, Ideal polyA sequence (e.g., AATAAA, ATTAAA, AGTAAA), bovine Growth hormone polyA sequence (BGHpA), rabbit β-globin polyA sequence (rβgpA) or another suitable heterologous or endogenous polyA sequence known in the art. Some examples include:

[0224] In certain embodiments, retroviral or lentiviral vectors The insulator element further comprises one or more insulator elements. This is mediated by cis-acting elements present in A, resulting in unregulated expression of the transported sequences. The lentivirus expression sequence (e.g., Therapeutic polypeptides) (e.g., Burgess-Beuss e et al.,2002,Proc.Natl.Acad.Sci.,USA,99 :16433; and Zhan et al., 2001, Hum. Genet., 109 In some embodiments, the transfer vector comprises a 3′ LTR contains one or more insulator elements, and when the provirus is integrated into the host genome In the present study, the provirus replicates only at the 3'LTR, and therefore both the 5'LTR and the 3'LTR are replicated. The insulators suitable for use in the present invention include one or more insulators. include, but are not limited to, chicken β-globin insulator (C hung et al.,1993.Cell 74:505;Chung et al. ., 1997. PNAS 94:575; and Bell et al., 1999. ll 98:387, which are incorporated herein by reference. Examples of insulator elements include those derived from the β-globin locus, such as chicken HS4. Examples of such devices include, but are not limited to, photocouplers.

[0225] According to certain specific embodiments of the present invention, most of the viral vector backbone sequence All or most are derived from lentiviruses, such as HIV-1. Many different sources of viral and / or lentiviral sequences can be used, or or combinations thereof, and substitutions and alterations in a particular lentiviral sequence may also be used. Multiple applications without compromising the functional capabilities of the transfer vectors described herein. It should be understood that various lentiviral vectors can be used. It is known that Naldini et al. 1998);Zufferey et al.,(1997);Dull et al. ., 1998, U.S. Patent Nos. 6,013,516; and 5,994,136. Many of these can be expressed as viral vectors or transfer plasmids of the present invention. The method can be adapted to produce

[0226] In various embodiments, the vector of the invention comprises a polypeptide encoding a CAR polypeptide. The vector comprises a promoter operably linked to the nucleotide sequence of one or more LTs. R, any of the LTRs may have one or more nucleotide substitutions, additions, or deletions, etc. The vector contains one or more modifications to enhance transduction efficiency. accessory elements (e.g., cPPT / FLAP), viral packaging (e.g., promoter Increase expression of the rhino (Ψ) packaging signal (RRE) and / or therapeutic gene It may further comprise other elements (e.g., a poly(A) sequence) that facilitate synthesis of the nucleic acid. , WPRE or HPRE.

[0227] In a particular embodiment, the transfer vector of the invention comprises a left (5') retrotransferase. virus LTR; central polypurine tract / DNA flap (cPPT / FLAP); a torovirus nuclear export element; a polypeptide encoding a CAR polypeptide as contemplated herein; a promoter active in T cells operably linked to a nucleotide; and 3') retroviral LTR; and optionally a WPRE or HPRE.

[0228] In a particular embodiment, the transfer vector of the invention comprises a left (5') retrotransferase. retroviral LTR; retroviral nuclear export element; CAR polypeptide as contemplated herein a promoter active in T cells operably linked to a polynucleotide encoding the right (3') retroviral LTR; and a poly(A) sequence; and optionally In another specific embodiment, the invention provides a left (5') nucleotide sequence comprising a WPRE or a HPRE. ) LTR; cPPT / FLAP; RRE; a promoter active in T cells operably linked to a polynucleotide encoding the the right (3') LTR; and a polyadenylation sequence; and optionally a WPRE or provides a lentiviral vector comprising an HPRE.

[0229] In certain embodiments, the present invention provides a method for the preparation of a HIV-1 LTR comprising the steps of: Ψ) packaging signal; cPPT / FLAP; RRE; CA as contemplated herein operably linked to a polynucleotide encoding an R polypeptide, the right (3') self-inactivating (SIN) HIV-1 LTR; and Heron β-globin polyadenylation sequence; and optionally a WPRE or HPRE The present invention provides a lentiviral vector comprising:

[0230] In another embodiment, the present invention provides a method for the preparation of a nucleic acid sequence comprising: retroviral nuclear export element; and operably linked to a polynucleotide encoding a CAR polypeptide as contemplated herein. also a promoter active in T cells; and optionally a WPRE or HPR A vector comprising E.

[0231] In certain embodiments, the present invention provides a method for the preparation of a polypeptide comprising at least one LTR; cPPT / FLAP; RRE; an RRE that acts on a polynucleotide encoding a CAR polypeptide as contemplated herein a promoter active in T cells; and a polyadenylation sequence; and optionally a WPRE or HPRE.

[0232] In certain embodiments, the present invention provides at least one SIN HIV-1 LT. R; Psi (Ψ) packaging signal; cPPT / FLAP; RRE; operably linked to a polynucleotide encoding a CAR polypeptide as shown in a promoter active in the cell; and a rabbit β-globin polyadenylation sequence; and optionally including a WPRE or HPRE.

[0233] In various embodiments, the vector is an integrating viral vector.

[0234] In various other embodiments, the vector is an episomal or a non-integrating viral vector. It is Tar.

[0235] In various embodiments, the vectors contemplated herein are non-integrating or integrating. In one embodiment, an "integration defective" retrovirus or Lentiviruses, or lentiviruses, are viruses that lack the ability to integrate the viral genome into the genome of a host cell. It refers to a retrovirus or lentivirus having tegulases. Therefore, the integrase protein is designed to specifically reduce its integrase activity. Integration-defective lentiviral vectors mutate the integrase protein. The pol gene encoding the integrase was modified to produce a mutant p Such integration-incompetent virus vectors can be obtained by introducing the ol gene. This technique is described in patent application WO2006 / 010834, the entire contents of which are incorporated herein by reference. No. 6,399,433, which is incorporated herein by reference.

[0236] Exemplary HIV-1 pol gene sites suitable for reducing integrase activity The most common mutations are H12N, H12C, H16C, H16V, S81R, D41A, and K4 2A, H51A, Q53C, D55V, D64E, D64V, E69A, K71A, E8 5A, E87A, D116N, D1161, D116A, N120G, N1201, N1 20E, E152G, E152A, D35E, K156E, K156A, E157A, K 159E, K159A, K160A, R166A, D167A, E170A, H171A , K173A, K186Q, K186T, K188T, E198A, R199c, R19 9T, R199A, D202A, K211A, Q214L, Q216L, Q221L, W 235F, W235E, K236S, K236A, K246A, G247W, D253A , R262A, R263A and K264H.

[0237] Exemplary HIV-1 pol gene sites suitable for reducing integrase activity The most common mutations are D64E, D64V, E92K, D116N, D1161, and D116A. , N120G, N1201, N120E, E152G, E152A, D35E, K156 E, K156A, E157A, K159E, K159A, W235F, and W235E These include, but are not limited to:

[0238] In certain embodiments, the integrase comprises amino acid D64, D116, or E15 In one embodiment, the integrase comprises a mutation at one or more of the amino acids D In certain embodiments, the defective HIV-1 vector comprises mutations at 64, D116, and E152. The integrase contains the D64V mutation.

[0239] A "host cell" refers to a cell that is capable of expressing a recombinant vector or polynucleotide of the invention in vivo. o, ex vivo, or in vitro by electroporation, transfection, Host cells include cells that have been transfected, infected, or transduced with the packaging cell. These may include cells, producer cells, and cells infected with a viral vector. In one embodiment, a host cell infected with the viral vector of the present invention is a target cell in need of therapy. In certain embodiments, the term "target cell" refers to a host cell. They are used interchangeably to refer to cells of the desired cell type that have been transfected, infected, or transduced. In a preferred embodiment, the target cell is a T cell.

[0240] Large-scale virus particle production is often required to achieve reasonable virus titers. The viral particles may contain viral structural and / or accessory genes, e.g., ga g, pol, env, tat, rev, vif, vpr, vpu, vpx, or ne Transfer into packaging cell lines containing the f gene or other retroviral genes It is produced by transfecting a vector.

[0241] As used herein, the term "packaging vector" refers to a packaging vector. lacking a transcription signal and one, two, three, four or more viral structural and / or accessory genes Refers to an expression vector or viral vector that contains a polynucleotide encoding a gene. Typically, the packaging vector is contained in a packaging cell and transfected. They are introduced into cells via injection, transduction or infection. Methods for transduction or infection are well known to those skilled in the art. / Lentiviral transfer vectors are used for transfection, transduction or transfection is introduced into a packaging cell line via transfection to generate a producer cell or cell line. The packaging vector of the present invention can be, for example, transfected with calcium phosphate. by standard methods, including transfection, lipofection or electroporation. In some embodiments, the package insert can be introduced into a human cell or cell line. The aging vector is designed to inhibit the expression of neomycin, hygromycin, puromycin, and blastomycin. Idine, Zeocin, Thymidine Kinase, DHFR, Gln Synthetase or ADA etc. is introduced into cells along with a dominant selectable marker, followed by selection in the presence of the appropriate drug. The selection marker gene is carried by the packaging vector. For example, the gene encoded by an IRES or a self-cleaving viral peptide may be can be logically linked.

[0242] The viral envelope protein (env) was expressed as a recombinant retroviral vector produced from a cell line. Determines the range of host cells that can ultimately be infected and transformed by the virus. HIV In the case of lentiviruses such as HIV-1, HIV-2, SIV, FIV and EIV, The nv proteins include gp41 and gp120. The viral env protein expressed by the cells is expressed by the viral gag and The pol gene and the pol gene are encoded on a separate vector.

[0243] Illustrative examples of env genes from retroviruses that can be utilized in the present invention include ML V envelope, 10A1 envelope, BAEV, FeLV-B, RD114, SSA V, Ebola, Sendai, FPV (fowl plague virus), and influenza virus E Similarly, RNA viruses (e.g., Picornaviridae, Calciviridae, Astroviridae , Togaviridae, Flaviviridae, Coronaviridae, Paramyxoviridae, Rhabdoviridae, Filoviridae e, Orthomyxoviridae, Bunyaviridae, Arenavir idae, Reoviridae, Birnaviridae, Retroviridae e RNA virus family) and DNA viruses (Hepadnaviridae, Circ oviridae, Parvoviridae, Papovaviridae, Aden oviridae, Herpesviridae, Poxyiridae, and Iridae Envelope-encoding genes from the genus Oviridae (family Bacillus subtilis) can also be used. Typical examples include FeLV, VEE, HFVW, WDSV, SFV, Rabies, and A. LV, BIV, BLV, EBV, CAEV, SNV, ChTLV, STLV, MPMV, These include SMRV, RAV, FuSV, MH2, AEV, AMV, CT10, and EIAV. can be done.

[0244] In another embodiment, the envelope for pseudotyping the viruses of the invention is The proteins are derived from the following viruses: H1N1, H1N2, H3N2 and H5N1 (avian influenza). Influenza A viruses, influenza B viruses, influenza C viruses, etc. Hepatitis B virus, Hepatitis C virus, Hepatitis D virus Hepatitis E virus, rotavirus, or any of the Norwalk virus groups enteric adenovirus, parvovirus, dengue virus, monkeypox, mononegavirus Lyssaviruses of the order Erythrocytosis, e.g., Rabies virus, Lagos bat virus, Mokolawi virus Russ, Duvenhage virus, European bat virus 1 & 2 and Australian Bat viruses, ephemeroviruses, vesiculoviruses, vesicular stomatitis viruses (V SV), herpes viruses, e.g., herpes simplex virus types 1 and 2, varicella zoster , cytomegalovirus, Epstein-Barr virus (EBV), human herpes virus Human herpesvirus (HHV), human herpesvirus types 6 and 8, human immunodeficiency virus (HIV) , papillomaviruses, murine gammaherpesviruses, arenaviruses, e.g., Zengin hemorrhagic fever virus, Bolivian hemorrhagic fever virus, Sabia-associated hemorrhagic fever virus, Venezuelan Gill hemorrhagic fever virus, Lassa fever virus, Machupo virus, Lymphocytic choriomeningitis virus Rus (LCMV), Bunyaviridiae, e.g., Crimean-Congo hemorrhagic fever virus Viruses causing hemorrhagic fever with renal syndrome, Rift Valley fever virus, Fil oviridae (Filoviruses), e.g., Ebola and Marburg hemorrhagic fever, Flaviviridae, e.g., Kyasanur Forest disease virus, Omsk hemorrhagic fever virus viruses, tick-borne encephalitis-causing viruses and Paramyxoviridae, e.g. Dora virus and Nipah virus, Variola major and Variola minor (smallpox), Alphaviruses, e.g. For example, Venezuelan equine encephalitis virus, Eastern equine encephalitis virus, Western equine encephalitis virus, SA Respiratory syncytial coronavirus (SARS-CoV), West Nile virus, and any The encephalitis-causing viruses include, but are not limited to, any of those derived from the encephalitis-causing viruses.

[0245] In one embodiment, the present invention relates to a method for the preparation of a virion that is pseudotyped with the VSV-G glycoprotein. The packaging cells that produce the recombinant retrovirus, e.g., lentivirus, provide.

[0246] As used herein, the term "pseudotype" or "pseudotyping" refers to In this way, the viral envelope proteins are replaced by those of another virus that has favorable properties. For example, HIV is a virus that has been modified by the G protein of the vesicular stomatitis virus. can be pseudotyped with the VSV-G envelope protein, This allows HIV to infect a wide range of cells. The V envelope protein (encoded by the env gene) normally binds to CD4 In a preferred embodiment of the present invention, the lentivirus The envelope protein is pseudotyped with VSV-G. The present invention relates to a method for the preparation of a virion-specific virion that is pseudotyped with the VSV-G envelope glycoprotein. The packaging cells that produce the recombinant retrovirus, e.g., lentivirus, provide.

[0247] As used herein, the term "packaging cell line" refers to a packaging A viral structural tag that does not contain a signal but is necessary for correct packaging of viral particles. Stably or transiently expressing proteins and replicase enzymes (e.g., gag, pol and env) The preparation of packaging cells of the present invention may include any of the following: Any suitable cell line may be employed. Generally, the cells are mammalian cells. In certain embodiments, In this case, the cells used to produce the packaging cell line are human cells. Suitable cell lines that can be used include, for example, CHO cells, BHK cells, MDCK cells, C3H1 0T1 / 2 cells, FLY cells, Psi-2 cells, BOSC23 cells, PA317 cells, W EHI cells, COS cells, BSC1 cells, BSC40 cells, BMT10 cells, VERO cells cells, W138 cells, MRC5 cells, A549 cells, HT1080 cells, 293 cells, 29 3T cells, B-50 cells, 3T3 cells, NIH3T3 cells, HepG2 cells, Saos- 2 cells, Huh7 cells, HeLa cells, W163 cells, 211 cells, and 211A cells. In a preferred embodiment, the packaging cells are 293 cells, 293T cells, In another preferred embodiment, the cell is an A549 cell. It is.

[0248] As used herein, the term "producer cell line" refers to a packaging Cell lines and transfer vector constructs containing packaging signals refers to a cell line capable of producing recombinant retroviral particles. Preparation of the antigen and virus stock solutions can be carried out using conventional techniques. Methods for preparing the chuck solution are known in the art and are described, for example, in Y. Sone oka et al. (1995) Nucl. Acids Res. 23:628-63 3, and NRLandau et al. (1992) J. Virol. 66:51 Infectious viral particles can be prepared by conventional techniques using packaged For example, infectious particles can be harvested from germinating cells using methods known in the art. The cells can be harvested by cell lysis or by harvesting the cell culture supernatant, as described above. Optionally, the recovered viral particles can be purified, if desired. The techniques are well known to those skilled in the art.

[0249] Retrovirus or lentivirus infection by virus rather than transfection Delivery of a gene(s) or other polynucleotide sequence using a vector is described in In one embodiment, a retroviral vector is used for infection and propagation. The cells are transduced by viral integration. In certain embodiments, the target cell A cell, e.g., a T cell, is "transduced" when the cell is transduced with a virus or retrovirus. Genes or other polynucleotides delivered to cells by infection with vectors In certain embodiments, the transduced cell comprises a nucleic acid sequence that is encoded by a nucleic acid sequence encoding ... , one or more genes delivered by retroviral or lentiviral vectors or other polynucleotide sequences.

[0250] In a specific embodiment, the vector of the invention is a virus that expresses one or more polypeptides. The transduced host cells are then used to treat and / or prevent B cell malignancies. In gene therapy that may be utilized according to certain embodiments of the present invention, Other methods for the use of virus vectors are described, for example, in Kay, MA (1997) Ch. est 111(6 Supp.):138S-142S;Ferry,N.and H eard, JM (1998) Hum. Gene Ther. 9:1975-81;S hiratory,Y.et al.(1999)Liver 19:265-74;O ka, K. et al. (2000) Curr. Opin. Lipidol. 11:17 9-86;Thule,PMand Liu,JM(2000)Gene Th er.7:1744-52;Yang, NS(1992)Crit.Rev.Bio technol.12:335-56;Alt, M. (1995) J. Hepatol. 23:746-58;Brody,SLand Crystal,RG(199 4)Ann.NYAcad.Sci.716:90-101;Strayer,D. S.(1999)Expert Opin.Investig.Drugs 8:215 9-2172;Smith-Arica,JRand Bartlett,JS (2001) Curr. Cardiol. Rep. 3:43-49; and Lee, H.C. .et al. (2000) Nature 408:483-8.

[0251] 5.6. Genetically modified cells The present invention, in certain embodiments, provides a method for producing a CAR gene that is genetically engineered to express a CAR as contemplated herein. The genetically altered cells are contemplated for use in treating B cell-related conditions. When used, the terms "genetically engineered" or "genetically modified" refer to Genetic modification refers to the addition of additional genetic material in the form of DNA or RNA to the total genetic material of a gene. The terms "genetically modified cell," "modified cell," and "redirected cell" are distinct. As used herein, the term "gene therapy" refers to the expression of a gene. restore, correct, or modify expression, or express a therapeutic polypeptide, e.g., a CAR Additional genetic material in the form of DNA or RNA may be added to the total genetic material in the cell for the purpose of This refers to the introduction of

[0252] In certain embodiments, the CARs contemplated herein are capable of expressing specific functions as immune effector cells. To redirect isomerization to a target antigen of interest, e.g., a BCMA polypeptide, An "immune effector cell" is a cell that contains one or more Effector functions (e.g., cytotoxic cell killing activity, cytokine secretion, ADCC and and / or induction of CDC).

[0253] Immune effector cells of the present invention may be autologous / autologous ("self") or non-autologous (" The recombinant gene may be "non-autologous," e.g., allogeneic, syngeneic, or xenogeneic.

[0254] "Autologous," as used herein, refers to cells derived from the same subject.

[0255] "Allogeneic" as used herein refers to a cell of the same species that is genetically distinct from the cell being compared. Refers to cells.

[0256] "Syngeneic," as used herein, refers to a different counterpart that is genetically identical to the cell being compared. Refers to elephant cells.

[0257] "Xenogeneic," as used herein, refers to a cell of a different species than the cell being compared. In a preferred embodiment, the cells of the invention are allogeneic.

[0258] Exemplary immune effector cells for use with the CARs contemplated herein include The term "T cell" or "T lymphocyte" is used in the art. It is recognized in the field that thymocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, The term "T-cells" is intended to include T helper (Th) lymphocytes, or activated T lymphocytes. The cells can be, for example, T helper 1 (Th1) or T helper 2 (Th2) cells. T cells are helper T cells (HTL; CD4 + T cells)CD4 + T cells, cytotoxic T cells (CTL; ​​CD8 + T cells), CD4 + CD8 + T cells, CD4 - CD8 - The present invention relates to a method for the production of T cells, the method comprising: Other exemplary populations of T cells suitable for inducing the expression of T cells include naive T cells and memory T cells. Examples include:

[0259] As will be appreciated by those of skill in the art, other cells can also be used to induce immune effectors, including the CARs described herein. In particular, immune effector cells can also be used as NK cells, NK Immune effector cells include T cells, neutrophils, and macrophages. Also included are precursors of vector cells, such precursor cells being derived from cells that are either in vivo or in vivo. It is possible to induce differentiation into immune effector cells in vitro. In one embodiment, the immune effector cells, when administered to a subject, produce mature immune effector either differentiate into IL-16 cells or be induced in vitro to differentiate into mature immune effector cells. The CD34 expression of cells obtained from umbilical cord blood, bone marrow or induced peripheral blood can be induced to + includes precursors of immune effector cells, such as hematopoietic stem cells (HSCs), contained within the population .

[0260] As used herein, a BCMA-specific CAR is a marker for a BCMA-specific CAR. The immune effector cells were termed "BCMA-specific redirected immune effector cells." It is possible.

[0261] As used herein, "CD34 + The term "cell" refers to a cell that has the CD34 tag on its cell surface. As used herein, "CD34" refers to cells that express the CD34 protein. A cell surface glycoprotein that acts as a cell-cell adhesion molecule and is involved in the entry of T cells into lymph nodes. CD34 refers to proteins (e.g., sialomucin proteins). + The cell population is hematopoietic stem cells ( When administered to a patient, the HSCs differentiate into T cells, NK cells, NKT cells, and neutrophils. They differentiate and contribute to all hematopoietic lineages, including cells of the cytoplasmic and monocyte / macrophage lineages.

[0262] The present invention provides a method for generating immune effector cells expressing the CARs contemplated herein. In one embodiment, the method comprises administering to the subject the immune effector cells as described herein. Immune effector cells isolated from an individual are cultured to express one or more of the CARs described. In certain embodiments, the immunosuppressant comprises transfecting or transducing an immunosuppressant. Immunologic effector cells can be isolated from an individual and used without further manipulation in vitro. Such cells can then be directly readministered back into the individual. In a further embodiment, the immune effector cells are first activated in vitro. The cells are then stimulated to grow and then genetically engineered to express the CAR. Thus, immune effector cells are genetically modified (i.e., as contemplated herein, Cultured before and / or after (transduced or transfected to express AR) It can be done.

[0263] In certain embodiments, the cell source is the iPSC of the immune effector cells described herein. In certain embodiments, the nucleic acid is obtained from a subject prior to in vitro manipulation or genetic modification. CAR-modified immune effector cells include, but are not limited to, T cells. , peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue obtained from the site of infection, It can be obtained from a number of sources, including ascites, pleural fluid, splenic tissue, and tumors. In an embodiment, the T cells are isolated by sedimentation, e.g., by methods known to those of skill in the art, such as FICOLL™ separation. The blood sample may be obtained from a unit of blood drawn from a subject using any number of techniques currently available. In one embodiment, cells derived from the circulating blood of an individual are obtained by apheresis. Apheresis products typically contain T cells, monocytes, granulocytes, B cells, and other nucleated white blood cells. In one embodiment, the apheresis comprises lymphocytes, including red blood cells, and platelets. The cells harvested by the method are then depleted of the plasma fraction and placed in a buffer or medium appropriate for further processing. The cells may be washed with PBS or with calcium, calcium phosphate, or calcium phosphate buffer to place the cells in a PBS-containing medium. Another preferred embodiment is free of magnesium and most, if not all, other divalent cations. As will be appreciated by those skilled in the art, the washing step may be carried out using a solution such as By methods known to those skilled in the art, for example, using a semi-automated flow-through centrifuge. For example, the Cobe2991 cell processor After washing, cells were incubated in various biocompatible buffers, or other saline solutions, with or without buffer. In this embodiment, the undesirable components of the apheresis sample are directly transferred to the medium in which the cells are resuspended. may be removed from

[0264] In certain embodiments, T cells inhibit proliferation by lysing red blood cells and removing monocytes. For example, peripheral blood mononuclear cells are isolated by centrifugation through a PERCOLL™ density gradient. (PBMC) and the following markers: CD3, CD28, CD4, CD8, CD A specific subpopulation of T cells expressing one or more of CD45RA and CD45RO is In one embodiment, the mutants can be further isolated by selective or negative selection techniques. They express CD3, CD28, CD4, CD8, CD45RA, and CD45RO. Specific subpopulations of T cells can be further isolated by positive or negative selection techniques. For example, enrichment of a T cell population by negative selection results in the retention of negatively selected cells. This can be achieved by a combination of antibodies against specific surface markers. One method used is to use the antibody against a cell surface marker present on the negatively selected cells. Negative magnetic immunoadhesion or flow cytometry using a cocktail of monoclonal antibodies cell sorting and / or cell selection via cytogenetics. For example, negative selection Depending on the selection, CD4 + To enrich for cells, monoclonal antibody cocktails are typically used. Contains antibodies against D14, CD20, CD11b, CD16, HLA-DR and CD8 Flow cytometry and cell sorting are used to identify cells of interest for use in the present invention. It may also be used to isolate groups.

[0265] PBMCs can be directly transfected to express a CAR using the methods contemplated herein. In certain embodiments, after isolation of the PBMCs, the T lymphocytes may be further In certain embodiments, isolated cytotoxic T lymphocytes and helper T lymphocytes. Both are naive, memory, and either before or after genetic modification and / or expansion. , and effector T cell subpopulations.

[0266] CD8 + The cells can be obtained by using standard methods. In an embodiment, CD8 + The cells are CD8 + The cell surface antigens associated with each cell type By identifying naive cells, central memory cells, and effector cells, are further selected.

[0267] In certain embodiments, naive CD8 + T lymphocytes express CD62L, CCR 7. Phenotype of naive T cells, including CD28, CD3, CD127, and CD45RA It is characterized by the expression of a marker.

[0268] In certain embodiments, memory T cells are CD8 + CD62L on peripheral blood lymphocytes + and CD62L - PBMCs express anti-CD8 and anti-CD After staining with CD62L antibody, - CD8 + Fractionation and CD62L + CD8 + Selected fractions In some embodiments, the phenotypic markers of central memory T cells are Expression includes CD45RO, CD62L, CCR7, CD28, CD3, and CD127. In some embodiments, the Centra Memory T cells are CD45RO + , CD62L + , CD8 + T cells.

[0269] In some embodiments, effector T cells are CD62L, CCR7, CD2 8 and CD127, and negative for granzyme B and perforin. It is positive.

[0270] In certain embodiments, CD4 + T cells can be further sorted into subpopulations. For example, CD4 +T helper cells identify cell populations that carry cell surface antigens. By using this method, naive cells, central memory cells, and effector cells can be selected. CD4 + Lymphocytes can be obtained by standard methods. In this state, naive CD4 + T lymphocytes are CD45RO - , CD45RA + , CD 62L + CD4 + In some embodiments, the central memory T cell is a CD4 + The cells are CD62L positive and CD45RO positive. In an embodiment, the effector CD4 + The cells were CD62L and CD45RO negative. It is Bu.

[0271] Immune effector cells, such as T cells, are isolated using known methods and then genetically modified. or immune effector cells can be activated and expanded in vitro. (or differentiation in the case of precursors) before genetic modification can be performed. In this embodiment, immune effector cells, such as T cells, are capable of expressing the chimeric antigen receptors contemplated herein. A vector that is genetically modified with a receptor (e.g., a viral vector that contains a nucleic acid encoding a CAR) are transduced), then activated and expanded in vitro. In certain embodiments, the T cells may be derived from T cells as described, e.g., in U.S. Pat. Nos. 6,352,694; 6,534,0 No. 55; No. 6,905,680; No. 6,692,964; No. 5,858,35 No. 8; No. 6,887,466; No. 6,905,681; No. 7,144,575 No. 7,067,318; No. 7,172,869; No. 7,232,566 ; Same No. 7, 175,843; Same No. 5,883,223; Same No. 6,905,874; Nos. 6,797,514; 6,867,041; and U.S. Patent Application No. 20060 The gene was then transfected to express CAR using methods such as those described in US Pat. No. 5,310,555. The activation and expansion can occur before or after modification.

[0272] In general, T cells respond to stimulatory factors and signals associated with the CD3 TCR complex. The cells are expanded by contact with surfaces that have ligands that stimulate costimulatory molecules on the cell surface. The T cell population is stimulated with anti-CD3 antibody or an antigen-binding fragment thereof immobilized on a surface, or The CD2 antibody was contacted with the protein in combination with a calcium ionophore. can be stimulated by contact with an kinase C activator (e.g., bryostatin) Costimulation of accessory molecules on the surface of T cells is also contemplated.

[0273] In certain embodiments, the PBMCs or isolated T cells are administered IL-2, IL-7, and / or IL-15 in a medium containing an appropriate cytokine, such as beads or It interacts with other surface-bound stimulatory and costimulatory factors, such as anti-CD3 and anti-CD28 antibodies. Contacted. CD4 + T cells or CD8 + To stimulate the proliferation of any of the T cells Examples of anti-CD28 antibodies include 9.3 and BT. 3. XR-CD28 (Diacione, Besancon, France) , as well as other methods commonly known in the art (B erg et al.,Transplant Proc.30(8):3975-39 77,1998;Haanen et al.,J.Exp.Med.190(9):1 3191328,1999;Garland et al., J. Immunol Me th.227(1-2):53-63, 1999). Anti-CD3 antibodies bound to the same beads The body and anti-CD28 antibodies function as "surrogate" antigen-presenting cells (APCs). In embodiments, the T cells are those described in US6040177; US5827642; and WO20 Feeder cells as well as suitable They can be activated and stimulated to proliferate by various antibodies and cytokines.

[0274] In another embodiment, artificial APCs (aAPCs) are capable of expressing various costimulatory molecules and cytokines. We developed K562, U937, 721.221, and T 2, and C1R cells. In certain embodiments, K3 2 or U32 aAPCs, one or more antibody-based stimulators on the aAPC cell surface Induce the expression of various combinations of genes on aAPCs. This allows for precise determination of the activation requirements of human T cells, which in turn allows for the identification of specific growth requirements. and tailoring aAPCs for optimal proliferation of T cell subsets with different functions. In contrast to the use of natural APCs, aAPCs do not require the addition of exogenous cytokines. Ex vivo growth and long-term expansion of functional human CD8 T cells without the need for T cell populations include, but are not limited to, CD137L (4-1BBL), Various co-expressing genes, including CD134L (OX40L), and / or CD80 or CD86 Finally, aAPCs can be expanded by expressing stimulatory molecules. An efficient platform for expanding engineered T cells and maintaining CD28 expression on CD8 T cells The platform is provided in WO03 / 057171 and US2003 / 0147869. The aAPCs provided herein are incorporated by reference in their entirety.

[0275] In one embodiment, CD34 + The cells are transfected with a nucleic acid construct according to the invention. In certain embodiments, transduced CD34 + Cells are objects, generally After administration to the subject from whom the cells were isolated, they develop into mature immune effector cells in vivo. In another embodiment, CD34 + The cells are exposed to a CAR as described herein. Before exposure to the CAR or after genetic modification with the CAR, the CAR is subjected to the following steps according to the method described above: Cytokines: Flt-3 ligand (FLT3), stem cell factor (SCF), megakaryocyte growth factor In vitro differentiation of IL-1 by one or more of differentiation factors (TPO), IL-3 and IL-6 (Asheuer et al., 2004, PNAS 101(10) :3557-3562; Imren, et al., 2004).

[0276] The present invention provides a population of modified immune effector cells for the treatment of cancer, The engineered immune effector cells include the CARs disclosed herein. The population of immune effector cells is a subset of the population of immune effector cells that is expressed in a patient diagnosed with a B cell malignancy as described herein. PBM is prepared from peripheral blood mononuclear cells (PBMCs) obtained from a patient (autologous donor). C is CD4 + , CD8 + , or CD4 + and CD8 + Possible T lymphocyte heterogeneity form a group.

[0277] PBMCs may also contain other cytotoxic lymphocytes, such as NK cells or NKT cells. An expression vector carrying the coding sequence of a CAR as contemplated herein is introduced into the human donor. It can be introduced into populations of T cells, NK cells or NKT cells. T cells carrying the expression vector were identified as CD3 positive T cells using flow cytometry. The cells are then screened for and subsequently treated with anti-CD3 and / or anti-CD28 antibodies and or any of the compounds known in the art as described elsewhere herein. In addition to activating the cells using other methods, further propagation can be used to express these CAR proteins. The number of T cells expressing the CAR protein can be increased in human subjects. Standard procedures are used to cryopreserve T cells for storage and / or preparation for use. In one embodiment, the in vitro transduction, culture and / or expansion of T cells is The assay is carried out in the absence of non-human animal derived products such as calf serum and fetal bovine serum. Since a heterogeneous population of BMCs is genetically modified, the resulting transduced cells are A heterogeneous population of engineered cells comprising a BCMA-targeted CAR as contemplated herein.

[0278] In a further embodiment, genetically modifying the donor population of immune effector cells includes For example, a mixture of 1, 2, 3, 4, 5 or more different expression vectors is used. Each vector can contain a different chimeric antigen receptor protein as contemplated herein. The resulting modified immune effector cells are a mixed population of modified cells. A population is formed, with a proportion of the modified cells expressing more than one different CAR protein.

[0279] In one embodiment, the present invention provides a genetically modified mAb that targets the BCMA protein. We present a method to preserve mouse, human or humanized CAR protein-expressing immune effector cells. Cryopreservation of immune effector cells ensures that cells remain viable upon thawing A portion of the immune effector cells expressing the CAR protein are involved in B cell-associated To provide a permanent source of such cells for future treatment of patients suffering from related conditions. For storage, the cells can be cryopreserved by methods known in the art. In such cases, cryopreserving transformed immune effector cells may provide a greater number of cells of interest. It can thaw, grow and expand in order to

[0280] As used herein, "cryopreservation" refers to storage at temperatures (typically) 77K or -196°C. This refers to the preservation of cells by cooling to subzero temperatures, such as the boiling point of liquid nitrogen. To prevent damage to cells from freezing at low temperatures or from warming to room temperature, cryopreservation is often used. A preservative is used at sub-zero temperatures. The cryopreservative and optimal cooling rate prevent cell damage. Cryopreservation agents that can be used include, but are not limited to, dichloromethane. Methyl sulfoxide (DMSO) (Lovelock and Bishop, Nature re,1959;183:1394-1395;Ashwood-Smith,Natu re,1961;190:1204-1205), glycerol, polyvinylpyrrolidone (Rinfret,Ann.NYAcad.Sci.,1960;85:576) and polyethylene glycol (Sloviter and Ravdin, Nature The preferred cooling rate is 1 to 3°C / min. After at least 2 hours, the T cells reach a temperature of -80°C and can be stored in a cryogenic container for a long period of time. Can be placed directly into liquid nitrogen (-196°C) for permanent storage.

[0281] 5.7.T cell maturation process The T cells produced by the methods contemplated herein are useful in improved adoptive immunotherapy compositions. Without wishing to be bound by any particular theory, the present invention provides The T cell compositions produced by the contemplated methods have increased survival rates, relatively little differentiation, and These compounds are believed to have superior properties, including rapid expansion and persistence in vivo. In one embodiment, the method of producing a T cell includes modulating the PI3K cell signaling pathway. In one embodiment, the method comprises contacting the cells with one or more factors that induce T cell proliferation and / or proliferation. The method includes administering to a subject one or more factors that modulate the PI3K / Akt / mTOR cell signaling pathway. In various embodiments, the T cells are contacted with and can be contacted with the agent during the activation and / or expansion steps of the manufacturing process. The resulting T cell composition proliferates and expresses the following biomarkers: CD62L, CCR7, One of CD28, CD27, CD122, CD127, CD197, and CD38 In one embodiment, the present invention is enriched for developmentally potent T cells capable of expressing The population of cells containing T cells treated with one or more PI3K inhibitors showed the following biomarkers: - One or more or all of CD62L, CD127, CD197, and CD38 The co-expressing CD8+ T cell population is enriched for.

[0282] In one embodiment, modified T cells with maintained proliferation levels and reduced differentiation are In certain embodiments, the T cells are produced by inducing one or more stimulatory signals and a PI3K T cells are activated and proliferated in the presence of factors that are inhibitors of cell signaling pathways. It is produced by stimulation.

[0283] The T cells can then be engineered to express the anti-BCMA CAR. In embodiments, the T cells are immunized with a viral vector comprising an anti-BCMA CAR as contemplated herein. In certain embodiments, the T cell is modified by transducing the vector into the T cell. T cells were modified prior to stimulation and activation in the presence of inhibitors of the PI3K cell signaling pathway. In another embodiment, the T cells are mutated with an inhibitor of the PI3K cell signaling pathway. In certain embodiments, T cells are modified following stimulation and activation in the presence of PI. Stimulation and activation in the presence of inhibitors of the 3K cell signaling pathway for 12 h, 24 h, The change will occur within 36 or 48 hours.

[0284] Once the T cells are activated, they are cultured and expanded. T cells are expanded by at least 1, 2, or 3 , 4, 5, 6, or 7 days, at least 2 weeks, at least 1, 2, 3, 4, 5, or 6 months or more, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more expansion rounds and can be cultured.

[0285] In various embodiments, the T cell composition is administered in the presence of one or more inhibitors of the PI3K pathway. Inhibitors can target one or more activities in a pathway or a single activity. Without wishing to be bound by any particular theory, it is believed that the stimulation stage of the manufacturing process Treatment with one or more inhibitors of the PI3K pathway during the activation and / or expansion phase or contact with the T cells preferentially increases immature T cells, thereby providing superior therapeutic It is contemplated that a therapeutic T cell composition may be produced.

[0286] In certain embodiments, the proliferation of T cells expressing an engineered T cell receptor is increased. Such methods may include, for example, harvesting a source of T cells from a subject. and stimulating and activating T cells in the presence of one or more inhibitors of the PI3K pathway. By modifying T cells to express a CMA CAR, e.g., an anti-BCMA02 CAR, and expanding the T cells in culture.

[0287] In certain embodiments, the following biomarkers: CD62L, CCR7, CD28 , CD27, CD122, CD127, CD197, and CD38. In one embodiment, the immature T cells are generated by a method for generating an enriched population of immature T cells, comprising: Biological markers: one or more of CD62L, CD127, CD197, and CD38 In one embodiment, CD57, CD244, CD160, PD The present invention provides immature T cells lacking expression of T-1, CTLA4, TIM3, and LAG3. As discussed elsewhere in the document, expression levels of immature T cell biomarkers were higher than those of more differentiated T cell compared to the expression level of that marker in the T cell or immune effector cell population. .

[0288] In one embodiment, peripheral blood mononuclear cells (PBMCs) are used to generate T cells as contemplated herein. PBMCs are used as the source of T cells for the production process. + , CD8 + , or CD4 + and CD8 + Form a heterogeneous population of T lymphocytes, monocytes, B cells, NK cells that may and other mononuclear cells such as NKT cells. Alternatively, an expression vector comprising a polynucleotide encoding a CAR can be expressed in T cells of a human donor. , can be introduced into a population of NK cells or NKT cells. Vector-carrying T cells were identified using flow cytometry to identify CD3 positive T cells. and then reacting with anti-CD3 and / or anti-CD28 antibodies and IL- 2, IL-7, and / or IL-15, or any other method in the art as described herein. In addition to activating the cells using any other method known in the art, further propagation may be performed. The number of modified T cells can be expanded.

[0289] The manufacturing methods contemplated herein include methods for storing and / or preparing the pharmaceutical composition for use in human subjects. The T cells may further comprise cryopreserving the modified T cells for the purpose of administering the modified T cells to a patient in need thereof, such that the cells remain viable upon thawing. If necessary, the cryopreserved transformed immune effector cells are cryopreserved. The cultured cells can be thawed, grown and expanded to obtain more of the cells. As used herein, "cryopreservation" refers to storage at temperatures (typically) 77 K or -196°C ( It refers to the preservation of cells by cooling to subzero temperatures, such as the boiling point of liquid nitrogen. To prevent damage caused by freezing cells at low temperatures or by warming them to room temperature, cells are often stored frozen. Cryopreservation agents are used at subzero temperatures. The cryopreservation agents and optimal cooling rates prevent cell damage. Cryopreservation agents that can be used include, but are not limited to, dimethylformamide, dimethyl ether, dimethyl methacrylate ... Dimethyl sulfoxide (DMSO) (Lovelock and Bishop, Nature e,1959;183:1394-1395;Ashwood-Smith,Natur e,1961;190:1204-1205), glycerol, polyvinylpyrrolidone ( Rinfret, Ann. NYAcad. Sci., 1960;85:576), and and polyethylene glycol (Sloviter and Ravdin, Nature, 1962;196:48). The preferred cooling rate is 1 to 3°C / min. After at least 2 hours, the T cells reach a temperature of -80°C and are ready for long-term cryogenic storage. It can be placed directly into liquid nitrogen (-196°C) for permanent storage.

[0290] 5.8.T cells The present invention contemplates the production of improved CAR T cell compositions. The T cells used may be autologous / autologous ("self") or non-autologous ("non-self", e.g. In a preferred embodiment, the T cells are derived from mammalian T cells. In a more preferred embodiment, the T cells are obtained from a primate subject. In a most preferred embodiment, the T cells are obtained from a human subject.

[0291] T cells may be derived from, but are not limited to, peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, Multiple sources include thymus tissue, tissue obtained from an infected site, ascites, pleural fluid, splenic tissue, and tumors. In certain embodiments, T cells can be obtained by precipitation, e.g., FIC. from a subject using any number of techniques known to those of skill in the art, such as OLL™ isolation. In one embodiment, the cells can be obtained from a unit of blood that has been isolated from the circulating blood of an individual. The cells are obtained by apheresis. The apheresis product typically contains T cells. It contains lymphocytes, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells and platelets. In an embodiment, cells harvested by apheresis are subjected to removal of the plasma fraction and subsequent The cells may be washed to place them in a buffer or medium appropriate for treatment of P. BS or calcium, magnesium, and most if not all others The washing can be performed with another suitable solution that does not contain divalent cations. As will be appreciated, the washing step can be carried out by methods known to those skilled in the art, e.g., by a semi-automated This can be achieved, for example, by using a flow-through centrifuge. , Cobe2991 cell processor, Baxter CytoMate, etc. After washing, The cells are cultured in a variety of biocompatible buffers or other saline solutions with or without buffering agents. In certain embodiments, undesirable configurations of the apheresis sample may be Components may be removed from the medium in which the cells are directly resuspended.

[0292] In certain embodiments, the methods of manufacture contemplated herein include the use of T cells, e.g., PB A population of cells containing MCs is used. In another embodiment, the production contemplated herein The method uses an isolated or purified population of T cells. The cells lyse red blood cells. By dissolving the cells and removing the monocytes, for example, centrifuging on a PERCOLL™ density gradient It can be isolated from peripheral blood mononuclear cells (PBMCs) by cardiac separation. In an embodiment, after isolation of PBMCs, both cytotoxic T lymphocytes and helper T lymphocytes are isolated. The methods include naive, metastatic, or mitotic cell death, either before or after activation, expansion, and / or genetic modification. The T cells can be sorted into immune, immunizing, and effector T cell subpopulations.

[0293] The following markers: CD3, CD4, CD8, CD28, CD45RA, CD45RO, C A specific subset of T cells expressing one or more of D62, CD127, and HLA-DR The population can be further isolated by positive or negative selection techniques. In some embodiments, (i) CD62L, CCR7, CD28, CD27, CD122, CD 127, CD197; or (ii) CD38 or CD62L, CD127, CD1 T cells expressing one or more markers selected from the group consisting of CD38, CD40, CD50, CD60, and CD81. Specific subpopulations of cells can be further isolated by positive or negative selection techniques. In various embodiments, the T cell compositions produced are characterized by the following markers: CD57, CD2 44, CD160, PD-1, CTLA4, TIM3, and / or LAG3. Not expressed or substantially not expressed.

[0294] In one embodiment, the group consisting of CD62L, CD127, CD197, and CD38. The expression of one or more of the markers selected from the group consisting of PI3K activation and at least 1.5-fold, at least 2-fold, at least At least three times, at least four times, at least five times, at least six times, at least seven times, at least Increases by 8-fold, at least 9-fold, at least 10-fold, at least 25-fold, or more. do.

[0295] In one embodiment, CD57, CD244, CD160, PD-1, CTLA4, T Expression of one or more markers selected from the group consisting of IM3, and LAG3 is indicative of P at least 1.5% compared to a population of T cells activated and expanded with an I3K inhibitor fold, at least 2x, at least 3x, at least 4x, at least 5x, at least 6x times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least A decrease of 25 times or more.

[0296] In one embodiment, the methods of production contemplated herein involve the use of naive or developmental T cells. Increase the number of CAR T cells that contain one or more markers of potent T cells in any Without wishing to be bound by any particular theory, the present inventors believe that the Treatment of the population with one or more PI3K inhibitors demonstrated Compared to placebo, this resulted in increased expansion of developmentally potent T cells, leading to more robust and effective adoptive CAR T cells. We believe that cell immunotherapy will be provided.

[0297] Naive T cells or T cells expanded with T cells produced using the methods contemplated herein Illustrative examples of developmentally potent T cell markers include CD62L, CD127, C D197, and CD38. Naive T cells express the following markers: CD57, CD244, CD160, PD-1, Expresses one or more of BTLA, CD45RA, CTLA4, TIM3, and LAG3 Not expressed or substantially not expressed.

[0298] With respect to T cells, the T cell populations resulting from the various expansion methods contemplated herein may be Depending on the conditions under which they are grown, they may have a variety of specific phenotypic properties. The expanded T cell population was identified by the following phenotypic markers: CD62L, CD127, CD197, C D38, and one or more of HLA-DR.

[0299] In one embodiment, such phenotypic markers include CD62L, CD127, CD1 97, and CD38. In this state, naive T cells express Characterized by expression of CD8 phenotypic markers + T lymphocytes are expanded.

[0300] In certain embodiments, CD45RO, CD62L, CD127, CD197, and Central memory T cells contain CD38 and are negative for granzyme B T cells characterized by expression of the phenotypic markers are expanded. In this state, central memory T cells express CD45RO + , CD62L + , CD8 + T cells.

[0301] In certain embodiments, CD62L, CD45RA and / or CD45 Naive CD4 negative for expression of RO + Expression of phenotypic markers in cells CD4 is characterized as + T lymphocytes are expanded. In some embodiments, Central memory CD4, including CD62L and CD45RO positive + Cell phenotype Characterized by expression of the marker CD4 + In some embodiments, Fector CD4 + The cells are CD62L positive and CD45RO negative.

[0302] In certain embodiments, T cells are isolated from an individual and activated in vitro. These cells were then genetically engineered to express the anti-BCMA CAR. In this regard, T cells may be genetically modified (i.e., to express the antigen as contemplated herein). Before and / or after transduction or transfection to express BCMA CAR or later cultured.

[0303] 5.8.1. Activation and expansion To achieve a sufficient therapeutic dose of a T cell composition, T cells are often stimulated, activated, and / or undergo one or more rounds of expansion. T cells are generally cultured as described, for example, in US Pat. 6,352,694; 6,534,055; 6,905,680; 6,905,680; No. 6,692,964; No. 5,858,358; No. 6,887,466; No. 6 , 905,681; 7,144,575; 7,067,318; 7, No. 172,869; No. 7,232,566; No. 7,175,843; No. 5,8 Nos. 83,223; 6,905,874; 6,797,514; and 6, The method of claim 867,041 is also disclosed in US Pat. No. 5,399,623. Each is incorporated herein by reference in its entirety. The engineered T cells can be activated and expanded before and / or after the T cells are engineered. In addition, T cells may be immunized with P In one embodiment, the subject may be contacted with one or more factors that modulate the I3K cell signaling pathway. In one embodiment, the T cells produced by the methods contemplated herein are 1, 2, 3, 4, or It has undergone more than five rounds of activation and expansion, each of which involves the activation of PI3K cellular signaling It may include one or more factors that regulate the transduction pathway.

[0304] In one embodiment, the costimulatory ligand is a ligand that stimulates antigen-presenting cells (e.g., aAPCs, dendritic cells). They are present on immune cells (e.g., B cells) and bind specifically to the cognate costimulatory molecules on T cells. In order to induce a desired T cell response, for example, a single T cell response mediated by the engagement of the TCR / CD3 complex is In addition to the primary signal, it also mediates the signal. Suitable costimulatory ligands include CD7 , B7-1(CD80), B7-2(CD86), PD-L1, PD-L2, 4-1BB L, OX40L, inducible costimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM) , CD30L, CD40, CD70, CD83, HLA-G, MICA, MICB, HV EM, lymphotoxin beta receptor, ILT3, ILT4, agonist or Toll These include antibodies that bind to ligand receptors, and ligands that specifically bind to B7-H3. But not limited to these.

[0305] In certain embodiments, the costimulatory ligand includes, but is not limited to, CD27, C D28, 4-IBB, OX40, CD30, CD40, PD-1, 1COS, lymphocyte LFA-1, CD7, LIGHT, NKG2C, B7-H3, and CD Binds specifically to costimulatory molecules present on T cells, including a ligand that specifically binds to 83 The present invention includes an antibody or antigen-binding fragment thereof that binds to the antibody or antigen-binding fragment thereof.

[0306] Suitable costimulatory ligands are provided in soluble form or expressed on the modified T cells. A target expressed on an APC or aAPC that binds to an engineered TCR or CAR. The antibody further comprises a target antigen.

[0307] In various embodiments, the methods for producing T cells contemplated herein include These include activating a population of cells, including the T cells, and expanding a population of T cells. Activation occurs via the T cell TCR / CD3 complex or through stimulation of the CD2 surface protein. By providing a primary stimulatory signal via the IL-1 receptor and also by inducing accessory molecules, e.g., C This can be achieved by providing a second costimulatory signal with D28.

[0308] The TCR / CD3 complex may be coupled to a suitable CD3 binding agent, such as a CD3 ligand or anti-CD3 ligand. The T cells can be stimulated by contacting them with the CD3 monoclonal antibody. Illustrative examples include OKT3, G19-4, BC3, and 64.1, Not limited to these.

[0309] In another embodiment, the CD2 binding agent is a stimulatory agent for providing a primary stimulatory signal to a T cell. Illustrative examples of CD2 binding agents include CD2 ligands and anti-CD2 antibodies. Antibodies, such as T11.3 antibodies (Me) in combination with T11.1 or T11.2 antibodies uer, SC et al. (1984) Cell 36:897-906) and 9- 9.6 antibody (which recognizes the same epitope as TI1.1) combined with TI1.1 antibody (Yang ,SYet al.(1986)J.Immunol.137:1097-1100 ) are included, but are not limited to, those that bind to the same epitope as any of the above antibodies. Other antibodies that can be used in combination with the antibody may also be used. Additional antibodies, or combinations of antibodies, may be used in accordance with the present invention. They can be prepared and characterized by standard techniques, as disclosed elsewhere herein.

[0310] The primary stimulatory signal is delivered by the TCR / CD3 complex or via CD2. In addition, induction of a T cell response requires a second costimulatory signal. In this regard, the CD28 binding agent can be used to provide a costimulatory signal. Illustrative examples of CD28 binding agents include natural CD28 ligands, e.g., Natural ligands for B7, such as B7-1 (CD80) and B7-2 (CD86), family protein); and anti-CD2 capable of cross-linking the CD28 molecule. 8 Monoclonal antibodies or fragments thereof, such as monoclonal antibodies 9.3, B-T3, XR-CD28, KOLT-2, 15E8, 248.23.2, and EX5.3D10 These include, but are not limited to:

[0311] In one embodiment, the molecule that provides the primary stimulatory signal, e.g., the TCR / CD3 complex Molecules that mediate stimulation via the CD2 receptor and costimulatory molecules are bound to the same surface. .

[0312] In certain embodiments, the binding factors that provide the stimulatory and costimulatory signals are This allows the protein to be localized on the surface of the cell in a form suitable for its expression on the cell surface. by transfecting or transducing a cell with a nucleic acid encoding a binding factor, Alternatively, this can be achieved by binding the binding agent to the cell surface in another manner.

[0313] In another embodiment, the molecule that provides the primary stimulatory signal, e.g., a TCR / CD3 complex, Molecules that stimulate fusion or CD2, and costimulatory molecules, are presented on antigen-presenting cells. As shown.

[0314] In one embodiment, the molecule that provides the primary stimulatory signal, e.g., the TCR / CD3 complex Molecules that provide stimulation via the CD4+ or CD2 and costimulatory molecules are provided on different surfaces. can be.

[0315] In certain embodiments, the binding factors that provide the primary stimulatory signal and the costimulatory signal One of the factors is soluble (provided in solution) and the other factor(s) is one or more is provided on the upper surface.

[0316] In certain embodiments, the binding factors that provide the stimulatory and costimulatory signals are Both are provided in a soluble form (provided in solution).

[0317] In various embodiments, the methods for producing T cells contemplated herein include anti-C This involves activating T cells with anti-CD3 antibody and anti-CD28 antibody.

[0318] The T cell compositions produced by the methods contemplated herein may be used to inhibit PI3K cell signaling. The present invention relates to a method for treating T cells that is activated and / or expanded in the presence of one or more factors that inhibit the signaling pathway. T cells engineered to express an anti-BCMA CAR can be used to treat a variety of conditions, including those that occur before and after the T cells are engineered. In certain embodiments, T cell populations can be activated and / or expanded later. The swarms are activated, engineered to express anti-BCMA CAR, and then cultured for expansion. are cultivated in

[0319] In one embodiment, the T cells produced by the methods contemplated herein are highly proliferative. Express markers of reproduction and self-renewal, but not of T cell differentiation The present invention includes increased numbers of T cells that express substantially no detectable marker. These T cells can be repeatedly activated and robustly expanded, thereby allowing for improved therapeutics. A T cell composition for use is provided.

[0320] In one embodiment, the presence of one or more factors that inhibit the PI3K cell signaling pathway. The population of T cells activated and expanded under PI3K inhibitors was similar to that activated and expanded without PI3K inhibitors. at least 1.5-fold, at least 2-fold, at least 3-fold, At least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, At least 9 times, at least 10 times, at least 25 times, at least 50 times, at least 100-fold, at least 250-fold, at least 500-fold, at least 1000-fold, or more It will be expanded even further.

[0321] In one embodiment, a population of T cells characterized by expression of markers of immature T cells is The cluster was activated and expanded in the presence of one or more factors that inhibit the PI3K cell signaling pathway. The number of T cells increased by 100,000, compared with the population of T cells activated and expanded without PI3K inhibitors. At least 1.5 times, at least 2 times, at least 3 times, at least 4 times, at least 5 times, At least 6 times, at least 7 times, at least 8 times, at least 9 times, at least 10 times , at least 25 times, at least 50 times, at least 100 times, at least 250 times, It is magnified at least 500 times, at least 1000 times, or more.

[0322] In one embodiment, the T cells activated by the methods contemplated herein are expanded. The time can be set in units of a few hours (approximately 3 hours) to about 7 days to about 28 days, or any time unit therebetween. In another embodiment, the method further comprises culturing the population of cells comprising T cells for a period of time. The T cell composition may be cultured for 14 days. In certain embodiments, the T cells are cultured for about 21 days. In another embodiment, the T cell composition is cultured for about 2 to 3 days. Several cycles of stimulation / activation / expansion are recommended so that cell culture times can exceed 60 days. In some cases, this is not possible.

[0323] In certain embodiments, suitable conditions for T cell culture include a suitable medium (e.g., minimum essential medium or RPMI medium 1640 or X-vivo15, (Lonza)) and One or more factors necessary for growth and survival, such as, but not limited to, serum (e.g. , fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN -γ, IL-4, IL-7, IL-21, GM-CSF, IL-10, IL-12, IL -15, TGFβ, and TNF-α, or any suitable cell growth enhancer known to those of skill in the art. Contains other additives.

[0324] Further illustrative examples of cell culture media include, but are not limited to, RPMI 1640. , Clicks, AIM-V, DMEM, MEM, a-MEM, F-12, X-Vivo 15, and X-Vivo20, Optimizer, which contain amino acids, Sodium pyruvate and vitamins have been added, and the blood is serum-free or in the appropriate amount. Serum (or plasma) is added or a defined set of hormones and / or T cell Cytokine(s) are added in an amount sufficient for growth and expansion.

[0325] Illustrative examples of other additives for T cell expansion include surfactants, piercemanate, pH buffers such as HEPES, and N-acetyl-cysteine ​​and 2-mercaptoethanol. Reducing agents include, but are not limited to, ethanol.

[0326] Antibiotics, such as penicillin and streptomycin, are included only in the experimental media; The culture of cells that is injected into the subject is not included. The target cells are necessary to support growth. Under suitable conditions, for example, at a suitable temperature (e.g., 37°C) and atmosphere (e.g., atmospheric pressure + 5% C O2).

[0327] In certain embodiments, the PBMCs or isolated T cells are administered IL-2, IL-7, and / or IL-15 in a medium containing an appropriate cytokine, such as beads or It interacts with other surface-bound stimulatory and costimulatory factors, such as anti-CD3 and anti-CD28 antibodies. Be contacted.

[0328] In another embodiment, artificial APCs (aAPCs) are capable of expressing various costimulatory molecules and cytokines. We developed K562, U937, 721.221, and T 2, and C1R cells. In certain embodiments, K 32 or U32 aAPCs to generate one or more antibody-based targets on the aAPC cell surface. The T cell population includes, but is not limited to, CD13 7L (4-1BBL), CD134L (OX40L), and / or CD80 or C They can be expanded with aAPCs expressing various costimulatory molecules, including D86. Later, the aAPCs expanded the genetically modified T cells and maintained CD28 expression on CD8 T cells. WO03 / 057171 and US200 The aAPCs provided in US Pat. No. 3,313,333, are incorporated herein by reference in their entirety. It is used.

[0329] 5.8.2. Agents In various embodiments, the T cell is contacted with an agent that modulates the PI3K pathway in the cell. and expanding undifferentiated or developmentally potent T cells, for producing T cells. In various embodiments, a method is provided for inhibiting the PI3K / AKT / mTOR pathway in a cell. and contacting the T cells with a factor that regulates differentiation of undifferentiated or developmentally potent T cells. Methods are provided for producing T cells that are expanded. Prior to activation and expansion, the cells are: The contact can be performed during and / or after the T cell composition has been tested. and retain sufficient T cell efficacy to undergo multiple rounds of expansion. do.

[0330] As used herein, the terms "modulate," "modulator," or "modulator" refer to The term, or equivalent terms, refers to the ability of a factor to induce a change in a cell signaling pathway. Nodal factors increase or decrease the amount or activity of pathway components or mediate cell signaling. The desired effect or output of the transduction pathway may be increased or decreased. The modulator is an inhibitor, hi another embodiment, the modulator is an activator.

[0331] "Factor" means a compound, compound that is used to modulate the PI3K / AKT / mTOR pathway. Small molecules, e.g., small organic molecules, nucleic acids, polypeptides, or fragments or isoforms thereof; Refers to a variant, analog, or derivative.

[0332] A "small molecule" refers to a molecule that is less than about 5 kD, less than about 4 kD, less than about 3 kD, less than about 2 kD, less than about 1 kD, Small molecules refer to compositions having a molecular weight of less than about 0.5 kD, or about 0.5 kD. Small molecules include nucleic acids, peptides, Polypeptides, peptidomimetics, peptoids, carbohydrates, lipids, components thereof or Chemical and biological agents such as fungal, bacterial, or algal extracts may be included. Libraries of biological mixtures and / or biological mixtures are known in the art and are useful in the present invention. The assay can be used to screen for any of the following: Methods for synthesis are known in the art (e.g., Carell et al., 1994a;Carell et al.,1994b;Cho et al.,199 3;DeWitt et al.,1993;Gallop et al.,1994; Zuckermann et al., 1994).

[0333] "Analog" refers to a compound, nucleotide, protein or other compound that has the desired activity of the present invention. is a small molecule that has a similar or identical activity or function(s) to a polypeptide or compound. It refers to any organic compound, nucleotide, protein, or polypeptide, although the preferred embodiment It does not necessarily have to include a sequence or structure similar or identical to that of the form.

[0334] A "derivative" is a parent compound that is modified by the introduction of substitutions, deletions or additions of amino acid residues. It may contain the amino acid sequence of a protein or polypeptide or may contain nucleotide substitutions. or a nucleic acid or nucleotide that has been modified by the introduction of any of a deletion, addition or mutation. It refers to any compound, protein or polypeptide that contains an oxidase. , nucleotides, proteins or polypeptides that are similar or identical to the parent polypeptide. It has functions.

[0335] In various embodiments, the factor that modulates the PI3K pathway is a factor that modulates a component of the PI3K pathway. An "activator" or "agonist" includes, but is not limited to, a PI Molecules in the PI3K / AKT / mTOR pathway, including molecules that inhibit the activity of one or more of the 3Ks It refers to a factor that promotes, increases, or induces one or more activities of a

[0336] In various embodiments, the factor that modulates the PI3K pathway is a factor that modulates a component of the PI3K pathway. The term "inhibitor" or "antagonist" includes, but is not limited to, an inhibitor of PI3 Agents that inhibit, decrease, or reduce the activity of one or more molecules in the PI3K pathway, including K In one embodiment, the inhibitor is a dual molecule inhibitor. In this study, the inhibitor was able to inhibit a class of molecules with the same or substantially the same activity (p an inhibitor), or may specifically inhibit the activity of a molecule (selective or specific inhibitors). The inhibition can also be irreversible or reversible.

[0337] In one embodiment, the inhibitor is at least 1 nM, at least 2 nM, at least 5 nM, at least 10 nM, at least 50 nM, at least 100 nM, at least 2 00nM, at least 500nM, at least 1μM, at least 10μM, at least 50 μM, or at least 100 μM. Determination of IC50 is performed by those skilled in the art. This can be accomplished using any conventional technique known in the art. For example, IC50 measures the activity of a given enzyme in the presence of a range of concentrations of a test inhibitor. The experimentally obtained enzyme activity value can then be used The concentration of inhibitor that gives 50% enzyme activity (any inhibitor concentration) is plotted against the concentration of inhibitor used. The IC50 value is the activity of the compound in the absence of any inhibitor. The concentration can also be defined through appropriate determination of activity.

[0338] In various embodiments, the T cells are administered one or more modulators of the PI3K pathway and at least one At least 1 nM, at least 2 nM, at least 5 nM, at least 10 nM, at least 50 nM, at least 100 nM, at least 200 nM, at least 500 nM, at least At least 1 μM, at least 10 μM, at least 50 μM, at least 100 μM, or at least The antibody or antibody is contacted, treated or cultured at a concentration of at least 1M.

[0339] In certain embodiments, T cells are administered one or more modulators of the PI3K pathway and at least one For at least 12 hours, 18 hours, at least 1, 2, 3, 4, 5, 6, or 7 days, 2 weeks, at least 1, 2, 3, 4, 5, or 6 months or more, 1, 2, 3, 4, 5, 6, It may be contacted or treated or cultured for 7, 8, 9, 10 or more expansion rounds.

[0340] 5.8.3.PI3K / Akt / mTOR pathway Phosphatidyl-inositol-3 kinase / Akt / mammalian target of rapamycin pathway The goal is to serve as a conduit linking growth factor signaling to cell proliferation, differentiation, metabolism, and survival. PI3Ks are a family of highly conserved intracellular lipid kinases. Class IA PI3Ks either directly or via the insulin receptor-based adaptor molecule The receptor tyrosine kinase inhibitors, which are growth factors, either through interactions with the tyrosine kinase family This activity is activated by serine / threonine kinases (RTKs). Phosphatidyl-inositol-3,4,5-trisphosphate (P mTOR has different binding partners that confer distinct activities. canonical PI3K via two distinct complexes, each characterized by It acts through the mTORC1 (PRAS40, Raptor, and mLST8 / Gb The mTOR complex (containing the L complex) mediates growth factor signals to promote protein translation, cell growth, proliferation, and It functions as a downstream effector of PI3K / Akt signaling, which is associated with proliferation and survival. mTORC2 (mTOR complex, including rictor, mSIN1, protor, and mLST8) fusion) functions as an upstream activator of Akt.

[0341] Upon growth factor receptor-mediated activation of PI3K, Akt mediates its pleckstrin It is recruited to the membrane via the interaction of its homology domain with PIP3, thereby activating The kinase domain is exposed and constitutively active phosphoinositide-dependent protein kinase 1 (PDK 1) allows phosphorylation at threonine 308 (Thr308). Maximal activation In the case of Akt, serine 473 (Ser473) in its C-terminal hydrophobic motif is also involved in the It is phosphorylated by TORC2. DNA-PK and HSP also regulate Akt activity. Akt has been shown to be important in the regulation of mTO via inhibitory phosphorylation of TSC2. Activates RC1 and TSC2, together with TSC1, is a positive regulator of mTORC1 Negatively regulates mTORC1 by inhibiting Rheb GTPase. C1 expresses two well-defined substrates, p70S6K (hereafter referred to as S6K1) and 4E- mTORC1 has BP1 and both tightly regulate protein synthesis. The importance of PI3K, which links growth factor signaling to protein translation and cell proliferation It is a downstream effector.

[0342] PI3K Inhibitors As used herein, the term "PI3K inhibitor" refers to an inhibitor that binds to and inhibits PI3K. The term refers to a nucleic acid, peptide, compound, or small organic molecule that inhibits at least one activity of. PI3K proteins are classified into class 1 PI3K, class 2 PI3K, and class 3 PI Class 1 PI3Ks are catalyzed by four p110 kinases. One of the subunits (p110α, p110β, p110δ, and p110γ) They exist as heterodimers consisting of one of two families of ribosomal and regulatory subunits. The PI3K inhibitors of the present invention preferably target Class 1 PI3K inhibitors. In one embodiment, the PI3K inhibitor is one or more isoforms of a Class 1 PI3K inhibitor. It shows selectivity for the forms (i.e., p110α, p110β, p110δ, and p110γ or one or more of p110α, p110β, p110δ, and p110γ In another embodiment, the PI3K inhibitor exhibits isoform selectivity. In one embodiment, the present invention is directed to a method for treating PI3K-related diseases, which is considered a "pan-PI3K inhibitor." Thus, PI3K inhibitors compete with ATP for binding to the PI3K catalytic domain.

[0343] In certain embodiments, the PI3K inhibitor is, for example, a PI3K inhibitor, Additional proteins in the AKT-mTOR pathway can be targeted. In this study, PI3K inhibitors that target both mTOR and PI3K were used as mTOR inhibitors. or PI3K inhibitors. In one embodiment, a selective PI3K inhibitor is a PI3K inhibitor. The inhibitors have a 50% inhibitory concentration for PI3K, which is associated with mTOR and / or other tumors in the pathway. At least 10 times, at least 20 times, or at least at least 30 times, at least 50 times, at least 100 times, at least 1000 times, or It can be understood that this refers to an agent exhibiting a low IC50.

[0344] In certain embodiments, exemplary PI3K inhibitors are at or below about 200 nM, preferably , about 100 nm or less, even more preferably about 60 nM or less, about 25 nM, about 10 nM, About 5 nM, about 1 nM, 100 μM, 50 μM, 25 μM, 10 μM, 1 μM, or Inhibits PI3K with an IC50 (concentration that inhibits 50% of activity) of In this case, the PI3K inhibitor is preferably from about 2 nM to about 100 nM, more preferably from about 2 nM to about 50 nM. More preferably, the compounds inhibit PI3K with an IC50 of about 2 nM to about 15 nM.

[0345] Examples of PI3K inhibitors suitable for use in the T cell manufacturing methods contemplated herein Illustrative examples include BKM120 (Class 1 PI3K inhibitor, Novartis), X L147 (Class 1 PI3K inhibitor, Exelixis), (pan-PI3K inhibitor , GlaxoSmithKline), and PX-866 (class 1 PI3K inhibitor; p110α, p110β, and p110γ isoforms, Oncothyreon These include, but are not limited to:

[0346] Other illustrative examples of selective PI3K inhibitors include BYL719, GSK263677 1, TGX-221, AS25242, CAL-101, ZSTK474, and IPI- 145, but is not limited to these.

[0347] Further illustrative examples of pan-PI3K inhibitors include BEZ235, LY29400, 2, GSK1059615, TG100713, and GDC-0941. Not limited to these.

[0348] AKT inhibitors As used herein, the term "AKT inhibitor" refers to an inhibitor of at least one of the AKT AKT inhibitors refer to nucleic acids, peptides, compounds, or small organic molecules that inhibit the activity of Lipid-based inhibitors (e.g., AKT plexins that block AKT localization to the plasma membrane) Inhibitors targeting the ATP homology domain, ATP-competitive inhibitors, and allosteric inhibitors In one embodiment, AKT inhibitors are In certain embodiments, Akt acts by binding to the AKT catalytic site. Inhibitors act by blocking the phosphorylation of downstream AKT targets such as mTOR. In another embodiment, AKT activity is measured by inhibiting an input signal that activates Akt. For example, AKT activates DNA-PK, AKT activates PDK-1, and / or or by inhibiting mTORC2 activation of Akt.

[0349] AKT inhibitors target all three AKT isoforms, AKT1, AKT2, and AKT3. or isoform selective, targeting AKT isoforms. Only one or two of them may be targeted. In one embodiment, the AKT inhibitor is Additional proteins in the PI3K-AKT and mTOR pathways can be targeted AKT inhibitors that target only AKT may be referred to as selective AKT inhibitors. In this form, selective AKT inhibitors have a 50% inhibitory concentration that is higher than other AKT inhibitors in the pathway. At least 10-fold, at least 20-fold, less than the IC50 of the inhibitor for the protein at least 30 times, at least 50 times, at least 100 times, at least 1000 times, or It can be understood to refer to agents that exhibit a lower IC50 than this.

[0350] In certain embodiments, exemplary AKT inhibitors are about 200 nM or less, preferably about 100 nM or less, even more preferably about 60 nM or less, about 25 nM, about 10 nM, about 5 nM, about 1 nM, 100 μM, 50 μM, 25 μM, 10 μM, 1 μM, or more In one embodiment, the compound inhibits AKT with an IC50 (concentration that inhibits 50% of activity) below AKT is preferably from about 2 nM to about 100 nM, more preferably from about 2 nM to about 50 nM, and even more preferably from about 2 nM to about 50 nM. More preferably, they inhibit AKT with an IC50 of about 2 nM to about 15 nM.

[0351] AKT Used in Combination with Auristatin-Based Antibody-Drug Conjugates Illustrative examples of inhibitors include, for example, Perifosine (Keryx), MK2206 (Me rck), VQD-002 (VioQuest), XL418 (Exelixis), G SK690693, GDC-0068, and PX316 (PROLX Pharma uticals).

[0352] An illustrative, non-limiting example of a selective Akt1 inhibitor is A-674563.

[0353] An illustrative, non-limiting example of a selective Akt2 inhibitor is CCT128930.

[0354] In certain embodiments, the Akt inhibitors Akt DNA-PK activation, Akt PD K-1 activation, mTORC2 activation of Akt, or HSP activation of Akt.

[0355] Illustrative examples of DNA-PK inhibitors include NU7441, PI-103, and NU702. 6, PIK-75, and PP-121.

[0356] mTOR inhibitors The term "mTOR inhibitor" or "factor that inhibits mTOR" refers to the At least one activity of a protein, e.g., its substrate (e.g., p70S6 kinase 1, 4E - Serine / Trease to at least one of the following: BP1, AKT / PKB and eEF2 Nucleic acids, peptides, compounds, or small organic molecules that inhibit oncogenic protein kinase activity mTOR inhibitors are inhibitors of mTORC1, mTORC2, or mTORC1 and mTORC2. It binds directly to both mTORC1, mTORC2, or mTORC1 and mT Both ORC2 and IFN-γ can be inhibited.

[0357] Inhibition of mTORC1 and / or mTORC2 activity mediates PI3K / Akt / mTOR signaling. Such a signaling pathway can be determined by a decrease in signaling in the tract. A wide variety of readouts can be used to establish the reduction in pathway output. Some non-limiting exemplary reads include: (1) but are not limited to, 5473 and (2) reduced phosphorylation of Akt at residues including, but not limited to, T308 and T409; However, Fox01 / O3a T24 / 32, GSK3a / β;S21 / 9, and TSC2 Activation of Akt, as evidenced by decreased phosphorylation of Akt substrates, including T1462 (3) reduction of ribosomal S6 S240 / 244, 70S6 Signaling molecules downstream of mTOR, including K T389 and 4EBP1 T37 / 46 and (4) inhibiting the proliferation of cancerous cells.

[0358] In one embodiment, the mTOR inhibitors are active site inhibitors. It binds to the ATP-binding site (also called the ATP-binding pocket) of mTORC1 and mT The mTOR inhibitors contemplated herein are those that inhibit both catalytic activities of ORC2. One class of active site inhibitors suitable for use in the cell manufacturing method are PI3K and It is a dual specificity inhibitor that targets and directly inhibits both mTOR and mTOR. Such inhibitors bind to the ATP binding sites of both mTOR and PI3K. Illustrative examples of drugs include imidazoquinazoline, wortmannin, LY294002, PI -103 (Cayman Chemical), SF1126 (Semafore), B GT226 (Novartis), XL765 (Exelixis) and NVP-BEZ 235 (Novartis), but are not limited to these.

[0359] Other mTOR active site inhibitors suitable for use in the methods contemplated herein include The class includes one or more type I phosphatidylinositol 3-kinases, e.g., PI3 kinases. Selectively inhibits mTORC1 and mTORC2 activity compared to kinase α, β, γ, or δ These activation site inhibitors bind to the active site of mTOR but not to the PI3K Illustrative examples of such inhibitors are pyrazolopyrimidines, which do not bind to the active site. , Torin1(Guertin and Sabatini), PP242(2-(4 -amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)- 1H-indol-5-ol), PP30, Ku-0063794, WAY-600( Wyeth), WAY-687(Wyeth), WAY-354(Wyeth), and A ZD8055(Liu et al.,Nature Review,8,627-64 4, 2009), but are not limited to these.

[0360] In one embodiment, the selective mTOR inhibitor is selected from mTORC1 and / or mTORC PI3 with a 50% inhibitory concentration (IC50) of 1, 2, 3, or more against 2 -kinase or type I PI3-kinase inhibitor IC50 is less than At least 10 times, at least 20 times, at least 50 times, at least 100 times, at least 10 This refers to an agent that exhibits an IC50 that is 00 times or more lower.

[0361] Another class of mTOR inhibitors for use in the present invention is referred to herein as " As used herein, the term "rapalog" refers to mTO R Specific binding to the FKBP rapamycin-binding domain (FRB domain) of rapamycin The term rapalog refers to compounds that are structurally related to rapamycin and that retain mTOR inhibitory properties. excludes rapamycin. Rapalogs are esters, ethers, and oxyesters of rapamycin. The functional groups on the rapamycin core structure are The pharmaceutical uses of such compounds include compounds that have been modified, for example, by reduction or oxidation. Acceptable salts thereof are also considered to be rapamycin derivatives. Illustrative examples of rapalogs suitable for use in the present invention include, but are not limited to, rapalogs Musirolimus (CC1779), everolimus (RAD001), deforolimus (AP 23573), AZD8055 (AstraZeneca), and OSI-027 (OS I) can be mentioned.

[0362] In one embodiment, the agent is the mTOR inhibitor rapamycin (sirolimus).

[0363] In certain embodiments, exemplary mTOR inhibitors for use in the present invention include: About 200 nM or less, preferably about 100 nM or less, even more preferably about 60 nM or less. Bottom, about 25nM, about 10nM, about 5nM, about 1nM, 100μM, 50μM, 25μM, mTO at IC50 (concentration that inhibits 50% of activity) of 10 μM, 1 μM, or less It inhibits either mTORC1, mTORC2 or both mTORC1 and mTORC2. In one embodiment, the mTOR inhibitor for use in the present invention has a potency of about 2 nM to about 100 nm, more preferably about 2 nM to about 50 nM, and even more preferably about 2 nM to about 15 mTORC1, mTORC2 or both mTORC1 and mTORC2 with IC50 in nM It inhibits either

[0364] In one embodiment, the exemplary mTOR inhibitor is at or below about 200 nM, preferably at or below about 100 nM or less, even more preferably about 60 nM or less, about 25 nM, about 10 nM, about 5 nM, about 1 nM, 100 μM, 50 μM, 25 μM, 10 μM, 1 μM, or less The IC50 (concentration that inhibits 50% of activity) of PI3K and mTORC1 or mTOR It inhibits either mTORC2 or both mTORC1 and mTORC2 and PI3K. In embodiments, the mTOR inhibitor for use in the present invention has a concentration of from about 2 nM to about 100 nM. m, more preferably about 2 nM to about 50 nM, and even more preferably about 2 nM to about 15 nM. IC50 of PI3K and mTORC1 or mTORC2 or mTORC1 and m Inhibits both TORC2 and PI3K.

[0365] Further details of mTOR inhibitors suitable for use in certain embodiments contemplated herein are provided below. Illustrative examples include AZD8055, INK128, rapamycin, and PF-046. 91502, and everolimus.

[0366] mTOR is a physiological regulator of inflammatory bowel disease, as measured by fluorescent specific antibodies in Western blots. p70S6 ribosomal protein kinase I (p70S6 Robust and specific catalysis for eIF4E-binding protein 1 (4EBP1) and eIF4E-binding protein 1 (4EBP1) It has been shown to exhibit activity.

[0367] In one embodiment, the inhibitor of the PI3K / AKT / mTOR pathway is BI-D1870. , H89, PF-4708671, FMK, and AT7867. It is an s6 kinase inhibitor.

[0368] 5.9. Compositions and Formulations Compositions contemplated herein include one or more of the polypeptides, polypeptides, Nucleotides, vectors containing same, genetically modified immune effector cells, etc. The composition includes, but is not limited to, a pharmaceutical composition. , either alone or in combination with one or more other therapies, to cells or animals The composition is formulated into a pharma- ceutically acceptable or physiologically acceptable solution for administration. If desired, the compositions of the present invention may be administered in combination with other agents, such as cytokines, long-term factors, hormones, small molecules, chemotherapeutic agents, prodrugs, drugs, antibodies, or various other It should also be understood that the composition may be administered in combination with other pharma- ceutically active agents, etc. There is virtually no limit to the other components that may be included in the product, but the additional drug provided that such addition does not adversely affect the function of the composition to provide its intended therapeutic treatment.

[0369] The term "pharmaceutical acceptable" is used herein to mean any compound that is within the scope of sound medical judgment. without excessive toxicity, irritation, allergic reactions or other problems or complications. Chemicals suitable for use in contact with human and animal tissues, consistent with a reasonable benefit / risk ratio. It is used to refer to a compound, substance, composition and / or dosage form.

[0370] As used herein, a "pharmaceutically acceptable carrier, diluent or excipient" includes: It is not limited to any substance that is listed in the U.S. Food and Drug Administration as acceptable for use in humans or domestic animals. Any adjuvants, carriers, excipients, lubricants, sweeteners, diluents, detergents, preservatives, dyes / coloring agents, flavor enhancers, surfactants, wetting agents, dispersants, suspending agents, Exemplary pharma- ceutically acceptable salts include, but are not limited to, a fixing agent, an isotonicity adjusting agent, a solvent, a surfactant, or an emulsifier. Carriers that can be used include sugars such as lactose, glucose, and sucrose; corn denaturant; starches such as wheat and potato starch; sodium carboxymethylcellulose, Cellulose and its derivatives, such as ethyl cellulose and cellulose acetate; tragacanth; Malt; gelatin; talc; cocoa butter, waxes, animal and vegetable fats, paraffin, Silicone, bentonite, silicic acid, zinc oxide; peanut oil, cottonseed oil, safflower oil, Oils such as sesame oil, olive oil, corn oil and soybean oil; propylene glycol, etc. glycols; glycerin, sorbitol, mannitol and polyethylene glycol Polyols; esters such as ethyl oleate and ethyl laurate; agar; hydroxide Buffers such as magnesium and aluminum hydroxide; alginic acid; pyrogen-free water isotonic saline; Ringer's solution; ethyl alcohol; phosphate buffer; and pharmaceutical preparations The materials may include, but are not limited to, any other compatible material employed in the

[0371] In certain embodiments, the compositions of the invention contain an amount of CAR as contemplated herein. As used herein, the term "amount" refers to a clinically and / or administering to a subject a genetically modified organism, such as a mammal, a mammalian animal, or a mammalian species, to achieve a beneficial or desired prophylactic or therapeutic result, including a therapeutic outcome. Refers to an "effective amount" or "effective quantity" of modified therapeutic cells, e.g., T cells.

[0372] A "prophylactically effective amount" is an amount of a genetically modified antibody effective to achieve a desired prophylactic result. Typically, but not necessarily, a prophylactically effective amount is It is a prophylactic dose used in subjects before or at an early stage of disease, and therefore therapeutic. Less than an effective amount.

[0373] The "therapeutically effective amount" of genetically modified therapeutic cells will depend on the individual's medical condition, age, sex, and Factors such as body weight and the ability of stem and progenitor cells to elicit a desired response in an individual. A therapeutically effective amount may also vary depending on the strength of the therapeutically beneficial effect on the virus or organism. It also outweighs any toxic or adverse effects of the transduced therapeutic cells. The term "effective amount" includes an amount effective to "treat" a subject (e.g., a patient). When amounts are indicated, the exact amount of the composition of the invention to be administered will depend on the age, weight, and / or other characteristics of the patient (subject). The decision will be made by the doctor, taking into account the size of the tumor, the extent of infection or metastasis, and individual differences in the condition. The pharmaceutical compositions comprising the T cells described herein may be administered in a dose of 10 2 ~10 10 cells / k g body weight, preferably 10 5 ~10 6 Dosage of cells / kg body weight (all within these ranges) It can be generally stated that the number of cells may be administered in any number (including integer values) depending on the number of cells contained in the composition. It will depend not only on the type of cells to be incorporated, but also on the intended end use of the composition. For the uses provided herein, the cells are generally in a volume of 1 liter or less, It may be 500 mL or less, or even 250 mL or 100 mL or less. The cell density is typically 10 6 cells / ml, typically >10 7 cells / ml, typically 1 0 8 Clinically meaningful numbers of immune cells can be achieved by dividing the number of immune cells into multiple infusions. You can earn 10 points. 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , or 10 12 In some embodiments of the invention, the cells to be injected are Since all of the cells are redirected to a specific target antigen (e.g., κ or λ light chain), 6 / kilogram (10 per patient) 6 ~10 11 ) smaller numbers of cells were administered The CAR-expressing cell composition may be administered multiple times at dosages within these ranges. The desired therapeutic agent may be allogeneic, syngeneic, xenogeneic, or autologous to the patient receiving the therapy. In this case, the treatment may include administration of a mitogen (e.g., P HA) or lymphokines, cytokines, and / or chemokines (e.g., IFN -gamma, IL-2, IL-12, TNF-alpha, IL-18, and TNF-beta, G M-CSF, IL-4, IL-13, Flt3-L, RANTES, MIP1α, etc. It may include administration.

[0374] Generally, compositions comprising cells activated and expanded as described herein are administered to In particular, the C The compositions comprising AR-modified T cells are used to treat B-cell malignancies. The modified T cells may be administered alone or in combination with a carrier, diluent, excipient, and / or IL-2 or other As a pharmaceutical composition in combination with other components such as cytokines or cell populations In certain embodiments, the pharmaceutical compositions contemplated herein can be administered in either In one embodiment, the method comprises administering to the subject a therapeutically effective amount of the genetically modified T cells in a therapeutically effective amount ... of one or more pharma- ceutical or physiologically acceptable carriers, Included in combination with a diluent or excipient.

[0375] The pharmaceutical compositions of the invention comprising a population of CAR-expressing immune effector cells, such as T cells, are Buffer solutions such as buffered saline and phosphate buffered saline; glucose, mannose, sucrose carbohydrates such as glucose, dextran, mannitol; proteins; polypeptides; are amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; Adjuvants (e.g., aluminum hydroxide); as well as preservatives. The composition is preferably administered parenterally, for example intravascularly (intravenously or intraarterially), intraperitoneally or is formulated for intramuscular administration.

[0376] A liquid pharmaceutical composition, whether in the form of a solution, suspension or other similar form, may comprise any one of the following: One or more of: water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride Synthetic monoglycerides which may serve as sterile diluents, solvents or suspending media for aqueous solutions of glycols, etc. Non-volatile oils such as diglycerides, polyethylene glycol, glycerin, propylene glycol or other solvent; antibacterial agents such as benzyl alcohol or methylparaben; Antioxidants such as corbic acid or sodium bisulfite; ethylenediaminetetraacetic acid, etc. chelating agents; buffers such as acetate, citrate or phosphate, and sodium chloride or Parenteral preparations may contain agents to adjust tonicity, such as glass or dextrose. or packed in plastic ampoules, disposable syringes or multi-dose vials. Injectable pharmaceutical compositions are preferably sterile.

[0377] In certain embodiments, the compositions contemplated herein comprise an effective amount of a CAR-expressing immune response vector. The vectors include vector cells alone or in combination with one or more therapeutic agents. The CAR-expressing immune effector cell composition may be used alone or in combination with other known cancer treatments, e.g. , in combination with radiation therapy, chemotherapy, transplantation, immunotherapy, hormone therapy, photodynamic therapy, etc. The composition may be administered in combination with an antibiotic. Suitable therapeutic agents include those that are not standard treatments for certain disease conditions described herein, e.g., certain cancers. Exemplary contemplated treatments include those that are art-recognized as treatments. Therapeutic drugs include cytokines, growth factors, steroids, NSAIDs, DMARDs, anti-inflammatory drugs, These include chemotherapeutic agents, radiotherapeutic agents, therapeutic antibodies, or other active and adjuvant agents.

[0378] In certain embodiments, the CAR-expressing immune effector cells disclosed herein The composition comprising the compound may be administered with any number of chemotherapeutic agents. Illustrative examples of chemotherapeutic agents include: Examples include alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN™). agents; alkyl sulfonates such as busulfan, improsulfan and piposulfan; Aziridines such as benzodopa, carboquone, meturedopa, and uredopa; altretamine , triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimethylol melamine regimes, including ethylenimine and methylamelamine; Lorambucil, chlornaphazine, chlorophosphamide, estramustine, ifospha mido, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, nobembitin, Nitric oxide such as phenesterin, prednimustine, trofosfamide, and uracil mustard Trogen mustard; carmustine, chlorozotocin, fotemustine, lomustine, Nitrosoureas such as nimustine and ranimustine; aclacinomycin, actinomycin ausramycin, azaserine, bleomycin, cactinomycin, calicheamicin carabicin, carminomycin, carzinophilin, chromomycin, dactinomycin daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, Xorubicin, Epirubicin, Esorubicin, Idarubicin, Marcelomycin, Mito mycophenolic acid, nogalamycin, olivomycin, peplomycin, potho Philomycin, puromycin, queramycin, rodrubicin, streptonigrin , streptozocin, tubercidin, ubenimex, zinostatin, zorubicin, etc. Antibiotics; antimetabolites such as methotrexate and 5-fluorouracil (5-FU) ;Folates such as denopterin, methotrexate, pteropterin, and trimetrexate Purine analogs: Fludarabine, 6-mercaptopurine, thiamiprine, thioguanine, etc. Analogs: ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, Dideoxyuridine, Doxifluridine, Enocitabine, Floxuridine, 5-FU pyrimidine analogues such as calsterone, dromostanolone propionate, epithiosta androgens such as taurate, mepitiostane, and testolactone; Antiadrenal drugs such as tothane and trilostane; folic acid supplements such as floric acid; aceglatone; Ludophosphamide glycoside; Aminolevulinic acid; Amsacrine; Bestravsil; Visa Ntren; Edatraxate; Defofamine; Demecolcine; Diazicon; Eformici elliptinium acetate etoglucide gallium nitrate hydroxyurea lentinan ;Lonidamine;Mitoguazone;Mitoxantrone;Mopidamol;Nitracrine;Pentol Statins;Fenamet;Pirarubicin;Podophyllic acid;2-Ethylhydrazide;Pro Carbazine; PSK (registered trademark); Razoxane; Sizophyllan; Spirogermanium; Te Nuazonic acid;Triazicon;2,2',2”-trichlorotriethylamine;Urethane; Vindesine; Dacarbazine; Mannomustine; Mitobronitrile; Mitolactol; Pipo Broman; Gacytosine; Arabinoside ("Ara-C"); Cyclophosphamide; Thiote Pa; Taxoids, e.g., paclitaxel (TAXOL®, Bristol- Myers Squibb Oncology, Princeton, NJ and Cetaxel (TAXOTERE®, Rhone-Poulenc Rohre r,Antony,France);Chlorambucil;Gemcitabine;6-Thioguanine ;mercaptopurine;methotrexate;platinum derivatives such as cisplatin and carboplatin analogues;vinblastine;platinum;etoposide (VP-16);ifosfamide;mitomycin Syn C; Mitoxantrone; Vincristine; Vinorelbine; Navelbine; Novantrone ;Teniposide;Daunomycin;Aminopterin;Xeloda;Ibandronate;CPT -11;Topoisomerase inhibitor RFS2000;Difluoromethylamitin (DMFO ); Targretin(TM) (bexarotene), Panretin(TM) (aritidine) Retinoic acid derivatives such as ONTAK (Denileukin difutilin) esperamicin; capecitabine; and pharma- ceutically acceptable salts of any of the above. , acids or derivatives. This definition includes those that regulate or act on hormones to regulate the action of hormones on cancer. Anti-hormonal agents that act to inhibit the Matase inhibitors 4(5)-imidazole, 4-hydroxytamoxifen, trioxyphen Fare, ketoxifene, LY117018, onapristone, and toremifene antiestrogens, including ston; as well as flutamide, nilutamide, bicalutamide, loxacinamide, antiandrogens, such as iprolide, and goserelin; and any of the above pharmaceutical Also included are acceptable salts, acids or derivatives thereof.

[0379] A variety of other therapeutic agents may be used in conjunction with the compositions described herein. In one embodiment, the composition comprising the CAR-expressing immune effector cells is administered with an anti-inflammatory drug. Inhibitory drugs or medications include steroids and glucocorticoids (betamethasone, budesonide, dexamethasone, hydrocortisone acetate, hydrocortisone, hydrocortisone, methylpropane including rednisolone, prednisolone, prednisone, and triamcinolone), nonsteroidal Non-steroidal anti-inflammatory drugs (NSAIDS), such as aspirin, ibuprofen, naproxen , methotrexate, sulfasalazine, leflunomide, anti-TNF drugs, cyclophosphamide Examples of antihistamines include, but are not limited to, cyclosporine and mycophenolic acid.

[0380] Other exemplary NSAIDs are ibuprofen, naproxen, naproxen sodium , VIOXX® (rofecoxib) and CELEBREX® (celebrex) Cox-2 inhibitors, such as coxibs, and sialylates. Exemplary analgesics are acetaminophen, oxycodone, tramadol, and propoxycodone. Exemplary glucocorticoids are selected from the group consisting of cortisone, dexamethasone, phenanthrene hydrochloride, and phenanthrene hydrochloride. xamethasone, hydrocortisone, methylprednisolone, prednisolone, and prednisone Exemplary biological response modifiers include those selected from the group consisting of cell surface markers, (e.g., CD4, CD5, etc.), TNF antagonists (e.g., ethan Rucept (ENBREL®), adalimumab (HUMIRA®) and and cytokine inhibitors such as infliximab (REMICADE®), chemotherapy These include kine inhibitors and adhesion molecule inhibitors. Biological response modifiers include monoclonal Exemplary DMARDs include azathioprine, cyclosporine, and cyclosporine. clophosphamide, cyclosporine, methotrexate, penicillamine, leflunomide, Sulfasalazine, Hydroxychloroquine, Gold (Oral (Auranofin) and Intramuscular These include cyclosporine and minocycline.

[0381] Exemplary therapeutic antibodies suitable for combination with the CAR modified T cells contemplated herein Examples include bavituximab, bevacizumab (Avastin), bivacizumab, and blitzburg Momab, conatumumab, daratumumab, durigotumab, dacetuzumab, darotuzumab, Elotuzumab (HuLuc63), Gemtuzumab, Ibritumomab, Indatuximab, Inotuzumab, lorvotuzumab, lucatumumab, milatuzumab, moxetumomab, ocara Tuzumab, ofatumumab, rituximab, siltuximab, teprotumumab, and ubuntu These include, but are not limited to, rituximab.

[0382] Antibodies against PD-1 or PD-L1 and / or CTLA-4 are disclosed herein. CAR T cells, e.g., BCMA CAR T cells, e.g., BCMA-2- CAR T cells expressing chimeric antigen receptors containing two-chain Fv fragments, e.g., bb2121 In certain embodiments, the PD-1 antibody may be used in combination with nivolumab, In certain embodiments, the medicament is selected from the group consisting of pembrolizumab, and pidilizumab. The PD-L1 antibodies are atezolizumab, avelumab, durvalumab, and BMS-9. 86559. In certain embodiments, the CTLA-4 antibody is selected from the group consisting of: Selected from the group consisting of ipilimumab and tremelimumab.

[0383] In certain embodiments, the compositions described herein are administered in combination with cytokines. As used herein, the term "cytokine" refers to a compound that acts as an intercellular mediator. A collective term for proteins released by one cell population that act on another cell. Examples of such cytokines include lymphokines, monokines, and conventional polypeptides. Among cytokines, human growth hormone, N-methionyl hyaluronan, Growth hormones such as human growth hormone and bovine growth hormone; parathyroid hormone; thyrotropin; synthin; insulin; proinsulin; relaxin; prorelaxin; follicle-stimulating hormone ( FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH). Protein hormone;Hepatic growth factor;Fibroblast growth factor;Prolactin;Placental lactogen ;Tumor necrosis factor alpha and beta;Mullerian inhibitory factor;Mouse gonadotropin-related peptide peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin TGF-alpha; nerve growth factors such as NGF-beta; platelet growth factors; Transforming growth factors (TGFs), such as insulin-like growth factors (IGFs) and TGF-beta; Growth factors I and II; erythropoietin (EPO); bone morphogenetic factor; interferon-alanine Interferons such as fa, beta, and gamma; macrophage-CSF (M-CSF) colony-stimulating factors (CSFs), such as granulocyte-macrophage CSF (GM-CSF); ); and granulocyte-CSF (G-CSF); IL-1, IL-1 alpha, IL-2, IL -3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, I Interleukins (ILs) such as IL-11, IL-12; IL-15, IL-21, etc. Tumor necrosis factors such as F-alpha or TNF-beta; and LIF and kit ligands. As used herein, the term "cytosine" refers to a polypeptide that is produced by a cytosine kinase inhibitor, such as cytosine kinase inhibitor (KL), or other polypeptide factors, including cytosine kinase inhibitor (KL). The term tokine refers to proteins derived from natural sources or from recombinant cell culture, and to naturally occurring The sequence includes those having biological activity equivalent to cytokines.

[0384] In certain embodiments, the composition is administered in the presence of a PI3K inhibitor as disclosed herein. Cultured and shows the following markers: CD3, CD4, CD8, CD28, CD45RA, CD45 Positive expression of one or more of RO, CD62, CD127, and HLA-DR Alternatively, the C contemplated herein can be further isolated by negative selection techniques. In one embodiment, the composition comprises AR T cells. , CD27, CD122, CD127, CD197 and CD38, or CD62L, C One or more markers selected from the group consisting of D127, CD197, and CD38 A specific subpopulation of T cells expressing In various embodiments, the composition is further isolated by detecting the following markers: CD57, C One or more of D244, CD160, PD-1, CTLA4, TIM3, and LAG3 does not express or does not substantially express the above.

[0385] In one embodiment, the group consisting of CD62L, CD127, CD197, and CD38. The expression of one or more of the markers selected from the group consisting of PI3K activation and at least 1.5-fold, at least 2-fold, at least At least three times, at least four times, at least five times, at least six times, at least seven times, at least Increases by 8-fold, at least 9-fold, at least 10-fold, at least 25-fold, or more. do.

[0386] In one embodiment, CD57, CD244, CD160, PD-1, CTLA4, T Expression of one or more markers selected from the group consisting of IM3, and LAG3 is indicative of P at least 1.5% compared to a population of T cells activated and expanded with an I3K inhibitor fold, at least 2x, at least 3x, at least 4x, at least 5x, at least 6x times, at least 7 times, at least 8 times, at least 9 times, at least 10 times, at least A decrease of 25 times or more.

[0387] 5.10. Treatment method The genetically modified immune effector cells contemplated herein include, but are not limited to, However, there are several adoptive immunotherapy options for the treatment of B-cell-related conditions, including immunosuppressive conditions and hematological malignancies. This provides improved methods of therapy.

[0388] 5.10.1. Specific embodiment In one embodiment, provided herein is a method for depleting BCMA-expressing cells. in a subject in need thereof, comprising administering to the subject a B cell maturation antigen (BCM) A) administering a therapeutically effective amount of immune cells expressing a directed chimeric antigen receptor (CAR) The immune cells were 150 × 10 6 cells ~450×10 6 Cells are administered in doses Prior to said administration, the subject is receiving a proteasome inhibitor, lenalidomide, pomalidomide, Thalidomide, bortezomib, dexamethasone, cyclophosphamide, doxorubicin, Carfilzomib, ixazomib, cisplatin, doxorubicin, etoposide, anti-CD 38 antibodies (e.g., daratumumab), panobinostat, or elotuzumab Patients who have received one or more prior lines of therapy, including those listed above.

[0389] In another embodiment, provided herein is a method for treating BCMA-expressing cells. A method of treating a disease in a subject in need thereof, comprising administering to the subject In this study, we developed immune cells expressing B cell maturation antigen (BCMA)-directed chimeric antigen receptors (CARs). wherein the immune cells comprise 150×10 6 Cell ~450×1 0 6 and prior to said administration, said subject is administered a dosage of a proteasome inhibitor, Nalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone, cyclophosph Famid, doxorubicin, carfilzomib, ixazomib, cisplatin, doxorubicin bicine, etoposide, anti-CD38 antibodies (such as daratumumab), panobinostat, or have received at least one prior line of therapy that included at least one of the following: be.

[0390] In another embodiment, provided herein is a method for treating a BCMA-expressing cancer. The present invention relates to a method for administering to a subject in need thereof a B cell maturation antigen ( The present invention relates to a method for treating cancer, comprising administering to a patient a therapeutically effective amount of immune cells expressing a chimeric antigen receptor (CAR) directed against BCMA. The immune cells were administered at a concentration of 150 × 10 6 cells ~450×10 6 Cell dosage and prior to said administration, said subject is receiving a proteasome inhibitor, lenalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone, cyclophosphamide, doxorubicin Cinnamoyl, carfilzomib, ixazomib, cisplatin, doxorubicin, etoposide, Anti-CD38 antibodies (such as daratumumab), panobinostat, or elotuzumab Patients with BCMA-expressing cancer who have received at least one prior line of therapy, including Multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin's lymphoma (e.g., Burkitt's lymphoma) lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large cell lymphoma Follicular B-cell lymphoma, Follicular lymphoma, Large immunoblastic cell lymphoma, Precursor B-lymphoblast lymphoma, and mantle cell lymphoma.

[0391] In a specific embodiment of any of the above embodiments, prior to said administering, said subject , daratumumab, pomalidomide, and dexamethasone (DPd); daratumumab, bortezomib Zomib and dexamethasone (DVd); Ixazomib, lenalidomide, and dexamethasone daratumumab, lenalidomide and dexamethasone; bortezomib, lenalidomide and dexamethasone Lidomide and dexamethasone (RVd); Bortezomib, cyclophosphamide and dexamethasone Bortezomib, doxorubicin and dexamethasone (BCd); Bortezomib, doxorubicin and dexamethasone; Carfilzo mib, lenalidomide and dexamethasone (CRd); bortezomib and dexamethasone; Bortezomib, thalidomide and dexamethasone; lenalidomide and dexamethasone; de xamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, Toposide and bortezomib (VTD-PACE); lenalidomide and low-dose dexamethasone bortezomib, cyclophosphamide and dexamethasone; carfilzomib and dexamethasone Samethasone; lenalidomide alone; bortezomib alone; daratumumab alone; elotuzumab, Lenalidomide, and dexamethasone; elotuzumab, lenalidomide, and dexamethasone; Bendamustine, bortezomib and dexamethasone; Bendamustine, lenalidomide and and dexamethasone; pomalidomide and dexamethasone; pomalidomide, bortezomib and Dexamethasone; pomalidomide, carfilzomib and dexamethasone; bortezomib and and liposomal doxorubicin; cyclophosphamide, lenalidomide, and dexamethasone elotuzumab, bortezomib and dexamethasone; ixazomib and dexamethasone ;Panobinostat, bortezomib and dexamethasone;Panobinostat and Carfi or prior chemotherapy including pomalidomide, cyclophosphamide, and dexamethasone Have received at least one Inn.

[0392] In certain more specific embodiments of any of the above, the subject is 2 or more of the lines of prior therapy, 3 or more of the lines of prior therapy, 4 or more of the above, 5 or more of the above lines of prior therapy, 6 or more of the above lines of prior therapy, or have received seven or more of the above prior lines of therapy. In certain other more specific embodiments, the subject has received three or more of the prior lines of therapy. Patients who have received up to two of the prior lines of therapy or up to one of the prior lines of therapy I have done it before.

[0393] For any of the above embodiments, the subject undergoes lymphocyte depletion prior to said administration. For any of the above embodiments, the subject may then harvest and isolate the immune cells, e.g., T cells. In order to isolate the patient, the patient undergoes apheresis. In the method, the subject exhibits the following at the time of the apheresis: M protein (serum Protein electrophoresis (sPEP) or urinary protein electrophoresis (uPEP) (sPE) P ≥ 0.5 g / dL or uPEP ≥ 200 mg / 24 hours; measured in serum or urine No identifiable disease, serum immunoglobulin free light chains ≥ 10 mg / dL, and abnormal serum immunoglobulins globulin kappa lambda free light chain ratio; and / or East Coast of the United States Eastern Cooperative Oncology Group (ECOG) performance status ≦1. More Specific Embodiments In the method, the subject is further administered a proteasome inhibitor, an immunomodulatory agent, and / or a medicament for the treatment of apheresis. Prior treatment with anti-CD38 antibodies and anti-lenalidomide or pomalidomide was also included. Have received at least three of the prior lines of therapy; For at least three of each, at least one At least 2 consecutive cycles of chemotherapy; and / or evidence of progression within 1 day of Efficacy (minimal response or better) has been observed in one patient.

[0394] In another more specific embodiment, the subject further comprises one or more prior anti-myeloma treatments. regimen only; the following high-risk factors: R-ISS stage III, and (i ) If the subject has undergone induction therapy and stem cell transplant, progression within 12 months from the date of the first transplant or (ii) if the subject has received only an induction procedure, at least a proteasome inhibitor , immunomodulatory agents and dexamethasone. Patients with early relapse were randomized to receive CT scans or CT scans of patients with PD <12 months after onset.

[0395] In a specific embodiment of any of the above embodiments, the subject receives The patient will have a progression-free survival of at least 6 months or at least 12 months after administration of the drug.

[0396] In a specific embodiment of any of the above embodiments, the chimeric antigen receptor is B Antibodies or antibody fragments that target CMA, such as single chain Fv antibody fragments (scFv), e.g. For example, BCMA02 scFv. In one embodiment, the immune cells are bb2121 cells.

[0397] 5.10.2. General Implementation In certain embodiments, the specificity of the primary immune effector cells is as contemplated herein. By genetically modifying primary immune effector cells with a CAR that targets B cells, In various embodiments, a mouse antibody that binds to a BCMA polypeptide is BCMA antigen-binding domain; hinge domain; transmembrane (TM) domain; TM domain A short oligopeptide or polypeptide linked to the intracellular signaling domain of the CAR a linker; and one or more intracellular costimulatory signaling domains; and a primary signal transduction domain. A specific polynucleotide encoding a CAR containing a targeting domain is used to induce immune effectors. Viral vectors are used to genetically modify cells.

[0398] In one embodiment, the present invention provides a method for the preparation of a CAR-targeting B cell that is capable of expressing BCMA-expressing B cells. In another embodiment, the present invention includes a type of cell therapy in which T cells are genetically modified to: A CAR T cell was designed to increase the therapeutic properties and persistence of CAR T cells. The CAR T cells are then cultured in the presence of IgE-2 and a PI3K inhibitor. The cells are then infused into a recipient of interest. The infused cells then mutate the recipient's disease-causing B cells. Unlike antibody therapy, CAR T cells can replicate in vivo. It is manufacturable and long-lasting, which could lead to a sustainable cancer therapy.

[0399] In one embodiment, the CAR T cells of the present invention are robust in vivo T cells. In another embodiment, the CAR T cells of the present invention can undergo expansion and persist for a long period of time. The cells are capable of reactivating and inhibiting any further tumor formation or growth. become memory T cells.

[0400] In certain embodiments, immune effector cells comprising a CAR as contemplated herein The compositions comprising the same are used in the treatment of conditions associated with aberrant B cell activity.

[0401] Immune effector cells comprising the CARs contemplated herein can be used for therapeutic, prophylactic, or Illustrative examples of conditions that may be alleviated include systemic lupus erythematosus, rheumatoid arthritis, and the like. , myasthenia gravis, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, antiphospholipid syndrome group, Chagas disease, Graves' disease, Wegener's granulomatosis, polyarteritis nodosa, Sjögren's disease Pemphigus vulgaris, scleroderma, multiple sclerosis, antiphospholipid syndrome, ANCA-associated These include vasculitis, Goodpasture's disease, Kawasaki disease, and rapidly progressive glomerulonephritis. However, the present invention is not limited to the above.

[0402] The engineered immune effector cells can be used to treat heavy chain disease, primary or immune cell-associated amyloidosis. Plasma cell disorders such as monoclonal gammopathy of undetermined significance (MGUS) and It may also have applications in

[0403] As used herein, a "B cell malignancy" refers to a tumor of the B cell (immune This refers to a type of cancer that forms in the lining of the body (a type of cell in the body).

[0404] In certain embodiments, the compositions comprising the CAR modified T cells contemplated herein are, e.g., For example, but not limited to, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) It is used to treat hematologic malignancies, including B-cell malignancies such as pulmonary fibrosis (PFC) and pulmonary fibrosis (PFC).

[0405] Multiple myeloma is a B-cell malignancy with mature plasma cell morphology and is characterized by a monoclonal pattern of these cell types. These plasma cells proliferate in the bone marrow (BM) and It can invade adjacent bones and occasionally the blood. Multiple myeloma, plasma cell leukemia, non-secretory myeloma, IgD myeloma, osteosclerotic myeloma , isolated plasmacytoma of bone, and extramedullary plasmacytoma (e.g., Braunwald d,et al.(eds),Harrison's Principles of I nternal Medicine, 15th Edition (McGraw-Hil l 2001)).

[0406] Multiple myeloma can be staged as follows: Table 3: Durie-Salmon MM Staging Criteria [Table 3] Table 4: MM Staging Criteria According to the International Staging Classification [Table 4]

[0407] Non-Hodgkin's lymphomas encompass a large group of cancers of the lymphocytes (white blood cells). Jimin lymphoma can occur at any age and often presents with larger than normal lymph nodes, It is characterized by fever and weight loss. There are many different types of non-Hodgkin's lymphoma. Examples For example, non-Hodgkin's lymphomas are classified as aggressive (fast-growing) and indolent (slow-growing). Non-Hodgkin's lymphoma can be classified into two types: However, as used herein, "non-Hodgkin's lymphoma" and "B-cell non-Hodgkin's lymphoma" are The terms "non-Hodgkin's lymphoma" and "non-Hodgkin's lymphoma" are used interchangeably. B-cell non-Hodgkin's lymphoma (NHL) includes: Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), Diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma. Bone marrow transplant or stem cell Lymphomas that arise after transplantation are usually B-cell non-Hodgkin's lymphomas.

[0408] Chronic lymphocytic leukemia (CLL) is an indolent (slow-growing) cancer that affects the B lymphocyte. The increase in immature white blood cells called lymphocytes, or B cells, occurs slowly. It spreads through the blood and bone marrow, affecting lymph nodes or other organs such as the liver and spleen. CLL eventually causes bone marrow failure. Occasionally, in later stages of the disease, is called small lymphocytic lymphoma.

[0409] In certain embodiments, the CAR-expressing immune effector cells or or administering to a subject in need thereof a therapeutically effective amount of a composition comprising the same, either alone or in combination. Methods are provided that include administering the above in combination with the therapeutic agents. In one embodiment, the cells of the invention are used to treat conditions associated with aberrant B cell activity or B cell malignancies. The present invention is therefore useful in treating patients at risk of developing abnormal B cell activity. A method for treating or preventing a gender-related condition or B-cell malignancy, comprising: administering a therapeutically effective amount of a CAR modified cell as contemplated herein to a subject in need thereof The present invention provides a method, comprising:

[0410] As used herein, the terms "individual" and "subject" are often used interchangeably. These are commonly used in gene therapy vectors, cell-based therapies, and methods disclosed elsewhere herein. "Antibody" refers to any animal that exhibits symptoms of a disease, disorder or condition that can be treated by the methods. In a preferred embodiment, the subject is administered gene therapy vectors, cell-based therapies, and the present Hematopoietic diseases, disorders or conditions that can be treated by methods disclosed elsewhere herein, e.g. Suitable subjects (e.g., patients) include any animal that exhibits symptoms of a B cell malignancy. These include laboratory animals (such as mice, rats, rabbits, or guinea pigs), livestock and farm animals, or pets (such as cats or dogs). Exemplary subjects include human patients with B cell malignancies, The present invention includes human patients who have been treated with or are at risk for having a B cell malignancy.

[0411] As used herein, the term "patient" refers to a patient who is administered a gene therapy vector, cell-based and specific diseases, disorders that can be treated by the methods disclosed elsewhere herein. Or refers to a subject who has been diagnosed with a condition.

[0412] As used herein, "treatment" or "treating" refers to the treatment of a disease or pathological condition. and any beneficial or desired effect on the symptoms or pathology of the disease being treated. Or it may include a minimal decrease in one or more measurable markers of the condition. Optionally, reducing or alleviating the symptoms of a disease or condition, or "Treatment" may involve either the abolishment of a disease or condition or the delay of its progression. It does not represent a complete eradication or cure of associated symptoms.

[0413] As used herein, the terms "prevent," "prevented," "preventing," and the like are used interchangeably. Any similar terms may be used to describe preventing, inhibiting, or preventing the onset or recurrence of a disease or condition. It also describes approaches to prevent or reduce the onset of a disease or condition. delaying the onset or recurrence of symptoms of a disease or condition; As used herein, "prevention" and similar terms also refer to preventing or alleviating a disease or or reduce the intensity, impact, symptoms and / or burden of a disease or condition prior to the onset or recurrence of the disease or condition. This includes reducing

[0414] "Improve" or "promote" or "increase" or "expand" means Generally, the compositions contemplated herein, e.g., genetically modified T cells or CARs, The encoding vector is either induced by a vehicle or a control molecule / composition. produces a greater physiological response (i.e., downstream effects) compared to the response evoked by the A measurable physiological response refers to, among other things, the ability of the art to elicit or cause a physiological response. Increased T cell expansion, activation, and persistence as understood from current understanding and the description herein; and / or increased cancer cell killing ability. Typically a "statistically significant" amount, which is the amount of Responses 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15 , 20, 30 times, or more (e.g., 500, 1000 times) (anywhere between (including all integers and decimals over 1.5, 1.6, 1.7, 1.8, etc.) It may include some increase.

[0415] "reduce" or "decrease" or "weaken" or "reduce" or "Ameliorate" generally refers to the fact that the compositions contemplated herein are effective in reducing the The physiological response was smaller than that induced by either one of the Refers to the ability to generate, elicit, or cause a response (i.e., a downstream effect). Or the amount of "reduced" is typically a "statistically significant" amount, and is not greater than the vehicle, control, or The response induced by the IL-10 composition (reference response) or the response in a particular cell lineage 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 times , or more (e.g., 500, 1000 times) (all integers between and above 1 Includes reductions that are numbers and decimal points, e.g. 1.5, 1.6, 1.7, 1.8, etc. obtain.

[0416] "Maintain", or "Save", or "Keep", or "No change", or " "No substantial change" or "no substantial decrease" generally refers to the composition contemplated herein. Responses elicited by either the vehicle or a control molecule / composition; or substantially similar physiology in cells compared to responses in a particular cell lineage. Equivalent Response refers to the ability to generate, elicit, or cause a significant response (i.e., downstream effect). is one that is not significantly different or has no measurable difference from the reference response.

[0417] In one embodiment, treating a B cell related condition is performed in a subject in need thereof. The method of carrying out the method includes administering to a subject a composition comprising the genetically modified immune effector cells contemplated herein. This includes administering an effective amount, e.g., a therapeutically effective amount, of the compound. Appropriate dosages may be determined through clinical trials. The amount and frequency of administration can be determined according to the patient's condition, as well as the type and severity of the patient's illness. The duration of the treatment is determined by factors such as the severity of the condition and the severity of the symptoms.

[0418] In one embodiment, the amount of T cells i...

Claims

1. A method for depleting BCMA-expressing cells in a subject in need thereof. and administering to the subject a chimeric antigen receptor (CAR) directed against B cell maturation antigen (BCMA). The method includes administering a therapeutically effective amount of immune cells to a patient, the immune cells being 150×10 6 Cell ~450×10 6 and administering to the subject a dosage of cells, and prior to said administration, said subject is Inhibitors of thrombocytopenic purpura, lenalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone cyclophosphamide, doxorubicin, carfilzomib, ixazomib, cisplatin cyclosporine, doxorubicin, etoposide, anti-CD38 antibody, panobinostat, and elotizumab. The patient has received one or more prior lines of therapy including one or more of the following:

2. The present invention relates to treating a disease caused by BCMA-expressing cells in a subject in need thereof. The method comprises administering to the subject a chimeric antibody directed against B-cell maturation antigen (BCMA). administering to the patient a therapeutically effective amount of immune cells expressing a CAR-specific antigen receptor (CAR), The vaccine cells are 150 x 10 6 Cell ~450×10 6 a dosage of cells, The subject is receiving a proteasome inhibitor, lenalidomide, pomalidomide, thalidomide, Bortezomib, dexamethasone, cyclophosphamide, doxorubicin, carfilzomi ixazomib, cisplatin, doxorubicin, etoposide, anti-CD38 antibody, panobinostat Received at least one prior line of therapy including binostat and elotuzumab The method may include the steps of:

3. Methods of Treating BCMA-Expressing Cancer in a Subject in Need thereof The subject is administered a B cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR). The method comprises administering a therapeutically effective amount of immune cells expressing 150×1 0 6 Cell ~450×10 6 and administering to the subject a dosage of cells, and prior to said administration, said subject is Theasome inhibitors, lenalidomide, pomalidomide, thalidomide, bortezomib, dexamethasone Methasone, cyclophosphamide, doxorubicin, carfilzomib, ixazomib, Suplatin, doxorubicin, etoposide, anti-CD38 antibody, panobinostat, and The method includes administering to the patient one or more prior lines of therapy including one or more of rotuzumab. 。

4. The BCMA-expressing cancer is multiple myeloma, chronic lymphocytic leukemia, or non-Hodgkin lymphoma. Lymphoma (e.g., Burkitt's lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma) (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large lymphoma, precursor B-lymphoblastic lymphoma, and mantle cell lymphoma. The method according to claim 3.

5. The method according to any one of claims 1 to 4, wherein the subject has multiple myeloma that is high-risk multiple myeloma. The method according to any one of claims 1 to 5.

6. The method according to any one of claims 1 to 4, wherein the subject has multiple myeloma that is relapsed or refractory multiple myeloma. The method according to any one of claims 1 to 5.

7. Prior to said administering, said subject: Daratumumab, pomalidomide, and dexamethasone (DPd); b. Daratumumab, bortezomib, and dexamethasone (DVd); c. Ixazomib, lenalidomide, and dexamethasone (IRd); d. Daratumumab, lenalidomide and dexamethasone; e. Bortezomib, lenalidomide and dexamethasone (RVd); f. Bortezomib, cyclophosphamide and dexamethasone (BCd); g. Bortezomib, doxorubicin and dexamethasone; h. Carfilzomib, lenalidomide and dexamethasone (CRd); i. bortezomib and dexamethasone; j. bortezomib, thalidomide and dexamethasone; k. lenalidomide and dexamethasone; l. Dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide thiazolid, etoposide and bortezomib (VTD-PACE); m. Lenalidomide and low-dose dexamethasone; n. Bortezomib, cyclophosphamide and dexamethasone; o. Carfilzomib and dexamethasone; p. Lenalidomide alone; q. bortezomib alone; r. Daratumumab alone; s. elotuzumab, lenalidomide, and dexamethasone; t. elotuzumab, lenalidomide and dexamethasone; u. bendamustine, bortezomib and dexamethasone; v. bendamustine, lenalidomide, and dexamethasone; w. pomalidomide and dexamethasone; x. Pomalidomide, bortezomib and dexamethasone; y. pomalidomide, carfilzomib and dexamethasone; z. bortezomib and liposomal doxorubicin; aa. cyclophosphamide, lenalidomide, and dexamethasone; bb. Elotuzumab, bortezomib and dexamethasone; cc. ixazomib and dexamethasone; dd. Panobinostat, bortezomib and dexamethasone; ee. panobinostat and carfilzomib; or ff. One prior line of therapy including pomalidomide, cyclophosphamide, and dexamethasone The method according to any one of claims 1 to 6, wherein the patient has undergone at least one of the above-mentioned procedures.

8. 8. The method of claim 7, wherein the subject has received two or more of the prior lines of therapy. How to.

9. 8. The method of claim 7, wherein the subject has received three or more of the prior lines of therapy. How to.

10. 8. The method of claim 7, wherein the subject has received four or more of the prior lines of therapy. How to.

11. 8. The method of claim 7, wherein the subject has received five or more of the prior lines of therapy. How to.

12. 8. The method of claim 7, wherein the subject has received six or more of the prior lines of therapy. How to.

13. 8. The method of claim 7, wherein the subject has received seven or more of the prior lines of therapy. How to.

14. 8. The method of claim 7, wherein the subject has received no more than three of the prior lines of therapy. method.

15. 8. The method of claim 7, wherein the subject has received no more than two of the prior lines of therapy. method.

16. 8. The method of claim 7, wherein the subject has received no more than one of the prior lines of therapy. method.

17. The subject, at the time of administration, a. Serum M protein level (serum protein electrophoresis [sPEP]) of approximately 0.5 g / d L or higher, or urine M protein level (urine protein electrophoresis [uPEP]) of approximately 20 0 mg / 24 hours or more, and / or b. Absence of measurable disease in serum or urine and serum immunoglobulin free light chains of 10 m or less g / dL or higher and abnormal serum immunoglobulin kappa / lambda free light chain ratio Myeloma (MM); and / or c. Eastern Cooperative Oncology Group (ECOG) performance status of approximately 1 or less The method according to any one of claims 1 to 16, wherein

18. The object further comprises: a. Proteasome inhibitors, immunomodulatory agents (lenalidomide or pomalidomide) and anti-CD 38 antibody prior treatment, and at least three of the above lines of prior treatment. can be; b. Progression after treatment (PD) for each of at least three of the prior lines of therapy Have received at least 2 consecutive cycles, unless this is the best response to the line; c. Evidence of progressive disease (PD) at or within 60 days of the most recent line of therapy and / or d. Achieved a response (minimal response or better) to at least one of the above prior lines of therapy The method of claim 17, wherein

19. The object further comprises: a. only one prior regimen of anti-myeloma therapy; and / or b. The following high-risk factors: R-ISS stage III and early recurrence, The onset of the disease is, (i) if the subject has undergone induction and stem cell transplantation, 12 months after the date of the first transplantation. or (ii) if the subject has received induction therapy only, progression in at least The most common drug that should contain a proteasome inhibitor, an immunomodulatory agent, and dexamethasone 18. The method of claim 17, wherein progression (PD) is defined as progression less than 12 months from the date of a subsequent treatment regimen. The method described.

20. 20. The method of claim 1, wherein the subject exhibits a progression-free survival of at least 6 months after the administration.

2. The method according to claim 1 .

21. 1. The method of claim 1, wherein the subject exhibits a progression-free survival of at least 12 months after the administration.

10. The method according to any one of claims 9 to 10.

22. 1 , wherein the chimeric antigen receptor comprises an antibody or antibody fragment that targets BCMA.

22. The method according to any one of claims 1 to 21.

23. 23. The chimeric antigen receptor of claim 1, wherein the chimeric antigen receptor comprises a single chain Fv antibody fragment (scFv).

13. The method according to any one of claims 1 to 12.

24. Any of claims 1 to 22, wherein the chimeric antigen receptor comprises BCMA02 scFv.

2. The method according to claim 1.

25. The method according to any one of claims 1 to 22, wherein the immune cells are bb2121 cells. Law.

Citation Information

Patent Citations

  • Anti-BCMA car t cell compositions

    WO2018085690A1